

ONLINE SEARCH REQUEST FORM

USER

Tom Schenck

SERIAL NUMBER

07/003590

ART UNIT

1806

PHONE

308-3983

DATE

7/24/96

Please give a detailed statement of requirements. Describe as specifically as possible the subject matter to be searched. Define any terms that may have special meaning. Give examples or relevant citations, authors, or keywords, if known.

You may include a copy of the broadest and or relevant claim(s).

please do an interference
search for seq ID NOS.

5 thru 21

Thanks,

Toni

?t s9/7/1-16

9/7/1 (Item 1 from file: 351)
DIALOG(R)File 351:DERWENT WPI
(c) 1994 Derwent Info Ltd. All rts. reserv.

009855324 WPI Acc No: 94-135180/16
XRAM Acc No: C94-062475
XRPX Acc No: N94-106287

Notch protein and nuclear acid compositions - is used for treatment of disorders of cell fate or differentiation esp. breast, colon or cervical cancer

Patent Assignee: (UYYA) UNIV YALE
Author (Inventor): ARTAVANIS-TSAKONAS S; BLAUMUELLER C M; FEHON R G;
ZAGOURAS P

Number of Patents: 002
Number of Countries: 045
Patent Family:

CC Number	Kind	Date	Week	
WO 9407474	A1	940414	9416	(Basic)
AU 9453503	A	940426	9432	

Priority Data (CC No Date): US 955012 (920930); US 83590 (930625)
Applications (CC,No,Date): AU 9453503 (930930); WO 93US9338 (930930)
Language: English
EP and/or WO Cited Patents: 6.Jnl.Ref; US 5115096; US 5132212; US 5264557
Designated States

(National): AU; BB; BG; BR; BY; CA; CZ; FI; HU; JP; KP; KZ; LK; LV; MG; MN
; MW; NO; NZ; PL; RO; RU; SD; SK; UA; US; UZ; VN
(Regional): AT; BE; CH; DE; DK; ES; FR; GB; GR; IE; IT; LU; MC; NL; OA; PT
; SE

Filing Details: AU9453503 Based on WO 9407474
Abstract (Basic): WO 9407474 A

The pharmaceutical compsn. comprises a therapeutically effective amt. of a Notch protein (A) and a pharmaceutically acceptable carrier.

USE - The compsns. can be used for treatment of disorders of cell fats or differentiation. The therapeutic compsns. include Notch proteins and analogues, derivs. and fragments, antibodies, nucleic acid encoding, analogues and derivs., Notch antisense nucleic acids, toporythmic proteins and derivs. which bind or interact with Notch proteins, their encoding nucleic acids or Abs. The compsn. is pref. admin. to a cancerous condition, e.g. breast, colon or cervical cancer, or to prevent progression from a pre-neoplastic or non-malignant state into a neoplastic or malignant state. Dwg.0/17

Derwent Class: B04; D16; S03;
Int Pat Class: A61K-031/70; A61K-037/02; A61K-039/395; A61K-039/44;
C07H-021/04; G01N-033/53; G01N-033/68

9/7/2 (Item 1 from file: 357)
DIALOG(R)File 357:Derwent Biotechnology Abs
(c) 1994 Derwent Publ Ltd. All rts. reserv.

164909 DBA Accession No.: 94-07460 PATENT

Notch protein and antisense DNA - application in carcinoma diagnosis,
therapy and gene therapy

PATENT ASSIGNEE: Univ.Yale 1994

PATENT NUMBER: WO 9407474 PATENT DATE: 940414 WPI ACCESSION NO.:
94-135180 (9416)

PRIORITY APPLIC. NO.: US 83590 APPLIC. DATE: 930625

NATIONAL APPLIC. NO.: WO 93US9338 APPLIC. DATE: 930930

LANGUAGE: English

ABSTRACT: A pharmaceutical composition comprising a Notch protein (A) and a carrier is claimed. More specifically, the composition comprises a human Notch protein encoded by a specified DNA sequence which is bound by an antibody to a Notch protein. The following are also claimed: (1) a pure human Notch protein homolog of specified protein sequence; (2) nucleic acid encoding the protein of (1); (3) a recombinant cell containing the nucleic acid of (2); (4) a composition comprising a Notch protein or derivative (e.g. chimeric protein); (5) a composition comprising a molecule which antagonizes the function of a Notch protein; and (6) the use of the composition of (5) for treatment of cervix carcinoma, mamma carcinoma or colon carcinoma. In (4), the chimeric protein may include functionally active portions of the Notch protein encoded by human cDNA contained in plasmid pHN3k (ATCC 68609) and plasmid pHN5k (ATCC 68611). The therapeutic composition includes Notch proteins and analogs, antibodies, nucleic acid encoding the analogs, antisense nucleic acids, etc. which bind and interact with Notch proteins, their encoding nucleic acids or antibodies. (232pp)

9/7/3 (Item 1 from file: 399)

DIALOG(R)File 399:CA Search(R)

(c) 1994 American Chemical Society. All rts. reserv.

121026887 CA: 121(3)26887m PATENT

Therapeutic and diagnostic methods and compositions based on Notch
proteins and nucleic acids

INVENTOR(AUTHOR): Artavanis-Tsakonas, Spyridon; Fehon, Richard Grant;
Zagouras, Panayiotis; Blaumueller, Christine Marie

LOCATION: USA

ASSIGNEE: Yale University

PATENT: PCT International ; WO 9407474 A1 DATE: 940414

APPLICATION: WO 93US9338 (930930) *US 955012 (920930) *US 83590 (930625)

PAGES: 232 pp. CODEN: PIXXD2 LANGUAGE: English CLASS: A61K-031/00A;
A61K-031/70B; A61K-037/02B; A61K-039/44B; A61K-039/395B; C07H-021/04B;
G01N-033/53B; G01N-033/68B DESIGNATED COUNTRIES: AU; BB; BG; BR; BY; CA;
CZ; FI; HU; JP; KR; KZ; LK; LV; MG; MN; MW; NO; NZ; PL; RO; RU; SD; SK; UA;
US; UZ; VN DESIGNATED REGIONAL: AT; BE; CH; DE; DK; ES; FR; GB; GR; IE; IT
; LU; MC; NL; PT; SE; BF; BJ; CF; CG; CI; CM; GA; GN; ML; MR; NE; SN; TD;
TG

SECTION:

CA201006 Pharmacology

CA209XXX Biochemical Methods

IDENTIFIERS: human Notch protein therapeutic, cDNA antibody human Notch

DESCRIPTORS:

Gene,animal...

cDNA, for human Notch protein and Drosophila Delta protein
Deoxyribonucleic acid sequences,complementary...
for human Notch protein and Drosophila Delta protein

Alopecia... Cirrhosis... Intestine,neoplasm, colon, inhibitors... Keloid... Lung,neoplasm, inhibitors... Mammary gland,neoplasm, inhibitors... Neoplasm inhibitors,colon... Neoplasm inhibitors,lung... Neoplasm inhibitors,mammary gland... Neoplasm inhibitors,melanoma... Psoriasis...

Notch protein as diagnostics and
Proteins,specific or class, gene Delta...

Notch protein as therapeutics in relation to
Deoxyribonucleic acids,complementary, antisense...

of human Notch gene, for diagnostics and therapeutics
Protein sequences...

of human Notch protein and Drosophila Delta protein
Gene,animal, Serrate...

protein of, Notch protein as therapeutics in relation to
Antibodies... Antibodies,monoclonal...

to human Notch protein, for diagnostics and therapeutics
Testis,neoplasm, seminoma... Uterus,neoplasm, cervix...

treatment and diagnosis of, Notch protein as diagnostics and

CAS REGISTRY NUMBERS:

146636-21-7 amino acid sequence of

156067-46-8 156067-47-9 156067-48-0 156067-49-1 156067-50-4

156067-51-5 amino acid sequence of, therapeutics contg.

146636-19-3 human Notch protein homologous to, as therapeutics

148513-28-4 156067-52-6 156067-53-7 156067-54-8 156067-55-9 nucleotide
sequence of

146636-08-0 146636-13-7 156067-43-5 156067-44-6 156067-45-7 nucleotide
sequence of, therapeutics contg. protein encoded by

9/7/4 (Item 1 from file: 434)

DIALOG(R)File 434:SciSearch(R)

(c) 1994 Inst for Sci Info. All rts. reserv.

12982219 Genuine Article#: NF965 Number of References: 29

Title: EP-CAM - A HUMAN EPITHELIAL ANTIGEN IS A HOMOPHILIC CELL-CELL
ADHESION MOLECULE

Author(s): LITVINOV SV; VELDERIS MP; BAKKER HAM; FLEUREN GJ; WARNAAR SD

Corporate Source: LEIDEN UNIV,DEPT PATHOL,WASSENAARSEWEG 62,POB 9603/2300

RC LEIDEN//NETHERLANDS/

Journal: JOURNAL OF CELL BIOLOGY, 1994, V125, N2 (APR), P437-446

ISSN: 0021-9525

Language: ENGLISH Document Type: ARTICLE

Abstract: The epithelial glycoprotein 40 (EGP40, also known as GA733-2, ESA, KSA, and the 17-1A antigen), encoded by the GA-733-2 gene, is expressed on the baso-lateral cell surface in most human simple epithelia. The protein is also expressed in the vast majority of carcinomas and has attracted attention as a tumor marker. The function of the protein is unknown. We demonstrate here that EGP40 is an epithelium-specific intercellular adhesion molecule. The molecule mediates, in a Ca²⁺-independent manner, a homophilic cell-cell adhesion of murine cells transfected with the complete EGP40 cDNA. Two murine cell lines were tested for the effects of EGP40 expression: fibroblastic L cells and dedifferentiated mammary carcinoma L153S cells. The expression of the EGP40 protein causes morphological changes in cultures of transfected cells-increasing intercellular adhesion of the transfectants-and has a clear effect on cell aggregating behavior in suspension aggregation assays. EGP40 directs sorting in mixed cell

populations, in particular, causes segregation of the transfectants from the corresponding parental cells. EGP40 expression suppresses invasive colony growth of L cells in EHS-matrigel providing tight adhesions between cells in growing colonies. EGP40 can thus be considered a new member of the intercellular adhesion molecules. In its biological behavior EGP40 resembles to some extent the molecules of the immunoglobulin superfamily of cell adhesion molecules (CAMs), although no immunoglobulin-like repeats are present in the EGP40 molecule. Certain structural similarities in general organization of the molecule exist between EGP40 and the lin-12/Notch proteins. A possible role of this adhesion molecule in formation of architecture of epithelial tissues is discussed. To reflect the function of the molecule the name Ep-CAM for EGP40 seems appropriate.

9/7/5 (Item 1 from file: 442)
DIALOG(R)File 442:AMA Journals Online
(c) 1994 American Medical Assoc. All rts. reserv.

00085740
COPYRIGHT American Medical Association 1992

Idiopathic, Progressive Mononeuropathy in Young People (ARTICLE)

ENGSTROM, JOHN W.; LAYZER, ROBERT B.; OLNEY, RICHARD K.; EDWARDS, MICHAEL B.
Archives of Neurology
January, 1993; Original: p20
LINE COUNT: 00252
0003-9942

We describe six young patients with insidiously progressive, painless weakness in the distribution of a single major lower extremity nerve. No cause could be found despite extensive evaluation, including surgical exploration. At the time of diagnosis, all patients had weakness and three patients had sensory loss. In all cases, electromyography revealed a chronic axonal mononeuropathy without conduction block or focal conduction slowing. Magnetic resonance, computed tomographic, and ultrasound imaging studies did not identify a region of nerve swelling, mass, or compression. At surgical exploration, the nerve appeared atrophic in two patients, indurated in one patient, and normal in two patients. Biopsy specimens obtained from two abnormal nerves revealed either wallerian degeneration or endoneurial fibrosis. The clinical features of these patients comprise an unusual clinical entity with no known cause or treatment. (Arch Neurol. 1993;50:)

* * USE FORMAT 9 FOR FULL TEXT OF ARTICLE * *

9/7/6 (Item 2 from file: 442)
DIALOG(R)File 442:AMA Journals Online
(c) 1994 American Medical Assoc. All rts. reserv.

00052771

Mandibular Reconstruction With a Recombinant Bone-Inducing Factor: Functional, Histologic, and Biomechanical Evaluation (Article)

Toriumi, Dean M., MD; Kotler, Howard S., MD; Luxenberg; Deborah P.;
Holtrop, Marijke E., MD, PhD; Wang, Elizabeth A., PhD
Archives of Otolaryngology-Head & Neck Surgery
1991; 117: 1101 (12)
0003-9977

Bone morphogenetic protein-2 (BMP-2) is a human recombinant bone-inducing factor that stimulates bone formation within 14 days. Twenty-six dogs underwent reconstruction of 3-cm full-thickness mandibular defects. After stabilizing the defects with stainless steel reconstruction plates, test implants composed of inactive dog bone matrix carrier and human recombinant BMP-2 were placed in defects of 12 animals (group 1). Control implants (carrier without BMP-2) were used in 10 animals (group 2), and no implants were placed in mandibular defects of four animals (group 3). Animals were killed at 3 and 6 months. The reconstructed segments were evaluated by roentgenography, analysis of functional stability, histology, histomorphometry, and analysis of biomechanical strength using three-point bend testing. In group 1, reconstruction plates were removed at 10 weeks because stiff, noncompressible mineralized bone formed across the defects, allowing the animals to chew a solid diet. The defects from groups 2 and 3 showed minimal, if any, bone formation and remained grossly unstable, prohibiting plate removal or advancement to a solid diet. Histomorphometric analysis at 6 months revealed that 68% of the group 1 implants were replaced by mineralized bone, whereas mineralized bone occupied less than 4% of the implants in groups 2 and 3. Biomechanical testing at 6 months revealed that the average bending strength of the reconstructed hemimandibles (expressed as a percentage of the contralateral hemimandible) was 27% for group 1 and 0% for group 2. The biomechanical strength of the defects reconstructed with BMP-2 increased significantly from 3 to 6 months and was related to degree of mineralization and thickness of bone bridging the defect.

* * USE FORMAT 9 FOR FULL TEXT OF ARTICLE * *

9/7/7 (Item 3 from file: 442)
DIALOG(R)File 442:AMA Journals Online
(c) 1994 American Medical Assoc. All rts. reserv.

00050814

Ocular Findings in Patients With Autosomal Dominant Retinitis Pigmentosa and a Rhodopsin Gene Defect (Pro-23-His) (Article)

Berson, Eliot L., MD; Rosner, Bernard, PhD; Sandberg, Michael A., PhD;
Dryja, Thaddeus P. MD
Archives of Ophthalmology
1991; 109: 92 (9)
0003-9950

Ocular findings are presented from 17 unrelated patients with a form of autosomal dominant retinitis pigmentosa and the same cytosine-to-adenine transversion in codon 23 of the rhodopsin gene corresponding to a substitution of histidine for proline in the 23rd amino acid of rhodopsin (designated rhodopsin, Pro-23-His). On average, these patients (mean age, 37 years) had significantly better visual acuity and larger

electroretinographic amplitudes than 131 unrelated patients (mean age, 32 years) with autosomal dominant retinitis pigmentosa without this mutation. However, these 17 patients from separate families, as well as 12 relatives with the mutation from four of these families, showed interfamilial and intrafamilial variability with respect to severity of their ocular disease, suggesting that some factor(s) other than this gene defect itself is involved in the expression of their condition. This form of retinitis pigmentosa can now be detected by testing leukocyte DNA from peripheral blood. Some mechanisms by which this mutation in the rhodopsin gene could lead to rod photoreceptor cell death are suggested.

* * USE FORMAT 9 FOR FULL TEXT OF ARTICLE * *

9/7/8 (Item 4 from file: 442)
DIALOG(R)File 442:AMA Journals Online
(c) 1994 American Medical Assoc. All rts. reserv.

00039934
Copyright (C) 1987 American Medical Association

Surgical Disease in East Africa; Presidential Address (PAPERS READ BEFORE THE 67TH ANNUAL MEETING OF THE NEW ENGLAND SURGICAL SOCIETY DIXVILLE NOTCH, NH, SEPT 26-28, 1986)

MCDERMOTT, WILLIAM V.
Archives of Surgery
April, 1987; 122: 397-402
LINE COUNT: 00411 WORD COUNT: 05683
ISSN: 0004-0010

CORPORATE SOURCE: Accepted for publication Dec 9, 1986. From the Department of Surgery, Harvard Medical School, and the New England Deaconess Hospital, Boston. Read as the Presidential Address before the 67th Annual Meeting of the New England Surgical Society, Dixville Notch, NH, Sept 27, 1986. Reprint requests to New England Deaconess Hospital, 110 Francis St, Boston, MA 02115 (Dr McDermott).

* * USE FORMAT 9 FOR FULL TEXT OF ARTICLE * *

CITED REFERENCES:

1. Burkitt D: A sarcoma involving the jaws in African children. Br Med J 1958;46: 218-224.
2. Burkitt DP: A tumor safari in East and Central Africa. Br J Cancer 1962;16:379-386.
3. Ziegler JL: Burkitt's lymphoma. N Engl J Med 1981;305: 735-745.
4. Burkitt DP: Determining the climatic limitations of a children's cancer common in Africa. Br Med J 1962;2: 1019-1023.
5. Burkitt DP: A children's cancer development dependent on climatic factors. Nature 1962;194:232-234.
6. Haddow AJ: Climatic parameters of Burkitt's lymphoma. East Afr Med J 1963;40:429-437.
7. Epstein MA, Achong BC, Barr YM: Virus particles in cultured lymphoblasts from Burkitt's lymphoma. Lancet 1964;1:702-703.

8. Evans AS, Niederman JC, McCollun JW: Seroepidemiologic studies of infectious mononucleosis with Epstein-Barr virus. *N Engl J Med* 1968;279:1121-1127.
9. Henle G, Henle W, Clifford P, et al: Antibodies to Epstein-Barr virus in Burkitt's lymphoma and control groups. *JNCI* 1969;43:1147-1157.
10. Lindahl T, Klein G, Reedman BM, et al: Relationship between Epstein-Barr virus (EBV) DNA and the EBV determined nuclear antigen (EBNA) in Burkitt's lymphoma biopsies and other lymphoproliferative malignancies. *Int J Cancer* 1974;13:764-772.
11. Olweny CLM, Atine I, Kaddu-Mukasa A, et al: Epstein-Barr virus genome studies in Burkitt's lymphomas in Uganda. *JNCI* 1977; 58:1191-1196.
12. Burkitt DP: Long-term remissions following one- and two-dose chemotherapy for African lymphoma. *Cancer* 1967;20:756-759.
13. Ziegler JL, Carbone FP, Berard CW, et al: Burkitt's tumor in the United States: Diagnosis, treatment and prognosis, in Clifford P, Linsell CA, Timms GL (eds): *Cancer in Africa*. Nairobi, Kenya, East African Publishing House, 1968, pp 239-250.
14. Kaposi M: Idiopathic multiple pigmented sarcoma of the skin. *Arch Derm Syph* 1872;4:265.
15. Taylor JF, Templeton AC, Vogel CL, et al: Kaposi's sarcoma in Uganda: A clinico-pathological study. *Int J Cancer* 1971;8:122-135.
16. Williams EH, Williams PH. Simulium and Kaposi's sarcoma. *East Afr Med J* 1966;43:208-214.
17. Rogoff MG: Kaposi's sarcoma: Age, sex and tribal incidence in Kenya, in Clifford P, Linsell CA, Timms GL (eds): *Cancer in Africa*. Nairobi, Kenya, East African Publishing House, 1968, pp 445-448.
18. Levy JA, Ziegler JL: Acquired immunodeficiency syndrome is an opportunistic infection and Kaposi's sarcoma results from secondary immune stimulation. *Lancet* 1983;2:78-81.
19. Curran JW: AIDS: Two years later. *N Engl J Med* 1983;309:609-610.
20. Alpert ME, Hutt MSR, Wogan GN, et al: Association between aflatoxin content of food and hepatoma frequency in Uganda. *Cancer* 1971;28:253-260.
21. Wogan GN, Newberne PM: Dose and response characteristics of aflatoxin B in carcinogenesis in the rat. *Cancer Res* 1967;27:2370-2374.
22. Carnaghan RBA: Hepatic tumors in ducks fed a low level of toxic groundnut meal. *Nature* 1965;208:301-311.
23. Ashley LM, Halver JE, Gardner WK Jr, et al: Crystalline aflatoxins cause trout hepatomas. *Fed Proc* 1965;24:627-630.
24. Steiner PE: Cancer of the liver and cirrhosis in Trans-Saharan Africa

and the USA. Cancer 1960;13:1085-1089.

25. Brechot C, Nalpas B, Courouce AM, et al: Evidence that hepatitis B virus has a role in liver-cell carcinoma in alcoholic liver disease. N Engl J Med 1982;306:1384-1387.
26. Wood M: Epitheliomata, in Clifford P, Linsell CA, Timms GL (eds): Cancer in Africa, Nairobi, Kenya, East African Publishing House, 1968, pp 425-426.
27. Goldin BR, Adlercreutz H, Gorbach SL, et al: Estrogen excretion patterns and plasma levels in vegetarian and omnivorous women. N Engl J Med 1982;307:1542-1546.
28. Hutt MSR, Burkitt DP: Geographical distribution of cancer in East Africa: A new clinicopathological approach. Br Med J 1965;2: 719-722.
29. McDermott WV Jr, Adams RD: Episodic stupor associated with Eck fistula in human with particular reference to metabolism of ammonia. J Clin Invest 1954;1:1-9.
30. Hubbard TB: Carcinoma of the head of the pancreas: Resection of the portal vein and portacaval shunt. Ann Surg 1958;147:935-944.
31. Warren WD, Rudman D, Millikan W, et al: The metabolic basis of portasystemic encephalopathy and the effect of selective vs. nonselective shunts. Ann Surg 1958;147:935-943.
32. DaSilva LC, Strauss E, Gayotto LC, et al: A randomized trial for the study of elective surgical treatment of portal hypertension in mansonic schistosomiasis. Ann Surg 1986;204:148-153.

9/7/9 (Item 5 from file: 442)
DIALOG(R)File 442:AMA Journals Online
(c) 1994 American Medical Assoc. All rts. reserv.

00039528
Copyright (C) 1986 American Medical Association

The Boston Center for Liver Transplantation (BCLT); Initial Experience of a New Surgical Consortium (PAPERS READ BEFORE THE 66TH ANNUAL MEETING OF THE NEW ENGLAND SURGICAL SOCIETY, DIXVILLE NOTCH, NH, OCT 11-13, 1985)

JENKINS, ROGER L.
Archives of Surgery
April, 1986; 121: 424-430
LINE COUNT: 00310 WORD COUNT: 04290
ISSN: 0004-0010

CORPORATE SOURCE: Accepted for publication Jan 7, 1986. From the Department of Surgery, Harvard Medical School and New England Deaconess Hospital, Boston. Read before the 66th Annual Meeting of the New England Surgical Society, Dixville Notch, NH, Oct 12, 1985. Reprint requests to Department of Surgery, New England Deaconess Hospital, 185 Pilgrim Rd, Boston, MA 02215 (Dr Jenkins). Clinical membership of the Boston Center

for Liver Transplantation is as follows: Joseph p. Vacanti, MD, Robert C. Shamberger, MD, Craig W. Lillihai, MD, Raphael H. Levey, MD, and David H. Perlmutter, MD (Children's Hospital); Benedict A. Cosimi, MD, Francis L. Delmonico, MD, Paul S. Russell, MD, Patricia K. Donahoe, MD, Jules L. Deinstag, MD, and Ronald E. Kleinman, MD (Massachusetts General Hospital); Roger L. Jenkins, MD, Peter N. Benotti, MD, Albert Bothe, Jr, MD, Richard J. Rohrer, MD, William V. McDermott, Jr, MD, Anthony P. Monaco, MD, Thomas E. Dodson, MD, and Charles Trey, MD (New England Deaconess Hospital); Sang I. Cho, MD, Randolph B. Reinhold, MD, Alan W. Hackford, MD, Lucian L. Leape, MD, Burton H. Harris, MD, William C. Mackey, MD, Marshall M. Kaplan, MD, and Richard J. Grand, MD (New England Medical Center).

ABSTRACT: Improved survival following liver transplanatation has led to a rapid increase in the number of centers providing this expensive and demanding therapy. In January 1984, four Boston hospitals launched a cooperative program known as the Boston Center for Liver Transplantation (BCLT). From January 1984 through July 1985, 47 liver transplantations were performed in 41 patients ranging in age from 8 months to 60 years. Donor organs were retrieved from 22 states within a 2,500-mile radius. Thirty-five of the 47 procedures were performed by teams consisting of surgeons from at least two BCLT member hospitals. Twelve-month actuarial survival was 54.1% without significant institutional variability. The BCLT has developed into a unique transplant consortium capable of sharing manpower, equipment, and organs without sacrificing quality of care or disrupting preexisting medical services.

* * USE FORMAT 9 FOR FULL TEXT OF ARTICLE * *

CITED REFERENCES:

Discussion

FRANCIS D. MOORE, MD, Boston: The liver consortium established in Boston has very little to be modest about and a great deal to be proud of! I think that their work is a great achievement, and surely one of its most interesting accomplishments is on the organizational/financial side. The efforts of Paul Russell, MD, and myself to have a cardiac transplantation consortium in the Boston hospitals has just within the last few days been crowned with assent because of the success of the BCLT.

The results of Dr Jenkins' group show 54% survival at one year. This figure will improve. And yet they are light-years ahead of our early efforts of almost 30 years ago. Since that was a New England surgical story, a brief account is fitting for a meeting of this Society; Dr Jenkins has kindly asked me if I would tell that story, however briefly.

In 1957, three years after the twin kidneys and five years before Joe Murray, MD, and Roy Calne, MD, introduced imuran, we undertook experimental liver transplantation in the dog with the scientific objective of determining the immunologic effect of an antigen overload. The liver was the largest organ you could transplant, but there was evidence that this procedure might produce immunologic paralysis. Our team was an interesting one, consisting of two New England surgeons, Brownie Wheeler, MD (now professor and Chief of the Department of Surgery at the University of Massachusetts), and Alan Birch, MD (now professor and Chief of the Department of Surgery at Southern Illinois University), and a surgeon from England, Dr Calne (now Chairman and Chief of the Department of Surgery at Cambridge). The operation that we worked out involved two low-pressure venovenous shunts to decompress the portal and systemic circuits when they were cross-clamped; we just assumed that this procedure would always be

necessary and we did not make any great fuss about it. The animal showed satisfactory surgical recovery, and when immunosuppressive chemotherapy was developed a few years later we could abate rejection. But that is not, and still is not, the only problem in liver transplantation. In fact, Dr Jenkins only had two rejection deaths.

About eight years after our first animal experiments, and with immunosuppressive chemotherapy well established in our department, Dr Birch and I operated on four patients, an experience we have never published in detail. The patients all suffered from terminal liver disease. There were two adults, of whom one was a male, basketball-playing, high school student with multicentric hepatoma, and two children with very extensive and hopeless biliary atresia. The patient who survived the longest lived for only eight weeks. Right or wrong, we decided that the time to operate had not yet come.

The canine operation we performed was essentially the same as that done now. The hepatic artery in the dog has extensive branching and is a nuisance; sometimes we anastomosed it end-to-side to the renal artery. I would just like to agree with Sir Rodney Smith that radical approaches to cancer of the upper abdomen usually do not pay off. It may interest you to know that all of the large liver transplant series have reported a few very good results in that particular disease.

Tom Starzl, MD, and I knew of our mutual interest in this field. We kept a close cooperative relationship throughout the years. His experience now sets the world standard. Dr Calne was working with Dr Murray on kidney transplantation, but he went back to Cambridge and rapidly developed an extensive experience in liver transplantation.

I would like to emphasize that it was on the basis of the work of Drs Calne and Starzl, and not our cautious efforts, that the later experience of Dr Jenkins and William McDermott, MD, and their group has been built. All that we can state is that we were early workers in the field and maybe gave a little strength of conviction and determination to two younger men, Drs Starzl and Calne, who went ahead and did the job so beautifully well.

Of the organ and tissue transplantations now performed, I believe that the liver is the most technically challenging and will always have a lower long-term rate of survival than that of organs like the kidney and heart, which have a simple blood supply and no bile to drain off. The low pressure circuits in the liver are what cause the trouble. It takes a master surgeon to perform this operation and to do it well, and Dr Jenkins has shown us all that we have such a liver transplanter now in New England. I am very proud of his work and very pleased to be asked to discuss it 30 years after we worked at the problem.

DR JENKINS: Thank you very much, Dr Moore. I do want to emphasize that this is not an individual effort and really has been a team effort from its inception. There are really a lot of people to thank, including Dr Moore, Dr McDermott, Dr Russell, and all the people who made this consortium work at the administrative level, as well as in the operating room. We also need to thank all of the people in the operating room and on the wards that helped to take care of these patients. They are many times the forgotten people.

9/7/10 (Item 6 from file: 442)
DIALOG(R)File 442:AMA Journals Online
(c) 1994 American Medical Assoc. All rts. reserv.

00035019
Copyright (C) 1984 American Medical Association

Antibody-Dependent Cellular Cytotoxicity: Relation to Stage and Disease
Course in North American Patients With Nasopharyngeal Carcinoma (PAPERS
READ BEFORE THE AMERICAN SOCIETY FOR HEAD AND NECK SURGERY MEETING)

NEEL, H. BRYAN, III; PEARSON, GARY R.; TAYLOR, WILLIAM F.
Archives of Otolaryngology
November, 1984; 110: 742-747
LINE COUNT: 00281 WORD COUNT: 03878
ISSN: 0003-9977

CORPORATE SOURCE: Accepted for publication June 18, 1984. From the
Departments of Otorhinolaryngology (Dr Neel), Immunology (Dr Pearson), and
Medical Statistics and Epidemiology (Dr Taylor), Mayo Clinic and Mayo
Foundation, Rochester, Minn. Read before the American Society for Head and
Neck Surgery, Palm Beach, Fla, May 10, 1984. Reprint requests to
Department of Otorhinolaryngology, Mayo Clinic, 200 First St SW, Rochester,
MN 55905 (Dr Neel). This investigation was supported in part by contract
CP91006 from the Division of Cancer Cause and Prevention, National Cancer
Institute, Bethesda, Md, and the St Jude Fund for Research and Education in
Otolaryngology. Table 2 is reproduced with permission from the
International Agency for Research on Cancer.

ABSTRACT: A prospective study of North American patients, mostly white,
with different histopathologic types of nasopharyngeal carcinoma was
initiated approximately five years ago. Several anti-Epstein-Barr virus
(EBV) serologic tests are being evaluated; one is the antibody-dependent
cellular cytotoxicity (ADCC) assay, which measures antibodies to an
EBV-induced membrane antigen component. A low ADCC titer at diagnosis
reflects a poor prognosis, and the determination of antibody titers by this
assay identifies patients in whom recurrent disease is likely to develop
after conventional radiation therapy for World Health Organization types 2
and 3 carcinomas. Of the patients who had high ADCC titers at diagnosis,
80% survived three years or longer, whereas 50% of the patients with low
titers survived three years, and only 35% survived five years. High and low
ADCC titers were seen in all stages (except in Ho stage V), and the
distribution of patients by high and low ADCC titers was similar in each of
the stage groupings. We conclude that the ADCC titer at the time of
diagnosis is generally predictive of the prognosis. Clinical staging is the
traditional approach for predicting prognosis, but determination of the
ADCC titer can be used to segregate patients within the stage groups into
those with "good" and "poor" prognoses. Serologic testing may eventually
become one of the methods for staging patients with WHO types 2 and 3
nasopharyngeal carcinoma. (Arch Otolaryngol 1984; 110: 742-747)

* * USE FORMAT 9 FOR FULL TEXT OF ARTICLE * *

CITED REFERENCES:

1. Henle G, Henle W, Klein G: Demonstration of two distinct components in
the early antigen complex of Epstein-Barr virus-infected cells. Int J
Cancer 1971; 8: 272-282.

2. Henle W, Ho JHC, Henle G, et al: Nasopharyngeal carcinoma: Significance of changes in Epstein-Barr virus-related antibody patterns following therapy. *Int J Cancer* 1977; 20: 663-672.
3. Ho JHC: Stage classification of nasopharyngeal carcinoma: A review, in de-The G, Ito Y (eds): *Nasopharyngeal Carcinoma: Etiology and Control*. Lyons, France, International Agency for Research on Cancer, 1978, pp 99-113.
4. Ho HC, Ng MH, Kwan HC: Factors affecting serum IgA antibody to Epstein-Barr viral capsid antigens in nasopharyngeal carcinoma. *Br J Cancer* 1978; 37: 356-362.
5. Naegele RF, Champion J, Murphy S, et al: Nasopharyngeal carcinoma in American children: Epstein-Barr virus-specific antibody titers and prognosis. *Int J Cancer* 1982; 29: 209-212.
6. Neel HB III, Pearson GR, Weiland LH, et al: Anti-EBV serologic tests for nasopharyngeal carcinoma. *Laryngoscope* 1980; 90: 1981-1990.
7. Pearson GR: EBV immunology, in Klein G (ed): *Viral Oncology*. New York, Raven Press, 1980, pp 739-767.
8. Pearson GR, Johansson B, Klein G: Antibody-dependent cellular cytotoxicity against Epstein-Barr virus-associated antigens in African patients with nasopharyngeal carcinoma. *Int J Cancer* 1978; 22: 120-125.
9. Neel HB III, Pearson GR, Weiland LH, et al: Application of Epstein-Barr virus serology to the diagnosis and staging of North American patients with nasopharyngeal carcinoma. *Otolaryngol Head Neck Surg* 1983; 91 (June): 255-262.
10. Neel HB III, Pearson GR, Weiland LH, et al: Immunologic detection of occult primary cancer of the head and neck. *Otolaryngol Head Neck Surg* 1981; 89: 230-234.
11. Mathew GD, Qualtiere LF, Neel HB III, et al: IgA antibody, antibody-dependent cellular cytotoxicity and prognosis in patients with nasopharyngeal carcinoma. *Int J Cancer* 1981; 27: 175-180.
12. Pearson GR, Orr TW: Antibody-dependent lymphocyte cytotoxicity against cells expressing Epstein-Barr virus antigens. *JNCI* 1976; 56: 485-488.
13. Pearson GR, Qualtiere LF, Klein G, et al: Epstein-Barr virus-specific antibody-dependent cellular cytotoxicity in patients with Burkitt's lymphoma. *Int J Cancer* 1979; 24: 402-406.
14. Qualtiere LF, Chase R, Pearson GR: Purification and biologic characterization of a major Epstein-Barr virus-induced membrane glycoprotein. *J Immunol* 1982; 129: 814-818.
15. American Joint Committee for Cancer Staging and End-Results Reporting: *Manual for Staging of Cancer* 1977. Chicago, American Joint Committee, 1977.
16. Neel HB III, Taylor WF, Pearson GR, et al: Clinical staging of

- patients with nasopharyngeal carcinoma, in Grundmann, E, et al (eds): Cancer Campaign. Stuttgart, West Germany, Gustav Fischer Verlag, 1981, vol 5, pp 73-79.
17. Shanmugaratnam K, Sobin L: Histological typing of upper respiratory tract tumors, in International Histological Classification of Tumors. Geneva, World Health Organization, 1978, vol 19, pp 32-33.
 18. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
 19. Scanlon FW, Rhodes RE Jr, Woolner LB, et al: Cancer of the nasopharynx: 142 patients treated in the 11-year period 1950-1960. AJR 1967; 99: 313-325.
 20. Applebaum EL, Mantravadi P, Haas R: Lymphoepithelioma of the nasopharynx. Laryngoscope 1982; 92: 510-514.
 21. Dickson RI: Nasopharyngeal carcinoma: An evaluation of 209 patients. Laryngoscope 1981; 91: 333-354.
 22. Neel HB III, Taylor WF: Clinical presentation and diagnosis of nasopharyngeal carcinoma: Current status, in Prasad U, Ablashi DV, Levine PH, et al (eds): Proceedings of the Fourth International Symposium on Nasopharyngeal Carcinoma. Kuala Lumpur, Malaysia, University of Malaya Press, 1983, pp 1-10.
 23. Mathew GD, Qualtiere LF, Neel HB III, et al: Immunoglobulin A antibody to Epstein-Barr viral antigens and prognosis in nasopharyngeal carcinoma. Otolaryngol Head Neck Surg 1980; 88: 52-57.
 24. Bertram G, Pearson GR, Faggioni A, et al: A long-term study of EBV and non-EBV related tests and their correlation with the clinical course of nasopharyngeal carcinoma, in Prasad U, Ablashi DV, Levine PH, et al (eds): Proceedings of the Fourth International Symposium on Nasopharyngeal Carcinoma. Kuala Lumpur, Malaysia, University of Malaya Press, 1983, pp 115-124.
 25. Sundar SK, Ablashi DV, Kamaraju LS, et al: Sera from patients with undifferentiated nasopharyngeal carcinoma contain a factor which abrogates specific Epstein-Barr virus antigen-induced lymphocyte response. Int J Cancer 1982; 29: 407-412.

9/7/11 (Item 7 from file: 442)
DIALOG(R)File 442:AMA Journals Online
(c) 1994 American Medical Assoc. All rts. reserv.

00027835
Copyright (C) 1983 American Medical Association

Sequestered Substernal Goiter (CLINICAL OBSERVATIONS)

LADENSON, PAUL W.; VINEYARD, GORDON C.; PINKUS, GERALDINE S.; RIDGWAY, E.
CHESTER
Archives of Internal Medicine

May, 1983: 143: 1015-1017

LINE COUNT: 00090

WORD COUNT: 01251

ISSN: 0003-9926

CORPORATE SOURCE: Accepted for publication Nov 1, 1982. From the Thyroid Unit (Drs Ladenson and Ridgway), Department of Medicine, Massachusetts General Hospital, and the Departments of Surgery (Dr Vineyard) and Pathology (Dr Pinkus), Brigham and Women's Hospital, Boston. Reprint requests to Thyroid Unit, Massachusetts General Hospital, Boston, MA 02114 (Dr Ladenson).

ABSTRACT: A young woman with a normally located and only subtly nodular thyroid gland in the neck was found to have a clinically distinct and radioisotopically "cold" anterior mediastinal mass, which proved to be a benign colloid adenoma. While this constellation of findings usually suggests the presence of a nonthyroidal neoplasm, eg, lymphoma, thymoma, or teratoma, our case illustrates that sequestered benign nodular goiter should also be considered in the differential diagnosis. Clinical clues, such as a nodular thyroid gland, movement of the mass with deglutition, and a family history of nodular goiter, should suggest this possibility. A characteristic computed tomographic appearance may also prove useful in recognition of this rare disorder. (Arch Intern Med 1983;143:1015-1017)

* * USE FORMAT 9 FOR FULL TEXT OF ARTICLE * *

CITED REFERENCES:

1. Rogers WM: Anomalous development of the thyroid, in Werner SC, Ingbar SH (eds): The Thyroid: A Fundamental and Clinical Text, ed 4. Hagerstown, Md, Harper & Row, 1978, pp 416-420.
2. Ellis FH, Good CA: Intrathoracic goiter. Ann Surg 1952;135:79-90.
3. Irwin RS, Braman SS, Arvanitidis AN, et al: ^{131}I thyroid scanning in preoperative diagnosis of mediastinal goiter. Ann Intern Med 1978;89:73-74.
4. Sisson JC, Schmidt RW, Beierwaltes WH: Sequestered nodular goiter. N Engl J Med 1964;270: 927-932.
5. Rives JD: Mediastinal aberrant goiter. Ann Surg 1947;126:797-810.
6. Dundas F: Intrathoracic aberrant goiter. Acta Clin Scand 1964;128: 729-736.
7. Kaplan WD, Watnick M, Holman BL: Scintigraphic identification of complete thoracic goiter with normal-appearing cervical thyroid: A case report. J Can Assoc Radiol 1974;25: 193-195.
8. Pemberton JJ, Mationner HR: Retrofascial intrathoracic goiter: Congenital hemolytic icterus: Retroperitoneal cyst. Surg Clin North Am 1931;11:787-799.
9. Maloof F, Wang CA, Vickery AL Jr: Nontoxic goiter: Diffuse or nodular. Med Clin North Am 1975;59:1221-1232.

00112941

Copyright 1994 by the Massachusetts Medical Society

Treatment Of Refractory Disseminated Nontuberculous Mycobacterial Infection
With Interferon Gamma A Preliminary Report (Original Articles)

Holland, Steven M.; Eisenstein, Eli M.; Kuhns, Douglas B.; Turner,
Maria L.; Fleisher, Thomas A.; Strober, Warren; Gallin, John I.

The New England Journal of Medicine

May 12, 1994; 330 (19),pp 1348-1355

LINE COUNT: 00485

WORD COUNT: 06694

ISSN: 0028-4793

CORPORATE SOURCE: From the Laboratories of Host Defenses (S.M.H., J.I.G.)
and Clinical Investigation (E.M.E., W.S.), National Institute of Allergy
and Infectious Diseases; the Dermatology Branch, National Cancer Institute
(M.L.T.); and Warren Grant Magnuson Clinical Center (T.A.F.) -- all at the
National Institutes of Health, Bethesda, Md.; and PRI/DynCorp, Inc.,
Frederick, Md. (D.B.K.). Address reprint requests to Dr. Holland at the
Laboratory of Host Defenses, National Institute of Allergy and Infectious
Diseases, National Institutes of Health, Bldg. 10, Rm. 11N103, 9000
Rockville Pike, Bethesda, MD 20892.

Abstract

Background. Studies conducted in vitro and in animals suggest that
cytokine signals to monocytes or macrophages by interferon gamma are
important in the containment and clearance of disseminated nontuberculous
mycobacterial infections.

Methods. We studied seven patients with refractory disseminated
nontuberculous mycobacterial infections who were not infected with the
human immunodeficiency virus. Three patients were from a family predisposed
to the development of Mycobacterium avium complex infections; four patients
had idiopathic CD4+ T-lymphocytopenia. Their infections were culture- or
biopsy-proved, involved at least two organ systems, and had been treated
with the maximal tolerated medical therapy. Cellular proliferation,
cytokine production, and phagocyte function were assessed in
peripheral-blood cells. Interferon gamma was administered subcutaneously
two or three times weekly in a dose of 25 to 50 microg per square meter of
body-surface area in addition to antimycobacterial medications. Clinical
effects were monitored by cultures, biopsies, radiographs, and in one
patient a change in the need for paracentesis.

Results. In response to phytohemagglutinin, the production of
interferon gamma by mononuclear cells from the patients was lower than in
normal subjects ($P < 0.001$), whereas stimulation with ionomycin and phorbol
myristate acetate led to normal production of interferon gamma in the
patients. Within eight weeks of the start of interferon gamma therapy, all
seven patients had marked clinical improvement, with abatement of fever,
clearing of many lesions and quiescence of others, radiographic
improvement, and a reduction in the need for paracentesis.

Conclusions. Interferon gamma in combination with conventional therapy
may be effective for some cases of refractory disseminated nontuberculous
mycobacterial infection. (N Engl J Med 1994;330:1348-55.)

CITED REFERENCES

1. Stead WW. Genetics and resistance to tuberculosis: could resistance be enhanced by genetic engineering? *Ann Intern Med* 1992;116:937-41.
2. Nightingale SD, Byrd LT, Southern PM, Jockusch JD, Cal SX, Wynne BA. Incidence of *Mycobacterium avium-intracellulare* complex bacteremia in human immunodeficiency virus-positive patients. *J Infect Dis* 1992;165:1082-5.
3. Smith DK, Neal JJ, Holmberg SD, Centers for Disease Control Idiopathic CD4+ T-Lymphocytopenia Task Force. Unexplained opportunistic infections and CD4+ T-lymphocytopenia without HIV infection: an investigation of cases in the United States. *N Engl J Med* 1993;328:373-9.
4. Ho DD, Cao Y, Zhu T, et al. Idiopathic CD4+ T-lymphocytopenia -- immunodeficiency without evidence of HIV infection. *N Engl J Med* 1993;328:380-5.
5. Spira TJ, Jones BM, Nicholson JKA, et al. Idiopathic CD4+ T-lymphocytopenia -- an analysis of five patients with unexplained opportunistic infections. *N Engl J Med* 1993;328:386-92.
6. Duncan RA, von Reyn CF, Alliegro GM, Toossi Z, Sugar AM, Levitz SM. Idiopathic CD4+ T-lymphocytopenia -- four patients with opportunistic infections and no evidence of HIV infection. *N Engl J Med* 1993;328:393-8.
7. Fischer A, Virelizier JL, Griscelli C, Durandy A, Nezelof C, Trung FH. Defective monocyte functions in a child with fatal disseminated BCG infection. *Clin Immunol Immunopathol* 1980;17:296-306.
8. Uchiyama N, Greene GR, Warren BJ, Morozumi PA, Spear GS, Galant SP. Possible monocyte killing defect in familial atypical mycobacteriosis. *J Pediatr* 1981;98:785-8.
9. DiBella NJ, Buchanan BD, Koontz CH. Disseminated atypical tuberculosis antedating the clinical onset of neoplasia. *Cancer* 1977;40:1276-9.
10. Gallo JH, Young GAR, Forrest PR, Vincent PC, Jennis F. Disseminated atypical mycobacterial infection in hairy cell leukemia. *Pathology* 1983;15:241-5.
11. Horsburgh CR Jr, Mason UG III, Farhi DC, Iseman MD. Disseminated infection with *Mycobacterium avium-intracellulare*: a report of 13 cases and a review of the literature. *Medicine (Baltimore)* 1985;64:36-48.
12. Stone AB, Schelonka RL, Drehner DM, McMahon DF, Ascher DP. Disseminated *Mycobacterium avium* complex in non-human immunodeficiency virus-infected pediatric patients. *Pediatr Infect Dis J* 1992;11:960-4.
13. Nathan CF, Murray HW, Wiebe ME, Rubin BY. Identification of interferon-gamma as the lymphokine that activates human macrophage oxidative metabolism and antimicrobial activity. *J Exp Med* 1983;158:670-89.
14. The International Chronic Granulomatous Disease Cooperative Study Group. A controlled trial of interferon gamma to prevent infection in chronic granulomatous disease. *N Engl J Med* 1991;324:509-16.
15. Nathan CF, Kaplan G, Levis WR, et al. Local and systemic effects of intradermal recombinant interferon-gamma in patients with lepromatous leprosy. *N Engl J Med* 1986;315:6-15.
16. Badaro R, Falcoff E, Badaro FS, et al. Treatment of visceral leishmaniasis with pentavalent antimony and interferon gamma. *N Engl J Med* 1990;322:16-21.
17. Cregan P, Yajko DM, Ng VL, et al. Use of DNA probes to detect *Mycobacterium intracellulare* and ''X'' mycobacteria among clinical isolates of *Mycobacterium avium* complex. *J Infect Dis* 1992;166:191-4.
18. Viljanen MK, Olkkonen L, Katila M-L. Conventional identification characteristics, mycolate and fatty acid composition, and clinical significance of MAIX AccuProbe-positive isolates of *Mycobacterium avium*

- complex. J Clin Microbiol 1993;31:1376-8.
19. Ewel CH, Kuhns DB, Keller JR, Reading JP, Kopp WC. Clinical monitoring of immune and hematopoietic function. In: Rose NR, de Macario EC, Fahey JL, Friedman H, Penn GM, eds. Manual of clinical laboratory immunology. 4th ed. Washington, D.C.: American Society for Microbiology, 1992:923-32.
 20. Eisenstein EM, Jaffe JS, Strober W. Reduced interleukin-2 (IL-2) production in common variable immunodeficiency is due to a primary abnormality of CD4+ T cell differentiation. J Clin Immunol 1993;13:247-58.
 21. Nedorost ST, Elewski B, Tomford JW, Camisa C. Rosacea-like lesions due to familial Mycobacterium avium-intracellulare infection. Int J Dermatol 1991;30:491-7.
 22. Schwinzer R, Wonigeit K. Genetically determined lack of CD45R(sup -) T cells in healthy individuals: evidence for a regulatory polymorphism of CD45R antigen expression. J Exp Med 1990;171:1803-8.
 23. Cohen JI. Epstein-Barr virus lymphoproliferative disease associated with acquired immunodeficiency. Medicine (Baltimore) 1991;70:137-60.
 24. Shields ED, Russell DA, Pericak-Vance MA. Genetic epidemiology of the susceptibility to leprosy. J Clin Invest 1987;79:1139-43.
 25. Abel L, Demenais F. Detection of major genes for susceptibility to leprosy and its subtypes in a Caribbean island: Desirade island. Am J Hum Genet 1988;42:256-66.
 26. Comstock GW. Tuberculosis in twins: a re-analysis of the Frohit survey. Am Rev Respir Dis 1978;117:621-4.
 27. Engbaek HC. Three cases in the same family of fatal infection with M. avium. Acta Tuberc Scand 1964;45:105-17.
 28. Doleckova V, Viklicky J, Sula L, Kubecova D. Fatal generalized BCG histiocytosis. Tubercle 1977;58:13-8.
 29. Lincoln EM, Gilbert LA. Disease in children due to mycobacteria other than Mycobacterium tuberculosis. Am Rev Respir Dis 1972;105:683-714.
 30. Schonell ME, Crofton JW, Stuart AE, Wallace A. Disseminated infection with Mycobacterium avium. I. Clinical features, treatment and pathology. Tubercle 1968;49:12-30.
 31. Sechler JMG, Malech HL, White CJ, Gallin JI. Recombinant human interferon-gamma reconstitutes defective phagocyte function in patients with chronic granulomatous disease of childhood. Proc Natl Acad Sci U S A 1988;85:4874-8.
 32. Ezekowitz RAB, Orkin SH, Newburger PE. Recombinant interferon gamma augments phagocyte superoxide production and X-linked chronic granulomatous disease gene expression in X-linked variant chronic granulomatous disease. J Clin Invest 1987;80:1009-16.
 33. Kaplan G, Mathur NK, Job CK, Nath I, Cohn ZA. Effect of multiple interferon gamma injections on the disposal of Mycobacterium leprae. Proc Natl Acad Sci U S A 1989;86:8073-7.
 34. Sampaio EP, Moreira AL, Sarno EN, Malta AM, Kaplan G. Prolonged treatment with recombinant interferon gamma induces erythema nodosum leprosum in lepromatous leprosy patients. J Exp Med 1992;175:1729-37.
 35. Badaro R, Johnson WD Jr. The role of interferon-gamma in the treatment of visceral and diffuse cutaneous leishmaniasis. J Infect Dis 1993;167:Suppl 1: S13-S17.

* * USE FORMAT 9 FOR FULL TEXT OF ARTICLE * *

00109544

Copyright 1992 by the Massachusetts Medical Society

Weekly Clinicopathological Exercises: Case 1-1992: A 34-Year-Old Woman With
Dyspnea And Multiple Small Cystic Areas In The Lungs (Case Records of the
Massachusetts General Hospital)

Scully, Robert E.; Mark, Eugene, J.; McNeely, William F.; McNeely,
Betty U.

The New England Journal of Medicine

Jan 2, 1992; 326 (1),pp 44-54

LINE COUNT: 00811

WORD COUNT: 11200

ISSN: 0028-4793

CITED REFERENCES

1. Lander P, Palayew MJ. Infectious mononucleosis -- a review of chest roentgenographic manifestations. J Can Assoc Radiol 1974;25:303-6.
2. Klemola E, Stenstrom R, von Essen R. Pneumonia as a clinical manifestation of cytomegalovirus infection in previously healthy adults. Scand J Infect Dis 1972;4:7-10.
3. Kean BH. Clinical toxoplasmosis -- 50 years. Trans R Soc Trop Med Hyg 1972;66:549-71.
4. Remington JS. Toxoplasmosis in the adult. Bull N Y Acad Med 1974;50:211-27.
5. McCabe RE, Brooks RG, Dorfman RF, Remington JS. Clinical spectrum in 107 cases of toxoplasmic lymphadenopathy. Rev Infect Dis 1987;9:754-74.
6. Hilleman MR, Werner JH. Recovery of new agents from patients with acute respiratory illness. Proc Soc Exp Biol Med 1954;85:183-8.
7. Tindall B, Barker S, Donovan B, et al Characterization of the acute clinical illness associated with human immunodeficiency virus infection. Arch Intern Med 1988;148:945-9.
8. Rustin MHA, Ridley CM, Smith MD, Kelsey MC, Parker N. The acute exanthem associated with seroconversion to human T-cell lymphotropic virus III in a homosexual man. J Infect 1986;12:161-3.
9. Rich S, Levitsky S, Brundage BH. Pulmonary hypertension from chronic pulmonary thromboembolism. Ann Intern Med 1988;108:425-34.
10. Rich S. Primary pulmonary hypertension. Prog Cardiovasc Dis 1988;31:205-38.
11. Rich S, Pietra GG, Kieras K, Hart K, Brundage BH. Primary pulmonary hypertension: radiographic and scintigraphic patterns of histologic subtypes. Ann Intern Med 1986;105:499-502.
12. Weinberger SE, Johnson TS, Weiss ST. Use and interpretation of the single-breath diffusing capacity. Chest 1980;78:483-8.
13. Levine BW, Talamo RC, Shannon DC, Kazemi H. Alteration in distribution of pulmonary blood flow: an early manifestation of alpha(sub 1)-antitrypsin deficiency. Ann Intern Med 1970;73:397-401.
14. Niewoehner DE, Kleinerman J, Rice DB. Pathologic changes in the peripheral airways of young cigarette smokers. N Engl J Med 1974;291:755-8.
15. Myers JL, Veal CF Jr, Shin MS, Katzenstein AL. Respiratory bronchiolitis causing interstitial lung disease: a clinicopathologic study of six cases. Am Rev Respir Dis 1987;135:880-4.
16. Yousem SA, Colby TV, Gaensler EA. Respiratory bronchiolitis-associated

- interstitial lung disease and its relationship to desquamative interstitial pneumonia. Mayo Clin Proc 1989;64:1373-80.
17. Epler GR, McLoud TC, Gaensler EA, Mikus JP, Carrington CB. Normal chest roentgenograms in chronic diffuse infiltrative lung disease. N Engl J Med 1978;298:934-9.
 18. Fulmer JD, Roberts WC, von Gal ER, Crystal RG. Small airways in idiopathic pulmonary fibrosis: comparison of morphologic and physiologic observations. J Clin Invest 1977;60:595-610.
 19. Taylor JR, Ryu J, Colby TV, Raffin TA. Lymphangiomyomatosis: clinical course in 32 patients. N Engl J Med 1990;323:1254-60.
 20. Carrington CB, Cugell DW, Gaensler EA, et al Lymphangiomyomatosis: physiologic-pathologic-radiologic correlations. Am Rev Respir Dis 1977;116:977-95.
 21. Kawahara Y, Taniguchi T, Kadou T, et al Elevated pulmonary arterial pressure in pulmonary lymphangiomyomatosis. Jpn J Med 1989;28:520-2.
 22. Muller NL, Ostrow DN. High-resolution computed tomography of chronic interstitial lung disease. Clin Chest Med 1991;12:97-114.
 23. Muller NL, Miller RR. Computed tomography of chronic diffuse infiltrative lung disease. Am Rev Respir Dis 1990;142:1206-15, 1440-8.
 24. Klein J, Gamsu G. High resolution computed tomography of diffuse lung disease. Invest Radiol 1989;24:805-12.
 25. Swensen SJ, Aughenbaugh GL, Brown LR. High-resolution computed tomography of the lung. Mayo Clin Proc 1989;64:1284-94.
 26. Bergin CJ, Coblentz CL, Chiles C, Bell DY, Castellino RA. Chronic lung diseases: specific diagnosis by using CT. AJR Am J Roentgenol 1989;152:1183-8.
 27. Lenoir S, Grenier P, Brauner MW, et al Pulmonary lymphangiomyomatosis and tuberous sclerosis: comparison of radiographic and thin-section CT findings. Radiology 1990;175:329-34.
 28. Muller NL, Chiles C, Kullnig P. Pulmonary lymphangiomyomatosis: correlation of CT with radiographic and functional findings. Radiology 1990; 335-9.
 29. Rappaport DC, Weisbrod GL, Herman SJ, Chamberlain DW. Pulmonary lymphangiomyomatosis: high resolution CT findings in four cases. AJR Am J Roentgenol 1989;152:961-4.
 30. Sherrier RH, Chiles C, Roggli V. Pulmonary lymphangiomyomatosis: CT findings. AJR Am J Roentgenol 1989;153:937-40.
 31. Valensi QJ. Pulmonary lymphangiomyoma, a probable forme fruste of tuberous sclerosis. Am Rev Respir Dis 1973;108:1411-5.
 32. Eliasson AH, Phillips YY, Tenholder MF. Treatment of lymphangiomyomatosis: a meta-analysis. Chest 1989;196:1352-5.
 33. McCarty KS Jr, Mossler JA, McLelland R, Sieker HD. Pulmonary lymphangiomyomatosis responsive to progesterone. N Engl J Med 1980;303:1461-5.
 34. Corrin B, Liebow AA, Friedman PJ. Pulmonary lymphangiomyomatosis: a review. Am J Pathol 1975;79:348-82.
 35. Wall CP, Gaensler EA, Carrington CB, Hayes JA. Comparison of transbronchial and open biopsies in chronic infiltrative lung diseases. Am Rev Respir Dis 1981;123:280-5.
 36. Hammar S. Langerhans cells. Pathol Annu 1988;23:293-328.
 37. Basset F, Soler P, Wyllie L, Mazin F, Turiaf J. Langerhans cells and lung interstitium. Ann N Y Acad Sci 1976;278:599-611.
 38. Webber D, Tron V, Askin F, Chung A. S-100 staining in the diagnosis of eosinophilic granuloma of lung. Am J Clin Pathol 1985;84:447-53.
 39. Hammar S, Bockus D, Remington F, Bartha M. The widespread distribution of Langerhans cells in pathologic tissues: an ultrastructural and

- immunohistochemical study. Hum Pathol 1986;17:894-905.
40. Basset F, Soler P, Wyllie L, et al Langerhans cells in a bronchiolar-alveolar tumour of lung. Virchows Arch Pathol Anat] 1974;362:315-30.
 41. Nakajima T, Kodama T, Tsumuraya M, Shimosato Y, Kameya T. S-100 protein-positive Langerhans cells in various human lung cancers, especially in peripheral adenocarcinomas. Virchows Arch A] 1985;407:177-89.
 42. Ide F, Iwase T, Saito I, Umemura S, Nakajima T. Immunohistochemical and ultrastructural analysis of the proliferating cells in histiocytosis X. Cancer 1984;53:917-21.
 43. Soler P, Chollet S, Jacque C, Fukuda Y, Ferrans VJ, Basset F. Immunocytochemical characterization of pulmonary histiocytosis X cells in lung biopsies. Am J Pathol 1985;118:439-51.
 44. Flint A, Lloyd RV, Colby TV, Wilson BW. Pulmonary histiocytosis X: immunoperoxidase staining for HLA-DR antigen and S100 protein. Arch Pathol Lab Med 1986;110:930-3.
 45. Cagle PT, Mattioli CA, Truong LD, Greenberg SD. Immunohistochemical diagnosis of pulmonary eosinophilic granuloma on lung biopsy. Chest 1988; 94:1133-7.
 46. Corrin B, Basset F. A review of histiocytosis X with particular reference to eosinophilic granuloma of the lung. Invest Cell Pathol 1979;2:137-46.
 47. Brambilla E, Fontaine E, Pison CM, Coulomb M, Paramelle B, Brambilla C. Pulmonary histiocytosis X with mediastinal lymph node involvement. Am Rev Respir Dis 1990;142:1216-8.
 48. Friedman PJ, Liebow AA, Sokoloff J. Eosinophilic granuloma of lung: clinical aspects of primary pulmonary histiocytosis in the adult. Medicine (Baltimore) 1981;60:385-96.
 49. Lacronique J, Roth C, Battesti J-P, Basset F, Chretien J. Chest radiological features of pulmonary histiocytosis X: a report based on 50 adult cases. Thorax 1982;37:104-9.
 50. Case Records of the Massachusetts General Hospital (Case 5-1978). N Engl J Med 1978;298:327-32.
 51. Case Records of the Massachusetts General Hospital (Case 8-1986). N Engl J Med 1986;314:564-74.
 52. Johnson FB, De Vinatea ML, Macher AM, et al AIDS: case for diagnosis series, 1987. Milit Med 1987;152:M73-M80.
 53. Molnar JJ, Nathenson G, Edberg S. Fatal aspiration of talcum powder by a child: report of a case. N Engl J Med 1962;266:36-7.
 54. Hughes WT, Kalmer T. Massive talc aspiration: successful treatment with dexamethasone. Am J Dis Child 1966;111:653-4.
 55. Nam K, Gracey DR. Pulmonary talcosis from cosmetic talcum powder. JAMA 1972;221:492-3.
 56. Abraham JL, Brambilla C. Particle size for differentiation between inhalation and injection pulmonary talcosis. Environ Res 1980;21:94-6.
 57. Crouch E, Chung A. Progressive massive fibrosis of the lung secondary to intravenous injection of talc: a pathologic and mineralogic analysis. Am J Clin Pathol 1983;80:520-6.
 58. Dubeid M, Bickel JT, Ingram EA, Scott GC. Pulmonary talc granulomatosis in a cocaine sniffer. Chest 1990;98:237-9.
 59. Brown DG, Aguirre A, Weaver A. (sup 67)Gallium scanning in talc-induced pulmonary granulomatosis. Chest 1980;77:561-5.
 60. Farber HW, Fairman RP, Glauser FL. Talc granulomatosis: laboratory findings similar to sarcoidosis. Am Rev Respir Dis 1982;125:258-61.
 61. Macher AM, Tuur SM, Johnson FB, Kahn D, Garfinkle J. AIDS: case for

- diagnosis series, 1988. Milit Med 1988;153:M33-M40.
62. Racela LS, Papasian CJ, Watanabe I, McGregor DH, Lee SH, Talley R. Systemic talc granulomatosis associated with disseminated histoplasmosis in a drug abuser. Arch Pathol Lab Med 1988;112:557-60.
 63. Goldstein DS, Karpel JP, Appel D, Williams MH Jr. Bullous pulmonary damage in users of intravenous drugs. Chest 1986;89:266-9.
 64. Schmidt RA, Glenny RW, Godwin JD, Hampson NB, Cantino ME, Reichenbach DD. Panlobular emphysema in young intravenous Ritalin abusers. Am Rev Respir Dis 1991;143:649-56.
 65. Lombard CM, Medeiros LJ, Colby TV. Pulmonary histiocytosis X and carcinoma. Arch Pathol Lab Med 1987;111:339-41.
 66. L'Hoste RJ Jr, Arrowsmith WR, Leonard GL, McGaw H. Eosinophilic granuloma occurring in a patient with Hodgkin disease. Hum Pathol 1982;13:592-5.
 67. Sajjad SM, Luna MA. Primary pulmonary histiocytosis X in two patients with Hodgkin's disease. Thorax 1982;37:110-3.
 68. Neumann MP, Frizzera G. The coexistence of Langerhans' cell granulomatosis and malignant lymphoma may take different forms: report of seven cases with a review of the literature. Hum Pathol 1986;17:1060-5.
 69. Tomaszewski JF, Khiyami A, Kleinerman J. Neoplasms associated with pulmonary eosinophilic granuloma. Arch Pathol Lab Med 1991;115:499-506.
 70. Brauner MW, Grenier P, Mouelhi MM, Mompont D, Lenoir S. Pulmonary histiocytosis X: evaluation with high-resolution CT. Radiology 1989;172:255-8.
 71. Moore ADA, Godwin JD, Muller NL, et al Pulmonary histiocytosis X: comparison of radiographic and CT findings. Radiology 1989;172:249-54.

* * USE FORMAT 9 FOR FULL TEXT OF ARTICLE * *

9/7/14 (Item 3 from file: 444)
DIALOG(R)File 444:NEJM Online
(c) 1994 New England Journal of Medicine. All rts. reserv.

00108743
Copyright 1991 by the Massachusetts Medical Society

Medical Progress: Brain Tumors (second of Two Parts) (Review Articles)

Black, Peter McL.
The New England Journal of Medicine
May 30, 1991; 324 (22),pp 1555-1564
LINE COUNT: 00733 WORD COUNT: 10127
ISSN: 0028-4793

CORPORATE SOURCE: From the Neurosurgical Service and Brain Tumor Group, Brigham and Women's Hospital, Children's Hospital, and Dana-Farber Cancer Institute, and the Department of Surgery, Harvard Medical School, Boston. Address reprint requests to Dr. Black at Brigham and Women's Hospital, 75 Francis St., Boston, MA 02115.

CITED REFERENCES

104. Collins VP, Nordenskjold M, Dumanski JP. The molecular genetics of meningiomas. Brain Pathol 1990; 1:19-24.

105. Kepes JJ. Meningiomas: biology, pathology, and differential diagnosis. New York: Masson, 1982.
106. Lesch KP, Schott W, Engl HG, et al Gonadal steroid receptors in meningiomas. *J Neurol* 1987; 234:328-33.
107. Schrell UMH, Fahlbusch R. Hormonal manipulation of cerebral meningiomas. In: Al-Mefty O, ed. Meningiomas. New York: Raven Press, 1991:273-83.
108. Rubinstein AB, Schein M, Reichenthal E. The association of carcinoma of the breast with meningioma. *Surg Gynecol Obstet* 1989; 169:334-6.
109. Hoshino T, Nagashima T, Murovic JA, et al Proliferative potential of human meningiomas of the brain: a cell kinetic study with bromodeoxyuridine. *Cancer* 1986; 58:1466-72.
110. DeLaMonte SM, Flickinger J, Linggood RM. Histopathologic features predicting recurrence of meningiomas following subtotal resection. *Am J Surg Pathol* 1986; 10:836-43.
111. Maxwell RE, Chou SN. Preoperative evaluation and management of meningiomas. In: Schmidek HH, Sweet WH, eds. Operative neurosurgical techniques. 2nd ed. Vol. 1. New York: Grune & Stratton, 1988:547-54.
112. Djemmann RG, Black PM. Difficult decisions in managing patients with benign brain tumors. *Clin Neurosurg* 1989; 35:254-84.
113. Djemmann RG. Meningiomas: clinical features and surgical management. In: Wilkins RH, Rengacharry SS, eds. Neurosurgery. Vol. 1. New York: McGraw-Hill, 1985:635-54.
114. Al-Mefty O, Fox JL, Smith RR. Petrosal approach for petroclival meningiomas. *Neurosurgery* 1988; 22:510-7.
115. Samii M, Ammirati M, Mahran A, Bini W, Sepehrnia A. Surgery of petroclival meningiomas: report of 24 cases. *Neurosurgery* 1989; 24:12-7.
116. Mirimanoff RO, Dosoretz DE, Linggood RM, Djemmann RG, Martuza RL. Meningioma: analysis of recurrence and progression following neurosurgical resection. *J Neurosurg* 1985; 62:18-24.
117. Jaaskelainen J. Seemingly complete removal of histologically benign intracranial meningioma: late recurrence rate and facts predicting recurrence in 657 patients. *Surg Neurol* 1986; 26:461-9.
118. Quest DO. Meningiomas: an update. *Neurosurgery* 1978; 3:219-25.
119. Forbes AR, Goldberg ID. Radiation therapy in the treatment of meningioma: the Joint Center for Radiation Therapy experience 1970 to 1982. *J Clin Oncol* 1984; 2:1139-43.
120. Taylor BW Jr, Marcus RB Jr, Friedman WA, Ballinger WE Jr, Million RR. The meningioma controversy: postoperative radiation therapy. *Int J Radiat Oncol Biol Phys* 1988; 15:299-304.
121. Barbaro NM, Gutin PH, Wilson CB, Sheline GE, Boldrey EB, Wara WM. Radiation therapy in the treatment of partially resected meningiomas. *Neurosurgery* 1987; 20:525-8.
122. Kovacs K. Light and electron microscopic pathology of pituitary tumors: immunohistochemistry. In: Black PM, Zervas NT, Ridgway EC, Martin JB, eds. Secretory tumors of the pituitary gland. Vol. 1. New York: Raven Press, 1984:365-75.
123. Weiss MH. Treatment options in the management of prolactin-secreting pituitary tumors. *Clin Neurosurg* 1986; 33:547-52.
124. Hubbard JL, Scheithauer BW, Abboud CF, Laws ER Jr. Prolactin-secreting adenomas: the preoperative response to bromocriptine treatment and surgical outcome. *J Neurosurg* 1987; 67:816-21.
125. Faria MA Jr, Tindall GT. Transsphenoidal microsurgery for prolactin-secreting pituitary adenomas. *J Neurosurg* 1982; 56:33-43.
126. Serri O, Rasio E, Beauregard H, Hardy J, Somma M. Recurrence of

- hyperprolactinemia after selective transsphenoidal adenomectomy in women with prolactinoma. *N Engl J Med* 1983; 309:280-3.
127. Laws ER Jr. Pituitary surgery. *Endocrinol Metab Clin North Am* 1987; 16:647-65.
 128. Fahlbusch R, Schrell U. Surgical therapy for lesions within the hypothalamic region. *Acta Neurochir (Wien)* 1985; 75:125-35.
 129. Barkan AL, Lloyd RV, Chandler WF, et al Preoperative treatment of acromegaly with long-acting somatostatin analog SMS 201-995: shrinkage of invasive pituitary macroadenomas and improved surgical remission rate. *J Clin Endocrinol Metab* 1988; 67:1040-8.
 130. Boggan JE, Tyrrell JB, Wilson CB. Transsphenoidal microsurgical management of Cushing's disease: report of 100 cases. *J Neurosurg* 1983; 59:159-200.
 131. Hardy J. Presidential address: XVII Canadian Congress of Neurological Sciences: Cushing's disease: 50 years later. *Can J Neurol Sci* 1982; 9:375-80.
 132. Oldfield EH, Chrousos GP, Schulte HM, et al Preoperative lateralization of ACTH-secreting pituitary microadenomas by bilateral and simultaneous inferior petrosal venous sinus sampling. *N Engl J Med* 1985; 312:100-3.
 133. Klibanski A, Zervas NT. Diagnosis and management of hormone-secreting pituitary adenomas. *N Engl J Med* 1991; 324:822-31.
 134. Black PM, Hsu DW, Klibanski A, et al Hormone production in clinically nonfunctioning pituitary adenomas. *J Neurosurg* 1987; 66:244-50.
 135. Grossman A, Ross R, Charlesworth M, et al The effect of dopamine agonist therapy on large functionless pituitary tumors. *Clin Endocrinol* 1985; 22:679-86.
 136. Black PM, Zervas NT, Candia GL. Incidence and management of complications of transsphenoidal operation for pituitary adenomas. *Neurosurgery* 1987; 20:920-4.
 137. Chun M, Masko GB, Hetelekidis S. Radiotherapy in the treatment of pituitary adenomas. *Int J Radiat Oncol Biol Phys* 1988; 15:305-9.
 138. Cushing H. Intracranial tumors: notes upon a series of two thousand verified cases with surgical-mortality percentages pertaining thereto. Springfield, Ill.: Charles C Thomas, 1932.
 139. Wallace MR, Marchuk DA, Anderson LB, et al Type I neurofibromatosis gene: identification of a large transcript disrupted in three NF1 patients. *Science* 1990; 249:181-6.
 140. Mulvihill J, Parry DM, Sherman JL, Pikus A, Kaiser-Kupfer MI, Eldridge R. Neurofibromatosis 1 (Recklinghausen disease) and neurofibromatosis 2 (bilateral acoustic neurofibromatosis): an update. *Ann Intern Med* 1990; 113:39-52.
 141. Tator CH, Nedzelski JM. Preservation of hearing in patients undergoing excision of acoustic neuromas and other cerebellopontine angle tumors. *J Neurosurg* 1985; 63:168-74.
 142. Schramm J, Mokrusch T, Fahlbusch R, Hochstetter A. Detailed analysis of intraoperative changes monitoring brain stem acoustic evoked potentials. *Neurosurgery* 1988; 22:694-702.
 143. Moller AR, Jannetta PJ. Preservation of facial function during removal of acoustic neuromas: use of monopolar constant-voltage stimulation and EMG. *J Neurosurg* 1984; 61:757-60.
 144. Nadol JB Jr, Levine R, Ojemann RG, Martuza RL, Montgomery WW, de Sandoval PK. Preservation of hearing in surgical removal of acoustic neuromas of the internal auditory canal and cerebellar pontine angle. *Laryngoscope* 1987; 97:1287-94.
 145. Loeffler JA, Alexander E III. The role of stereotactic radiosurgery in

- the management of intracranial tumors. *Oncology (Williston Park)* 1990; 4:21-31.
146. Linskey ME, Lunsford LD, Flickinger JC. Radiosurgery for acoustic neuromas: early experience. *Neurosurgery* 1990; 26:336-44.
147. Baskin DS, Wilson CB. Surgical management of craniopharyngiomas: a review of 74 cases. *J Neurosurg* 1986; 65:22-7.
148. Hoffman HJ. Craniopharyngiomas. *Can J Neurol Sci* 1985; 12:348-52.
149. Fischer EG, Welch K, Belli JA, et al Treatment of craniopharyngiomas in children: 1972-1981. *J Neurosurg* 1985; 62:496-501.
150. Carmel FW. Tumors of the third ventricle. *Acta Neurochir (Wien)* 1985; 75:136-46.
151. Manaka S, Teramoto A, Takakura K. The efficacy of radiotherapy for craniopharyngioma. *J Neurosurg* 1985; 62:648-56.
152. Berger MS, Wilson CB. Epidermoid cysts of the posterior fossa. *J Neurosurg* 1985; 62:214-9.
153. Panagopoulos KP, el Azouzi M, Chisholm HL, Jolesz FA, Black PM. Intracranial epidermoid tumors: a continuing diagnostic challenge. *Arch Neurol* 1990; 47:813-6.
154. Hall WA, Lunsford LD. Changing concepts in the treatment of colloid cysts: an 11-year experience in the CT era. *J Neurosurg* 1987; 66:186-91.
155. Neumann HP, Eggert HR, Weigel K, Friedburg H, Wiestler OD, Schollmeyer P. Hemangioblastomas of the central nervous system: a 10-year study with special reference to von-Hippel-Lindau syndrome. *J Neurosurg* 1989; 70:24-30.
156. Bailey P, Cushing H. A classification of the tumors of the glioma group on a histogenetic basis with a correlated study of prognosis. Philadelphia: J.B. Lippincott, 1926.
157. Kernohan JW, Mabon RF, Svien HJ, Adson AW. A simplified classification of gliomas. *Proc Staff Meet Mayo Clin* 1949; 24:71-5.
158. Weir B, Grace M. The relative significance of factors affecting postoperative survival in astrocytomas, grades one and two. *Can J Neurol Sci* 1976; 3:47-50.
159. Weir B. The relative significance of factors affecting postoperative survival in astrocytomas, grades 3 and 4. *J Neurosurg* 1973; 38:448-52.
160. Burger PC, Vogel FS, Green SB, Strike TA. Glioblastoma multiforme and anaplastic astrocytoma: pathologic criteria and prognostic implications. *Cancer* 1985; 56:1106-11.
161. Chang CH, Horton J, Schoenfeld D, et al Comparison of postoperative radiotherapy and combined postoperative radiotherapy and chemotherapy in the multidisciplinary management of malignant gliomas. *Cancer* 1983; 52:997-1007.
162. Westermark B, Siegbahn A, Heldin CH, Slaesson-Welsh L. B-type receptor for platelet-derived growth factor mediates a chemotactic response by means of ligand-induced activation of the receptor protein-tyrosine kinase. *Proc Natl Acad Sci U S A* 1990; 87:128-32.
163. Humphrey PA, Wong AJ, Vogelstein B, et al Amplification and expression of the epidermal growth factor receptor gene in human glioma xenografts. *Cancer Res* 1988; 48:2231-8.
164. McCullough DC, Epstein F. Optic pathway tumors: a review with proposals for clinical staging. *Cancer* 1985; 56:1789-91.
165. Pierce SM, Barners PD, Loeffler JS, McGinn C, Tarbell NJ. Definitive radiation therapy in the management of symptomatic patients with optic glioma: survival and long-term effects. *Cancer* 1990; 65:45-52.
166. Epstein F, McCleary EL. Intrinsic brain-stem tumors of childhood: surgical indications. *J Neurosurg* 1986; 64:11-5.

167. Hoffman HJ, Becker L, Craven MA. A clinically and pathologically distinct group of benign brain stem gliomas. *Neurosurgery* 1980; 7:243-8.
168. Coffey RJ, Lunsford LD. Stereotactic surgery for mass lesions of the midbrain and pons. *Neurosurgery* 1985; 17:12-8.
169. Edwards MS, Wara WM, Urtasun RC, et al Hyperfractionated radiation therapy for brain-stem glioma: a phase I-II trial. *J Neurosurg* 1989; 70:691-700.
170. Laws ER Jr, Taylor WF, Clifton MB, Okazaki H. Neurosurgical management of low-grade astrocytoma of the cerebral hemispheres. *J Neurosurg* 1984; 61:665-73.
171. Palma L, Guidetti B. Cystic pilocytic astrocytomas of the cerebral hemispheres: surgical experience with 51 cases and long-term results. *J Neurosurg* 1985; 61:811-5.
172. Sutton LN. Current management of low-grade astrocytomas of childhood. *Pediatr Neurosci* 1987; 13:98-107.
173. Ammirati M, Vick N, Liao YL, Ciric I, Mikhael M. Effect of the extent of surgical resection on survival and quality of life in patients with supratentorial glioblastomas and anaplastic astrocytomas. *Neurosurgery* 1987; 21:201-6.
174. Levin VA, Wara WM, Davis RL, et al Phase III comparison of BCNU and the combination of procarbazine, CCNU, and vincristine administered after radiotherapy with hydroxyurea for malignant gliomas. *J Neurosurg* 1985; 63:218-23.
175. Walker MD, Alexander E Jr, Hunt WE, et al Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas: a cooperative clinical trial. *J Neurosurg* 1978; 49:333-43.
176. Nelson DF, Schoenfeld D, Weinstein AS, et al A randomized comparison of misonidazole sensitized radiotherapy plus BCNU and radiotherapy plus BCNU for treatment of malignant glioma after surgery: preliminary results of an RTOG study. *Int J Radiat Oncol Biol Phys* 1983; 9:1143-51.
177. Green SB, Byar DP, Strike TA, et al Randomized comparisons of BCNU, streptozocin, radiosensitizer, and fractionation of radiotherapy in the postoperative treatment of malignant glioma. *Proc Am Soc Clin Oncol* 1984; 3:260. abstract.
178. Wasserman TH, Stetz J, Phillips TL. Radiation Therapy Oncology Group clinical trials with misonidazole. *Cancer* 1981; 47:2382-90.
179. Trojanowski T, Peszynski J, Turowski K, et al Postoperative radiotherapy and radiotherapy combined with CCNU chemotherapy for treatment of brain gliomas. *J Neurooncol* 1988; 6:285-91.
180. Takakura K, Abe H, Tanaka R, et al Effects of ACNU and radiotherapy on malignant glioma. *J Neurosurg* 1986; 64:53-7.
181. Thomas DGT, Darling JL, Paul EA, et al Assay of anticancer drugs in tissue culture: relationship of relapse-free interval (RFI) and in vivo chemosensitivity in patients with malignant cerebral glioma. *Br J Cancer* 1985; 51:525-32.
182. Choucair AK, Levin VA, Gutin PH, et al Development of multiple lesions during radiation therapy and chemotherapy in patients with gliomas. *J Neurosurg* 1986; 65:654-8.
183. Heros DD, Renkens K, Kasdon DL, Adelman LS. Patterns of recurrence in glioma patients after interstitial irradiation and chemotherapy: report of three cases. *Neurosurgery* 1988; 22:474-8.
184. Bullard DE, Gillespie GY, Mahaley MS, Bigner DD. Immunobiology of human gliomas. *Semin Oncol* 1986; 13:94-109.
185. Mahaley MS Jr, Urso MB, Whaley RA, et al Immunobiology of primary

- intracranial tumors. Part 10: therapeutic efficacy of interferon in the treatment of recurrent gliomas. *J Neurosurg* 1985; 63:719-25.
186. Barba D, Saris SC, Holder C, Rosenberg SA, Oldfield EH. Intratumoral LAK cell and interleukin-2 therapy of human gliomas. *J Neurosurg* 1989; 70:175-82.
 187. Yung WKA, Frados M, Levin V, et al Recombinant beta interferon in patients with recurrent malignant gliomas. *J Neurooncol* 1989; 7:Suppl:S32. abstract.
 188. Merchant RE, McVicar DW, Merchant LH, Young HF. Treatment of patients with recurrent glioblastoma by repeated intralesional injections of human recombinant interleukin-2 (rIL-2) alone or in combination with systemic interferon-alpha. *J Neurooncol* 1989; 7:Suppl:S19. abstract.
 189. Miescher S, Whiteside TL, de Tribolet N, von Flidner V. In situ characterization, clonogenic potential, and antitumor cytolytic activity of T lymphocytes infiltrating human brain cancers. *J Neurosurg* 1988; 68:438-48.
 190. Tanaka R, Yoshida S, Ono K, Takai N. Long-term follow-up of patients with recurrent malignant glioma treated with repeated intratumoral injection of recombinant IL-2-activated killer cells. *J Neurooncol* 1989; 7:Suppl:S27. abstract
 191. Jacobs SK, Wilson DJ, Kornblith PL, Grimm EA. Interleukin-2 or autologous lymphokine-activated killer cell treatment of malignant glioma: phase I trial. *Cancer Res* 1986; 46:2101-4.
 192. Bullard DE, Bigner DD. Applications of monoclonal antibodies in the diagnosis and treatment of primary brain tumors. *J Neurosurg* 1985; 63:2-16.
 193. Harsh GR IV, Levin VA, Gutin PH, Seager M, Silver F, Wilson CB. Reoperation for recurrent glioblastoma and anaplastic astrocytoma. *Neurosurgery* 1987; 21:615-21.
 194. Ammirati M, Galicich JH, Arbit E, Liao Y. Reoperation in the treatment of recurrent intracranial malignant gliomas. *Neurosurgery* 1987; 21:607-14.
 195. Hochberg FH, Parker LM, Takvorian T, Canellos GP, Zervas NT. High-dose BCNU with autologous bone marrow rescue for recurrent glioblastoma multiforme. *J Neurosurg* 1981; 54:455-60.
 196. Bruner JM. Oligodendroglioma: diagnosis and prognosis. *Semin Diagn Pathol* 1987; 4:251-61.
 197. Bullard DE, Rawlings CE III, Phillips B, et al Oligodendroglioma: an analysis of the value of radiation therapy. *Cancer* 1987; 60:2179-88.
 198. Cairncross JG, MacDonald DR. Successful chemotherapy for recurrent malignant oligodendroglioma. *Ann Neurol* 1988; 23:360-4.
 199. Castillo M, Davis PC, Takei Y, Hoffman HC Jr. Intracranial ganglioglioma: MR, CT, and clinical findings in 18 patients. *AJR Am J Roentgenol* 1990; 154:607-12.
 200. Kalyan-Raman UP, Olivero WC. Ganglioglioma: a correlative clinicopathological and radiological study of ten surgically treated cases with follow-up. *Neurosurgery* 1987; 20:428-33.
 201. Healy EA, Barnes PB, Kupsky WJ, et al The prognostic significance of postoperative residual tumor in ependymoma. *Neurosurgery* (in press).
 202. Wallner KE, Wara WM, Sheline GE, Davis RL. Intracranial ependymomas: results of treatment with partial or whole brain irradiation without spinal irradiation. *Int J Radiat Oncol Biol Phys* 1986; 12:1937-41.
 203. Finlay F, August C, Packer R, et al High dose chemotherapy with marrow "rescue" in children with malignant brain tumors. *J Neurooncol* 1989; 7:Suppl:S11. abstract.
 204. Tomita T, McLone DG. Medulloblastoma in childhood: results of radical

- resection and low-dose neuraxis radiation therapy. *J Neurosurg* 1986; 64:238-42.
205. Levin VA, Rodriguez LA, Edwards MS, et al Treatment of medulloblastoma with procarbazine, hydroxyurea, and reduced radiation doses to whole brain and spine. *J Neurosurg* 1988; 68:383-7.
 206. Hughes EN, Shillito J, Sallan SE, Loeffler JS, Cassady JR, Tarbell NJ. Medulloblastoma at the Joint Center for Radiation Therapy between 1968 and 1984: the influence of radiation dose on the patterns of failure and survival. *Cancer* 1988; 61:1992-8.
 207. Hart MN, Earle KM. Primitive neuroectodermal tumors of the brain in children. *Cancer* 1973; 32:890-7.
 208. Gaffney CC, Sloane JP, Bradley NJ, Bloom HJ. Primitive neuroectodermal tumours of the cerebrum: pathology and treatment. *J Neurooncol* 1985; 3:23-33.
 209. Loeffler JS, Mauch P. Tumors in the pineal region. In: Williams CJ, Krikorian JC, Green MR, Raghavan D, eds. *Textbook of uncommon cancer*. New York: John Wiley, 1987:693-705.
 210. Rosenblum ML, Levy RM, Bredesen DE, So YT, Wara W, Ziegler JL. Primary central nervous system lymphomas in patients with AIDS. *Ann Neurol* 1988; 23:S13-S16.
 211. O'Neill BP, Illig JJ. Primary central nervous system lymphoma. *Mayo Clin Proc* 1989; 64:1005-20.
 212. Hochberg FH, Miller DC. Primary central nervous system lymphoma. *J Neurosurg* 1988; 68:835-53.
 213. DeAngelis LM, Yahalom J, Heinemann MH, Cirrincione C, Thaler HT, Krol G. Primary CNS lymphoma: combined treatment with chemotherapy and radiotherapy. *Neurology* 1990; 40:80-6.
 214. Delattre JY, Krol G, Thaler HT, Posner JB. Distribution of brain metastases. *Arch Neurol* 1988; 45:741-4.
 215. Sundaresan N, Galicich JH. Surgical treatment of brain metastases: clinical and computerized tomography evaluation of the results of treatment. *Cancer* 1985; 55:1382-8.
 216. Patchell RA, Tibbs PA, Walsh JW, et al A randomized trial of surgery in the treatment of single metastases to the brain. *N Engl J Med* 1990; 322:494-500.
 217. Loeffler JS, Kooy HM, Wen PY, et al The treatment of recurrent brain metastases with stereotactic radiosurgery. *J Clin Oncol* 1990; 8:576-82.
 218. Wasserstrom WR, Glass JP, Posner JB. Diagnosis and treatment of leptomeningeal metastases from solid tumors: experience with 90 patients. *Cancer* 1982; 49:759-72.
 219. Sze G, Soletsky S, Bronen R, Krol G. MR imaging of the cranial meninges with emphasis on contrast enhancement and meningeal carcinomatosis. *AJNR* 1989; 10:965-75.
 220. Yap HY, Yap BS, Rasmussen S, Levens ME, Hortobagyi GN. Treatment for meningeal carcinomatosis in breast cancer. *Cancer* 1982; 50:219-22.
 221. Lashford LS, Davies AG, Richardson RB, et al A pilot study of (Ref. 131)I monoclonal antibodies in the therapy of leptomeningeal tumors. *Cancer* 1988; 61:857-68.

* * USE FORMAT 9 FOR FULL TEXT OF ARTICLE * *

9/7/15 (Item 4 from file: 444)

DIALOG(R)File 444:NEJM Online

(c) 1994 New England Journal of Medicine. All rts. reserv.

Case 7-1989: Unilateral Exophthalmos Three Years After Treatment Of Cervical And Mediastinal Hodgkin's Disease (Case Records of the Massachusetts General Hospital)

Jakobiec, Frederick A.; Ferry, Judith A.

The New England Journal of Medicine

Feb 16, 1989; 320 (7),pp 447-457

LINE COUNT: 00842

WORD COUNT: 11627

ISSN: 0028-4793

CITED REFERENCES

1. Kaplan HS. Hodgkin's disease. Cambridge, Mass.: Harvard University Press, 1972.
2. Jones IS, Jakobiec FA. Diseases of the orbit. Hagerstown, Md.: Harper & Row, 1979:135-44, 187-262, 309-55, 371-416.
3. Henderson JW. Orbital tumors. 2nd ed. New York: Brian C. Decker, 1980:67-114, 344-76.
4. Shields JA, Bakewell B, Augsburger JJ, Flanagan JC. Classification and incidence of space-occupying lesions of the orbit: a survey of 645 biopsies. Arch Ophthalmol 1984; 102:1606-11.
5. Fratkin JD, Shammas HF, Miller SD. Disseminated Hodgkin's disease with bilateral orbital involvement. Arch Ophthalmol 1978; 96:102-4.
6. Patel S, Rootman J. Nodular sclerosing Hodgkin's disease of the orbit. Ophthalmology 1983; 90:1433-6.
7. Consul BN, Kulshrestha DP. Hodgkin's disease and bilateral exophthalmos. Am J Ophthalmol 1963; 56:462-5.
8. Sen DK, Mohan H, Chatterjee PK. Hodgkin's disease in the orbit. Int Surg 1971; 55:183-6.
9. Barr CC, Joondeph HC. Retinal periphlebitis as the initial clinical finding in a patient with Hodgkin's disease. Retina 1983; 3:253-7.
10. Mosteller MW, Margo CE, Hesse RJ. Hodgkin's disease and granulomatous uveitis. Ann Ophthalmol 1985; 17:787-90.
11. Bishop JE, Salmonsens PC. Presumed intraocular Hodgkin's disease. Ann. Ophthalmol 1985; 17:589-92.
12. Miller NR, Illiff WJ. Visual loss as the initial symptom in Hodgkin disease. Arch Ophthalmol 1975; 93:1158-61.
13. Larson DL, Robbins KT, Butler JJ. Lymphoma of the head and neck: a diagnostic dilemma. Am J Surg 1984; 148:433-7.
14. Shidnia H, Hornback NB, Lingemen R, Barlow P. Extranodal lymphoma of the head and neck area. Am J Clin Oncol 1985; 8:235-43.
15. Albada J, Hordijk GJ, van Unnik JAM, Dekker AW. Non-Hodgkin's lymphoma of Waldeyer's ring. Cancer 1985; 56:2911-3.
16. Jacobs C, Hoppe RT. Non-Hodgkin's lymphomas of head and neck extranodal sites. Int J Radiat Oncol Biol Phys 1985; 11:357-64.
17. Robbins KT, Fuller LM, Vlasak M, et al. Primary lymphomas of the nasal cavity and paranasal sinuses. Cancer 1985; 56:814-9.
18. Jakobiec FA, Font RL. Orbit. In: Spencer WH, Font RL, Green WR, et al., eds. Ophthalmic pathology: an atlas and textbook. 3rd ed. Vol. 3. Philadelphia: W.B. Saunders, 1986:2459-860.
19. Rootman J. Diseases of the orbit: a multidisciplinary approach. Philadelphia: J.B. Lippincott, 1988:143-97, 205-40, 293-305, 481-92.
20. Jakobiec FA, McLean I, Font RL. Clinicopathologic characteristics of orbital lymphoid hyperplasia. Ophthalmology 1979; 86:948-66.

21. Knowles DM II, Jakobiec FA. Orbital lymphoid neoplasms: a clinicopathologic study of 60 patients. *Cancer* 1980; 46:576-89.
22. Case Records of the Massachusetts General Hospital (Case 47-1986). *N Engl J Med* 1986; 315:1401-9.
23. Jakobiec FA, Iwamoto T. The ocular adnexa. In: Jakobiec FA, ed. *Ocular anatomy, embryology, and teratology*. Philadelphia: Harper & Row, 1982:677-732.
24. Wieczorek R, Jakobiec FA, Sacks EH, Knowles DM. The immunoarchitecture of the normal human lacrimal gland: relevancy for understanding pathologic conditions. *Ophthalmology* 1988; 95:100-9.
25. Sacks EH, Wieczorek R, Jakobiec FA, Knowles DM II. Lymphocytic subpopulations in the normal human conjunctiva: a monoclonal antibody study. *Ophthalmology* 1986; 93:1276-83.
26. Sigelman J, Jakobiec FA. Lymphoid lesions of the conjunctiva: relation of histopathology to clinical outcome. *Ophthalmology* 1978; 85:818-43.
27. Jakobiec FA, Lefkowitz J, Knowles DM II. B- and T-lymphocytes in ocular disease. *Ophthalmology* 1984; 91:636-54.
28. Jakobiec FA, Neri A, Knowles DM II. Genotypic monoclonality in immunophenotypically polyclonal orbital lymphoid tumors: a model of tumor progression in the lymphoid system. *Ophthalmology* 1987; 94:980-94.
29. Neri A, Jakobiec FA, Pelicci P-G, Dalla Favera R, Knowles DM II. Immunoglobulin and T cell receptor beta chain gene rearrangement analysis of ocular adnexal lymphoid neoplasms: clinical and biologic implications. *Blood* 1987; 5:1519-29.
30. Fishleder A, Tubbs R, Hesse B, Levine H. Uniform detection of immunoglobulin-gene rearrangement in benign lymphoepithelial lesions. *N Engl J Med* 1987; 316:1118-21.
31. Hanson CA, Frizzera G, Patton DF, et al. Clonal rearrangement for immunoglobulin and T-cell receptor genes in systemic Castleman's disease. Association with Epstein-Barr virus. *Am J Pathol* 1988; 131:84-91.
32. Jakobiec FA, Iwamoto T, Patell M, Knowles DM II. Ocular adnexal monoclonal lymphoid tumors with a favorable prognosis. *Ophthalmology* 1986; 93:1547-57.
33. Hornblass A, Jakobiec FA, Reifler DM, Mines J. Orbital lymphoid tumors located predominantly within extraocular muscles. *Ophthalmology* 1987; 94:688-97.
34. Jereb B, Lee H, Jakobiec FA, Kutcher J. Radiation therapy of conjunctival and orbital lymphoid tumors. *Int J Radiat Oncol Biol Phys* 1984; 10:1013-9.
35. Bookman MA, Longo DL. Concomitant illness in patients treated for Hodgkin's disease. *Cancer Treat Rev* 1986; 13:77-111.
36. Trokel SL, Jakobiec FA. Correlation of CT scanning and pathologic features of ophthalmic Graves' disease. *Ophthalmology* 1981; 88:553-64.
37. Kaye AH, Hahn JF, Craciun A, Hanson M, Berlin AJ, Tubbs RR. Intracranial extension of inflammatory pseudotumor of the orbit. *J Neurosurg* 1984; 60:625-9.
38. Jakobiec FA, Yeo JH, Trokel SL, Abbott GF. Combined clinical and computed tomographic diagnosis of primary lacrimal fossa lesions. *Am J Ophthalmol* 1982; 94:785-807.
39. Yeo JH, Jakobiec FA, Abbott GF, Trokel SL. Combined clinical and computed tomographic diagnosis of orbital lymphoid tumors. *Am J Ophthalmol* 1982; 94:235-45.
40. Wolk RB. Sarcoidosis of the orbit with bone destruction. *AJNR* 1984; 5:204-5.

41. Jakobiec FA, Depot MJ, Kennerdell JS, et al. Combined clinical and computed tomographic diagnosis of orbital glioma and meningioma. *Ophthalmology* 1984; 91:137-55.
42. Cushing H. Meningiomas: their classification, regional behaviour, life history, and surgical end results. Springfield, Ill.: Charles C Thomas, 1938.
43. Harris GJ, Jakobiec FA. Cavernous hemangioma of the orbit; a clinicopathologic analysis of sixty-six cases. In: Jakobiec FA, ed. *Ocular and adnexal tumors*. Birmingham, Ala.: Aesculapius Publishing, 1978.
44. Hornblass A, Kass LG, Reich R. Thyroid carcinoma metastatic to the orbit. *Ophthalmology* 1987; 94:1004-7.
45. Corvisier N, Gray F, Gherardi R, et al. Aspergillosis of ethmoid sinus and optic nerve, with arteritis and rupture of the internal carotid artery. *Surg Neurol* 1987; 28:311-5.
46. Harris GJ, Dixon TA, Haughton VM. Expansion of the lacrimal gland fossa by a lymphoid tumor. *Am J Ophthalmol* 1983; 96:546-7.
47. Meadows AT, Baum E, Fossati-Bellani F, et al. Second malignant neoplasms in children: an update from the Late Effects Study Group. *J Clin Oncol* 1985; 3:532-8.
48. Arkin CF, Kurtz SR, Sparks JT. Acute B-cell leukemia occurring with Hodgkin's disease. *Am J Clin Pathol* 1981; 75:406-10.
49. Ritch FS, Anderson T, Hanson GA, Pisciotta AV. Chronic granulocytic leukemia following radiation therapy for Hodgkin's disease. *Cancer* 1983; 52:462-4.
50. Crowther D, Fairley GH, Sewell RL. Significance of the changes in the circulating lymphoid cells in Hodgkin's disease. *Br Med J* 1969; 2:473-7.
51. Halie MR, Eibergen R, Nieweg HO. Observations on abnormal cells in the peripheral blood and spleen of Hodgkin's disease. *Br Med J* 1972; 2:609-11.
52. Halie MR, Huiges W, Nieweg HO. Abnormal cells in the peripheral blood of patients with Hodgkin's disease. I. Observation with light microscopy. *Br J Haematol* 1974; 28:317-22.
53. Miettinen M, Franssila KO, Saxen E. Hodgkin's disease, lymphocytic predominance nodular. Increased risk for subsequent non-Hodgkin's lymphomas. *Cancer* 1983; 51:2293-300.
54. Wallner KE, Leibel SA, Wara WM. Squamous cell carcinoma of the head and neck after radiation therapy for Hodgkin's disease: a report of two cases and a review of the literature. *Cancer* 1985; 56:1052-5.
55. Kramer EL, Sanger JJ, Benjamin DD, Tiu S. Detection of lacrimal gland infiltration on routine bone scintigraphy. *Clin Nucl Med* 1983; 8:546-9.
56. Ferrant A, Rodhain J, Michaux JL, Piret L, Maldague B, Sokal G. Detection of skeletal involvement in Hodgkin's disease: a comparison of radiography, bone scanning and bone marrow biopsy in 38 patients. *Cancer* 1975; 35:1346-53.
57. Schechter JP, Jones SE, Woolfenden JM, Lilien DL, O'Mara RE. Bone scanning in lymphoma. *Cancer* 1976; 38:1142-8.
58. Shields AF, Porter BA, Churchley S, Olson DO, Appelbaum FR, Thomas ED. The detection of bone marrow involvement by lymphoma using magnetic resonance imaging. *J Clin Oncol* 1987; 5:225-30.
59. Lee YY, Van Tassel F, Nauert C, North LB, Jing BS. Lymphomas of the head and neck: CT findings at initial presentation. *AJR* 1987; 149:575-81.
60. Yang PJ, Carmody RF, Seeger JF. Computed tomography in hematologic

- malignancies of paranasal sinuses. J Comput Assist Tomogr 1986; 10:1003-5.
61. Zahra M, Tewfik F. An unusual site of presentation for Hodgkin's disease in the middle ear. J Surg Oncol 1986; 33:227-30.
 62. Mikhael MA, Paige ML. Hodgkin's disease of the spine: computed tomography and magnetic resonance imaging. J Comput Tomogr 1987; 11:174-7.
 63. Bragg DG, Colby TV, Ward JH. New concepts in the non-Hodgkin lymphomas: radiologic implications. Radiology 1986; 159:291-304.
 64. Bragg DG. Radiology of the lymphomas. Curr Probl Diagn Radiol 1987; 16:177-206.
 65. Cuttner J, Meyer R, Huang YP. Intracerebral involvement in Hodgkin's disease: a report of 6 cases and review of the literature. Cancer 1979; 43:1497-506.
 66. Dujovny M, McBride D, Segal R. Intracranial manifestations of Hodgkin's disease. Surg Neurol 1980; 13:258-65.
 67. Alvarez F, Roda JM, Anciones B, Blazquez MG, Perez-Alvarez M. Intracranial Hodgkin's disease: report of two cases. J Neurosurg Sci 1985; 29:273-7.
 68. Blake PR, Carr DH, Goolden AWG. Intracranial Hodgkin's disease. Br J Radiol 1986; 59:414-6.
 69. Sapozink MD, Kaplan HS. Intracranial Hodgkin's disease: a report of 12 cases and review of the literature. Cancer 1983; 52:1301-7.
 70. Kennerdell JS, Dekker A, Johnson BL, Dubois PJ. Fine-needle aspiration biopsy: its use in orbital tumors. Arch Ophthalmol 1979; 97:1315-7.
 71. Liu D. Complications of fine needle aspiration biopsy of the orbit. Ophthalmology 1985; 92:1768-71.
 72. Rasbach DA, Mondschein MS, Harris NL, Kaufman DS, Wang CA. Malignant lymphoma of the thyroid gland: a clinical and pathologic study of twenty cases. Surgery 1985; 98:1166-70.
 73. Ashby MA, Barber PC, Holmes AE, Freer CEL, Collins RD. Primary intracranial Hodgkin's disease: a case report and discussion. Am J Surg Pathol 1988; 12:294-9.
 74. Sen DK, Mohan H, Chatterjee PK. Hodgkin's disease in the orbit. Int Surg 1971; 55:183-6.
 75. Papaleo G, Gallo AB, Zito G, Scarpa R, Manguso L. Su di un caso di malattia di Hodgkin con localizzazione endorbitaria. Haematologica 1977; 62:95-7.
 76. Ordonez-Gallego A, Montero-Garcia JM, Mate-Benito I, Duran A, Navarro P, Gonzalez-Baron M. Formas clinicas insolitas de la enfermedad de Hodgkin. Rev Clin Esp 1971; 122:313-22. t and discussion. Am J Surg Pathol 1988; 12:294-9.
 74. Sen DK, Mohan H, Chatterjee PK. Hodgkin's disease in the orbit. Int Surg 1971; 55:183-6.
 75. Papaleo G, Gallo AB, Zito G, Scarpa R, Manguso L. Su di un caso di malattia di Hodgkin con localizzazione endorbitaria. Haematologica 1977; 62:95-7.
 76. Ordonez-Gallego A, Montero-Garcia JM, Mate-Benito I, Duran A, Navarro
- * * USE FORMAT 9 FOR FULL TEXT OF ARTICLE * *

9/7/16 (Item 5 from file: 444)

DIALOG(R)File 444:NEJM Online

(c) 1994 New England Journal of Medicine. All rts. reserv.

00104268

Case 7-1988: A 27-Year-Old Man with Acute Myelomonocytic Leukemia in Remission and Repeated Intracranial Hemorrhages (Case Records of the Massachusetts General Hospital)

Kowall, Neil W.; Sobel, Raymond A.
The New England Journal of Medicine
February 18, 1988; 318 (7), pp 427-440
LINE COUNT: 01016 WORD COUNT: 14031
ISSN: 0028-4793

CITED REFERENCES

1. Fisher CM. Lacunar strokes and infarcts: a review. *Neurology* 1982; 32:871-6.
2. Caplan LR. ``Top of the basilar`` syndrome. *Neurology* 1980; 30:72-9.
3. Van Bogaert L. L'hallucinoze pedonculaire. *Rev Neurol (Paris)* 1927; 43:608-17.
4. Lhermitte J. Syndrome de la calotte du pedoncule cerebral: les troubles psycho-sensoriels dans les lesions du mesocephale. *Rev Neurol (Paris)* 1922; 38:1359-65.
5. Geller TJ, Bellur SN. Peduncular hallucinosis: magnetic resonance imaging confirmation of mesencephalic infarction during life. *Ann Neurol* 1987; 21:602-4.
6. Ash PR, Keltner JL. Neuro-ophthalmic signs in pontine lesions. *Medicine (Baltimore)* 1979; 58:304-20.
7. Pedersen RA, Troost BT. Abnormalities of gaze in cerebrovascular disease. *Stroke* 1981; 12:251-4.
8. Kistler JP. Management of subarachnoid hemorrhage from ruptured saccular aneurysm. In: Ropper AH, Kennedy SK, Zervas NT, eds. *Neurological and neurosurgical intensive care*. Baltimore: University Park Press, 1983:175-87.
9. Heidrich R. Subarachnoid haemorrhage. In: Vinken PJ, Bruyn GW, eds. *Handbook of clinical neurology*. Vol. 12. Vascular diseases of the nervous system. Part II. Amsterdam: Elsevier/North Holland, 1972:68-204.
10. Kistler JP, Crowell RM, Davis KR, et al. The relation of cerebral vasospasm to the extent and location of subarachnoid blood visualized by CT scan: a prospective study. *Neurology* 1983; 33:424-36.
11. Gralnick HR. Control of hemorrhagic diseases. In: Gunz FW, Henderson ES, eds. *Leukemia*. 4th ed. New York: Grune & Stratton, 1982:826-33.
12. Henderson ES. Acute leukemia -- general considerations. In: Williams WJ, Beutler E, Erslev AJ, Lichtman MA, eds. *Hematology*. 3rd ed. New York: McGraw-Hill, 1983:234-5.
13. Yuill GM. Leukaemia: neurological involvement. In: Vinken PJ, Bruyn GW, eds. *Handbook of clinical neurology*. Vol. 39. Neurological manifestations of systemic diseases. Part II. Amsterdam: Elsevier/North Holland, 1980:1-26.
14. Dawson DM, Rosenthal DS, Moloney WC. Neurological complications of acute leukemia in adults: changing rate. *Ann Intern Med* 1973; 79:541-4.
15. Law IP, Blom J. Adult acute leukemia: frequency of central nervous system involvement in long term survivors. *Cancer* 1977; 40:1304-6.
16. Le Beau MM, Larson RA, Bitter MA, Vardiman JW, Golomb HM, Rowley JD. Association of an inversion of chromosome 16 with abnormal marrow eosinophils in acute myelomonocytic leukemia: a unique

- cytogenetic-clinicopathological association. *N Engl J Med* 1983; 309:630-6.
17. Holmes R, Keating MJ, Cork A, et al. A unique pattern of central nervous system leukemia in acute myelomonocytic leukemia associated with inv(16)(p13q22). *Blood* 1985; 65:1071-8.
 18. Glass JP, Van Tassel F, Keating MJ, Cork A, Trujillo J, Holmes R. Central nervous system complications of a newly recognized subtype of leukemia: AMML with a pericentric inversion of chromosome 16. *Neurology* 1987; 37:639-44.
 19. Hurwitz BS, Sutherland JC, Walker MD. Central nervous system chloromas preceding acute leukemia by one year. *Neurology* 1970; 20:771-5.
 20. Salev O, Siew F, Yaar I, Rachmilewitz EA. Intracerebral tumor and diffuse central nervous system infiltration complicating acute myelogenous leukemia. *Cancer* 1979; 44:1066-9.
 21. Vinters HV, Gilbert JJ. Multifocal chloromas of the brain. *Surg Neurol* 1982; 17:47-51.
 22. Ho K-L. Neoplastic aneurysm and intracranial hemorrhage. *Cancer* 1982; 50:2935-40.
 23. Joshi JH, Schimpff SC. Infections in patients with acute leukemia. In: Mandell GL, Douglas RG Jr, Bennett JE, eds. *Principles and practice of infectious diseases*. 2nd ed. New York: John Wiley, 1985:1649-58.
 24. Pizzo PA, Robichard KJ, Wesley R, Commers JR. Fever in the pediatric and young adult patient with cancer: a prospective study of 1001 episodes. *Medicine (Baltimore)* 1982; 61:153-65.
 25. Ojemann RG, New PFJ, Fleming TC. Intracranial aneurysms associated with bacterial meningitis. *Neurology* 1966; 16:1222-6.
 26. Suwanwela C, Suwanwela N, Charuchinda S, Hongsaprabhas C. Intracranial mycotic aneurysms of extravascular origin. *J Neurosurg* 1972; 36:552-9.
 27. Osler W. Malignant endocarditis. *Br Med J* 1885; 1:467-70.
 28. Kirkes WS. On some of the principal effects resulting from the detachment of fibrous deposits from the interior of the heart, and their mixture with the circulating blood. *Med Chir Trans* 1852; 35:281-324.
 29. Jones HR Jr, Siekert RG, Geraci JE. Neurologic manifestations of bacterial endocarditis. *Ann Intern Med* 1969; 71:21-8.
 30. Greenlee JE, Mandell GL. Neurological manifestations of infective endocarditis: a review. *Stroke* 1973; 4:958-63.
 31. Pruitt AA, Rubin RH, Karchmer AW, Duncan GW. Neurologic complications of bacterial endocarditis. *Medicine (Baltimore)* 1978; 57:329-43.
 32. Fearnside EG. Intracranial aneurysms. *Brain* 1916; 39:224-96.
 33. McDonald CA, Korb M. Intracranial aneurysms. *Arch Neurol Psychiatr* 1939; 42:298-328.
 34. Roach MR, Drake CG. Ruptured cerebral aneurysms caused by micro-organisms. *N Engl J Med* 1965; 273:240-4.
 35. Lerner PI. Neurologic complications of infective endocarditis. *Med Clin North Am* 1985; 69:385-98.
 36. Bohmfalk GL, Story JL, Wissinger JP, Brown WE Jr. Bacterial intracranial aneurysm. *J Neurosurg* 1978; 48:369-82.
 37. Cantu RC, LeMay M, Wilkinson HA. The importance of repeated angiography in the treatment of mycotic-embolic intracranial aneurysms. *J Neurosurg* 1966; 25:189-93.
 38. Ziment I, Johnson BL Jr. Angiography in the management of intracranial mycotic aneurysms. *Arch Intern Med* 1968; 122:349-52.
 39. Katz RI, Goldberg HI, Selzer ME. Mycotic aneurysm: case report with novel sequential angiographic findings. *Arch Intern Med* 1974; 134:939-42.

40. Moskowitz MA, Rosenbaum AE, Tyler HR. Angiographically monitored resolution of cerebral mycotic aneurysms. *Neurology* 1974; 24:1103-8.
41. Molinari GF, Smith L, Goldstein MN, Satran R. Pathogenesis of cerebral mycotic aneurysms. *Neurology* 1973; 23:325-32.
42. Wade JC, Newman KA, Schimpff SC, et al. Two methods for improved venous access in acute leukemia patients. *JAMA* 1981; 246:140-4.
43. Begala JE, Maher K, Cherry JD. Risk of infection associated with the use of Broviac and Hickman catheters. *Am J Infect Control* 1982; 10:17-23.
44. Abrahm JL, Mullen JL. A prospective study of prolonged central venous access in leukemia. *JAMA* 1982; 248:2868-73.
45. Lowder JN, Lazarus HM, Herzig RH. Bacteremias and fungemias in oncologic patients with central venous catheters: changing spectrum of infection. *Arch Intern Med* 1982; 142:1456-9.
46. Young RC, Bennett JE, Geelhoed GW, Levine AS. Fungemia with compromised host resistance: a study of 70 cases. *Ann Intern Med* 1974; 80:605-12.
47. Stamm WE. Other corynebacteria. In: Mandell GL, Douglas RG Jr, Bennett JE, eds. *Principles and practice of infectious diseases*. 2nd ed. New York: John Wiley, 1985:1174-7.
48. Chernik NL, Armstrong D, Posner JB. Central nervous system infections in patients with cancer: changing patterns. *Cancer* 1977; 40:268-74.
49. Hooper DC, Pruitt AA, Rubin RH. Central nervous system infection in the chronically immunosuppressed. *Medicine (Baltimore)* 1982; 61:166-88.
50. Steele JJ, Kilburn HL, Leech RW. Phytotic (mycotic) intracranial aneurysm with an unusual pathogenesis: a case report. *Pediatrics* 1972; 50:936-9.
51. Rubin RH, Hooper DC. Central nervous system infection in the compromised host. *Med Clin North Am* 1985; 69:281-96.
52. Rubin RH. Infection in the renal transplant patient. In: Rubin RH, Young LS, eds. *Clinical approach to infection in the compromised host*. New York: Plenum Press, 1981; 564-9.
53. Mielke B, Weir B, Oldring D, von Westarp C. Fungal aneurysm: case report and review of the literature. *Neurosurgery* 1981; 9:578-82.
54. Visudhiphan P, Bunyaratavej S, Khantanaphar S. Cerebral aspergillosis: report of three cases. *J Neurosurg* 1973; 38:472-6.
55. Ahuja GK, Jain N, Vijayaraghavan M, Roy S. Cerebral mycotic aneurysm of fungal origin: case report. *J Neurosurg* 1978; 49:107-10.
56. Davidson P, Robertson DM. A true mycotic (*Aspergillus*) aneurysm leading to fatal subarachnoid hemorrhage in a patient with hereditary hemorrhagic telangiectasia: case report. *J Neurosurg* 1971; 35:71-6.
57. Young RC, Bennett JE, Vogel CL, Carbone PP, DeVita VT. Aspergillosis: the spectrum of the disease in 98 patients. *Medicine (Baltimore)* 1970; 49:147-73.
58. Price DL, Wolpow ER, Richardson EP Jr. Intracranial phycomycosis: a clinicopathological and radiological study. *J Neurol Sci* 1971; 14:359-75.
59. Kikuchi K, Watanabe K, Sugawara A, Kowada M. Multiple fungal aneurysms: report of a rare case implicating steroid as predisposing factor. *Surg Neurol* 1985; 24:253-9.
60. Hadley MN, Martin NA, Spetzler RF, Johnson FC. Multiple intracranial aneurysms due to *Coccidioides immitis* infection: case report. *J Neurosurg* 1987; 66:453-6.
61. Morriss FH Jr, Spock A. Intracranial aneurysms secondary to mycotic orbital and sinus infection: report of a case implicating penicillium as an opportunistic fungus. *Am J Dis Child* 1970; 119:357-62.
62. Shimosaka S, Waga S. Cerebral chromoblastomycosis complicated by

- meningitis and multiple fungal aneurysms after resection of a granuloma: case report. J Neurosurg 1983; 59:158-61.
63. Winston DJ, Jordan MC, Rhodes J. Allescheria boydii infections in the immunosuppressed host. Am J Med 1977; 63:830-5.
64. Oppe W. Zur Kenntniss der Schimmelmikosen beim Menschen. Zentralbl Allg Pathol 1897; 8:301-6.
65. Beal MF, O'Carroll CP, Kleinman GM, Grossman RI. Aspergillosis of the nervous system. Neurology 1982; 32:473-9.
66. Walsh TJ, Hier DB, Caplan LR. Aspergillosis of the central nervous system: clinicopathological analysis of 17 patients. Ann Neurol 1985; 18:574-82.
67. Stehbens WE. Atypical cerebral aneurysms. Med J Aust 1965; 1:765-6.
68. Horten BC, Abbott GF, Porro RS. Fungal aneurysms of intracranial vessels. Arch Neurol 1976; 33:577-9.

* * USE FORMAT 9 FOR FULL TEXT OF ARTICLE * *

?

11/TI/1 (Item 1 from file: 5)
DIALOG(R)File 5:(c) 1994 BIOSIS. All rts. reserv.

An activated Notch suppresses neurogenesis and myogenesis but not gliogenesis in mammalian cells

11/TI/2 (Item 2 from file: 5)
DIALOG(R)File 5:(c) 1994 BIOSIS. All rts. reserv.

Ed-CAM: A human epithelial antigen is a homophilic cell-cell adhesion molecule

11/TI/3 (Item 3 from file: 5)
DIALOG(R)File 5:(c) 1994 BIOSIS. All rts. reserv.

The level of cervical lymph node metastases: Their prognostic relevance and relationship with head and neck squamous carcinoma primary sites

11/TI/4 (Item 4 from file: 5)
DIALOG(R)File 5:(c) 1994 BIOSIS. All rts. reserv.

Transplantation tolerance

11/TI/5 (Item 5 from file: 5)
DIALOG(R)File 5:(c) 1994 BIOSIS. All rts. reserv.

CLINICAL UNDERESTIMATION OF LARYNGEAL CANCER PREDICTIVE INDICATORS

11/TI/6 (Item 6 from file: 5)
DIALOG(R)File 5:(c) 1994 BIOSIS. All rts. reserv.

DLK A PUTATIVE MAMMALIAN HOMEOTIC GENE DIFFERENTIALLY EXPRESSED IN SMALL CELL LUNG CARCINOMA AND NEUROENDOCRINE TUMOR CELL LINE

11/TI/7 (Item 7 from file: 5)
DIALOG(R)File 5:(c) 1994 BIOSIS. All rts. reserv.

EXPRESSION PATTERN OF NOTCH A MOUSE HOMOLOG OF DROSOPHILA NOTCH SUGGESTS AN IMPORTANT ROLE IN EARLY POSTIMPLANTATION MOUSE DEVELOPMENT

11/TI/8 (Item 8 from file: 5)
DIALOG(R)File 5:(c) 1994 BIOSIS. All rts. reserv.

POSSIBLE CONSEQUENCES OF INTENSIVE FISHING FOR MALES ON THE MATING OPPORTUNITIES OF DUNGENESS CRABS

11/TI/9 (Item 9 from file: 5)
DIALOG(R)File 5:(c) 1994 BIOSIS. All rts. reserv.

THE INFRAHYOID MUSCULOCUTANEOUS FLAP IN HEAD AND NECK RECONSTRUCTION

11/TI/10 (Item 10 from file: 5)
DIALOG(R)File 5:(c) 1994 BIOSIS. All rts. reserv.

THIN-SECTION CT IN SMALL PERIPHERAL ADENOCARCINOMA OF THE LUNG A
COMPARISON WITH CONVENTIONAL TOMOGRAPHY

11/TI/11 (Item 11 from file: 5)
DIALOG(R)File 5:(c) 1994 BIOSIS. All rts. reserv.

CHRONIC SCHISTOSOMIASIS JAPONICA IN FUJI CITY JAPAN

11/TI/12 (Item 12 from file: 5)
DIALOG(R)File 5:(c) 1994 BIOSIS. All rts. reserv.

EXPLOITATION AND MORTALITY OF MALE DUNGENESS CRABS CANCER-MAGISTER NEAR
TOFINO BRITISH COLUMBIA CANADA

11/TI/13 (Item 13 from file: 5)
DIALOG(R)File 5:(c) 1994 BIOSIS. All rts. reserv.

CT-PATHOLOGIC CORRELATION IN SMALL PERIPHERAL LUNG CANCERS

11/TI/14 (Item 14 from file: 5)
DIALOG(R)File 5:(c) 1994 BIOSIS. All rts. reserv.

PROSTATE SHAPE EXTERNAL STRIATED URETHRAL SPHINCTER AND RADICAL
PROSTATECTOMY THE APICAL DISSECTION

11/TI/15 (Item 15 from file: 5)
DIALOG(R)File 5:(c) 1994 BIOSIS. All rts. reserv.

IDIOPATHIC LARYNGEAL DEVIATION

11/TI/16 (Item 16 from file: 5)
DIALOG(R)File 5:(c) 1994 BIOSIS. All rts. reserv.

X-RAY MANIFESTATIONS OF ATYPICAL PERIPHERAL LUNG CANCER ANALYSIS OF 100
CASES

11/TI/17 (Item 17 from file: 5)
DIALOG(R)File 5:(c) 1994 BIOSIS. All rts. reserv.

BREAST CANCER METASTASIS TO INTRAMAMMARY LYMPH NODES

11/TI/18 (Item 18 from file: 5)
DIALOG(R)File 5:(c) 1994 BIOSIS. All rts. reserv.

HEPATIC SCHISTOSOMIASIS JAPONICA IDENTIFIED BY COMPUTED TOMOGRAPHY

11/TI/19 (Item 19 from file: 5)
DIALOG(R)File 5:(c) 1994 BIOSIS. All rts. reserv.

AN ANALYSIS OF 40 CASES OF CAVITARY BRONCHOGENIC CARCINOMA

11/TI/20 (Item 20 from file: 5)
DIALOG(R)File 5:(c) 1994 BIOSIS. All rts. reserv.

ELECTRO MYOGRAPHIC EVIDENCE OF INFERIOR GLUTEAL NERVE COMPROMISE AN EARLY REPRESENTATION OF RECURRENT COLO RECTAL CARCINOMA

11/TI/21 (Item 21 from file: 5)
DIALOG(R)File 5:(c) 1994 BIOSIS. All rts. reserv.

SCIRRHOUS CARCINOMA OF THE PYLORIC CHANNEL AND DISTAL ANTRUM

11/TI/22 (Item 1 from file: 73)
DIALOG(R)File 73:(c) 1994 Elsevier Science B.V. All rts. reserv.

Radiation effects on the optic nerve observed after brachytherapy of choroidal melanomas with 106Ru/106Rh plaques

11/TI/23 (Item 2 from file: 73)
DIALOG(R)File 73:(c) 1994 Elsevier Science B.V. All rts. reserv.

Adult T cell leukaemia-lymphoma

11/TI/24 (Item 3 from file: 73)
DIALOG(R)File 73:(c) 1994 Elsevier Science B.V. All rts. reserv.

Color Doppler sonography of ovarian masses: A multiparameter analysis

11/TI/25 (Item 4 from file: 73)
DIALOG(R)File 73:(c) 1994 Elsevier Science B.V. All rts. reserv.

Snapshots versus medical photographs: Understanding the difference is your key to better dermatologic office photography

11/TI/26 (Item 5 from file: 73)
DIALOG(R)File 73:(c) 1994 Elsevier Science B.V. All rts. reserv.

Adult T-cell leukemia and HTLV-I related diseases

11/TI/27 (Item 6 from file: 73)

DIALOG(R)File 73:(c) 1994 Elsevier Science B.V. All rts. reserv.

Microsurgical removal of petroclival meningiomas: A report of 33 patients

11/TI/28 (Item 7 from file: 73)

DIALOG(R)File 73:(c) 1994 Elsevier Science B.V. All rts. reserv.

Perifollicular hypopigmentation: A cause of variegate pigmentation and irregular border in melanocytic nevi

11/TI/29 (Item 8 from file: 73)

DIALOG(R)File 73:(c) 1994 Elsevier Science B.V. All rts. reserv.

Expression of an activated Notch-related int-3 transgene interferes with cell differentiation and induces neoplastic transformation in mammary and salivary glands

11/TI/30 (Item 9 from file: 73)

DIALOG(R)File 73:(c) 1994 Elsevier Science B.V. All rts. reserv.

TAN-1, the human homolog of the Drosophila Notch gene, is broken by chromosomal translocations in T lymphoblastic neoplasms

11/TI/31 (Item 10 from file: 73)

DIALOG(R)File 73:(c) 1994 Elsevier Science B.V. All rts. reserv.

The prevalence and distribution of well-circumscribed nodules on screening mammography. Analysis of 1500 mammograms

11/TI/32 (Item 11 from file: 73)

DIALOG(R)File 73:(c) 1994 Elsevier Science B.V. All rts. reserv.

Unilateral gate flap for reconstruction of the lower lip

11/TI/33 (Item 12 from file: 73)

DIALOG(R)File 73:(c) 1994 Elsevier Science B.V. All rts. reserv.

The inferior dermal-pyramidal type breast reduction: Long-term evaluation

11/TI/34 (Item 13 from file: 73)

DIALOG(R)File 73:(c) 1994 Elsevier Science B.V. All rts. reserv.

Role of computed tomography in selecting patients for hindquarter amputation

11/TI/35 (Item 14 from file: 73)
DIALOG(R)File 73:(c) 1994 Elsevier Science B.V. All rts. reserv.

MRI with surface coils for parathyroid tumors: Preliminary investigation

11/TI/36 (Item 15 from file: 73)
DIALOG(R)File 73:(c) 1994 Elsevier Science B.V. All rts. reserv.

Analysis of pulmonary tuberculomas diagnosed by exploratory excision

11/TI/37 (Item 16 from file: 73)
DIALOG(R)File 73:(c) 1994 Elsevier Science B.V. All rts. reserv.

Meningiomas of the basal posterior cranial fossa. Neuroradiologic diagnosis and its relation to clinical and surgical findings
POSTEROBASALE MENINGEOME. NEURORADIOLOGISCHE DIAGNOSTIK UND IHRE BEZIEHUNG ZU KLINISCHEN UND OPERATIVEN BEFUNDEN

11/TI/38 (Item 17 from file: 73)
DIALOG(R)File 73:(c) 1994 Elsevier Science B.V. All rts. reserv.

Hepatic schistosomiasis japonica identified by CT

11/TI/39 (Item 18 from file: 73)
DIALOG(R)File 73:(c) 1994 Elsevier Science B.V. All rts. reserv.

Coronary artery bypass in patients with total laryngectomy

11/TI/40 (Item 19 from file: 73)
DIALOG(R)File 73:(c) 1994 Elsevier Science B.V. All rts. reserv.

Radiology of large transincisural masses

11/TI/41 (Item 20 from file: 73)
DIALOG(R)File 73:(c) 1994 Elsevier Science B.V. All rts. reserv.

Breakaway safety feature for an intra-oral cone system

11/TI/42 (Item 21 from file: 73)
DIALOG(R)File 73:(c) 1994 Elsevier Science B.V. All rts. reserv.

Ultrastructural localization of acid phosphatase in immunologically defined neoplastic lymphocytic cells and hairy cells. A comparison between two different substrates

11/TI/43 (Item 22 from file: 73)
DIALOG(R)File 73:(c) 1994 Elsevier Science B.V. All rts. reserv.

Primary choroid plexus papilloma of the cerebellopontine angle

11/TI/44 (Item 23 from file: 73)

DIALOG(R)File 73:(c) 1994 Elsevier Science B.V. All rts. reserv.

Extra-cranial tumours of the infratemporal fossa

11/TI/45 (Item 24 from file: 73)

DIALOG(R)File 73:(c) 1994 Elsevier Science B.V. All rts. reserv.

Normal intramammary lymph nodes presenting as occult breast masses

11/TI/46 (Item 25 from file: 73)

DIALOG(R)File 73:(c) 1994 Elsevier Science B.V. All rts. reserv.

Electromyographic evidence of inferior gluteal nerve compromise: An early representation of recurrent colorectal carcinoma

11/TI/47 (Item 26 from file: 73)

DIALOG(R)File 73:(c) 1994 Elsevier Science B.V. All rts. reserv.

Malignant ameloblastoma with metastasis to the skull: Report of case

11/TI/48 (Item 27 from file: 73)

DIALOG(R)File 73:(c) 1994 Elsevier Science B.V. All rts. reserv.

Transcutaneous continuous wave Doppler ultrasound in the diagnosis of left atrial myxoma

11/TI/49 (Item 28 from file: 73)

DIALOG(R)File 73:(c) 1994 Elsevier Science B.V. All rts. reserv.

Facial reflex examination. A clinical and neurophysiological study on acoustic tumours and brain displacement at the tentorial notch

11/TI/50 (Item 29 from file: 73)

DIALOG(R)File 73:(c) 1994 Elsevier Science B.V. All rts. reserv.

M-mode echocardiography in the detection of intracardiac tumors
M-MODE ECHOKARDIOGRAPHIE BEI INTRAKARDIALEN TUMOREN

?

4/7/6 (Item 6 from file: 5)
DIALOG(R)File 5:BIOSIS PREVIEWS(R)
(c) 1994 BIOSIS. All rts. reserv.

6404069 BIOSIS Number: 85004590
THE EFFECT OF PRESTAINING PRIOR TO IMMUNOREACTION DURING ELECTROPHORETIC
BLOTTING OF PROTEINS

TRACY R P; MONKOVIC D; ANDRIANORIVO A; CALORE J; MACKAY A
DEP. PATHOL., HEALTH SCI. COMPLEX, UNIV. VT., BURLINGTON, VT.05405, USA.
ELECTROPHORESIS 8 (8). 1987. 350-355. CODEN: ELCTD
Full Journal Title: Electrophoresis
Language: ENGLISH

We have used six different monoclonal and polyclonal antibodies, four different antigen preparations and two different detection systems to compare Western blotting with Coomassie Blue prestained gels (Jackson and Thompson, Electrophoresis, 1984, 5, 35-42) to blotting of unstained gels with Amido Black or Fast Green post-transfer staining of the nitrocellulose. Contrary to a recent report (Harper et al., Anal. Biochem., 1986, 157, 270-274), in which post-staining with Coomassie Blue was determined to severely inhibit immunoreactivity, we find using prestained Coomassie Blue gels to be extremely useful in most cases, although, rarely, inhibition of the immune reaction may take place. Post-staining with Amido Black or Fast Green may also prove useful, but is not recommended since similar inhibition occurs, and there are the added disadvantages of not being able to "pre-view" the gel pattern and not being able to use stored gels. Further studies indicated that the rare loss of immunoreactivity seen with Coomassie Blue prestained gels is most likely due to the necessary fixation step, and not the stain itself (as has been suggested), since the protein-dye complex is dissociated during transfer.

4/7/9 (Item 9 from file: 5)
DIALOG(R)File 5:BIOSIS PREVIEWS(R)
(c) 1994 BIOSIS. All rts. reserv.

5234529 BIOSIS Number: 81001836
A SENSITIVE ASSAY OF CYTOTOXICITY APPLICABLE TO MIXED CELL POPULATIONS
DUERST R E; FRANTZ C N
DEP. PEDIATRICS, UNIV. ROCHESTER SCH. MED. AND DENTISTRY, ROCHESTER, N.Y.
14642, USA.
J IMMUNOL METHODS 82 (1). 1985. 39-46. CODEN: JIMMB
Full Journal Title: Journal of Immunological Methods
Language: ENGLISH

The fluorescent vital dye, Hoechst 33342, was used to stain cultured cells prior to assay of antibody dependent complement mediated cytotoxicity. The fluorescence of nonviable dye stained cell is quenched by cellular uptake of trypan blue, but trypan blue excluding cells remain intensely fluorescent. Detection by fluorescence microscopy of one viable prestained cell per 105 unstained cells was accurate and reliable. The technique was found to have sensitivity equal to a clonogenic assay for measuring cytotoxicity. The dye stained cell assay may be used to measure depletion of a selected cell type, when those cells are stained prior to mixing with another cell population. This technique may prove useful to

study model systems for depletion of tumor cells or T-cells from bone

marrow.

4/7/20 (Item 6 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 1994 Elsevier Science B.V. All rts. reserv.

103452 EMBASE No: 74105173
Nitroblue tetrazolium. A new lipoprotein stain
Segal A.W.; Putman D.; Minchin Clarke H.G.
Clin. Res. Cent., Harrow UNITED KINGDOM
ATHEROSCLEROSIS (AMST.) (NETHERLANDS) , 1973, 18/3 (499-504) CODEN:
ATHSB

LANGUAGES: ENGLISH

The diformazan of nitroblue tetrazolium (NBT) is presented as a new, specific pre stain for lipoproteins. NBT requires no organic solvent and is shown to be effective in agarose, cellulose acetate and polyacrylamide gel. When added in the correct concentrations, NBT does not appear to alter the electrophoretic migration or antigen antibody reaction of the lipoproteins.

4/7/21 (Item 1 from file: 155)
DIALOG(R)File 155:MEDLINE(R)
(c) format only 1994 Dialog Info.Svcs. All rts. reserv.

07308891 90215891
Coomassie brilliant blue R-250 as a highly sensitive pre-stain for immediate visualization of human serum proteins on polyacrylamide gel disc electrophoresis and raising monospecific antibodies.
Saoji AM; Kulkarni M; Naghi T
Indian J Pathol Microbiol (INDIA) Oct 1989, 32 (4) p286-90, ISSN
0377-4929 Journal Code: GKK

Languages: ENGLISH

Document type: JOURNAL ARTICLE

We hereby describe electrophoretic analysis of normal human serum pre-stained with Coomassie Brilliant Blue R-250 (CBB). The proposed method was optimized by studying as many as 450 disc electrophoretic separations and 30 variables. The method when compared with the post-electrophoretic staining by Amido Black (AB) revealed that the pre-stained discs were intensely well defined and resolved within 2 hours with a transparent gel. Gels stained with AB, despite a prolonged destaining, showed a residual dye retention making identification of the faint components difficult. Protein eluted from the CBB pre-stained gels retained its purity and immunoreactivity and conjugates of the two prototype proteins namely the albumin and the transferrin produced high-titre monospecific antisera in immunized rabbits.

4/7/22 (Item 2 from file: 155)
DIALOG(R)File 155:MEDLINE(R)
(c) format only 1994 Dialog Info.Svcs. All rts. reserv.

07077326 89379326
Identification of C-3 on polyacrylamide gel by pre-staining the normal human serum with Coomassie Brilliant Blue and raising monospecific anti C-3

antibody.

Saoji AM; Naghi T

Indian J Pathol Microbiol (INDIA) Jul 1989, 32 (3) p221-6, ISSN
0377-4929 Journal Code: GKK

Languages: ENGLISH

Document type: JOURNAL ARTICLE

Based on our earlier work we hereby describe pre-staining of normal human serum with Remazol Brilliant Blue (RBB) to precisely locate the third component of complement system (C3,B1C) on polyacrylamide gels. Testing the dye-protein complex eluted from different immunoreactive post-transferrin (origin to transferrin) components against the standards anti-C3 antibody in various gel precipitation techniques, revealed that the prominent band just posterior to the centrally placed transferrin is of complement. Subsequent to its identity, we also evolved a method to raise an anti-C3 antibody. The resulting antibody was found to be monospecific when assessed in different gel precipitation procedures.

4/7/29 (Item 3 from file: 442)
DIALOG(R)File 442:AMA Journals Online
(c) 1994 American Medical Assoc. All rts. reserv.

00046604

Copyright (C) 1989 American Medical Association

Intralaboratory Quality Assurance of Immunohistochemical Procedures;
Recommended Practices for Daily Application (COLLEGE OF AMERICAN
PATHOLOGISTS CONFERENCE XV AUGUST 22-24, 1988)

RICKERT, ROBERT R.
Archives of Pathology and Laboratory Medicine

June, 1989; 113: 673-679

LINE COUNT: 00422 WORD COUNT: 05824

ISSN: 0363-0153

CORPORATE SOURCE: Accepted for publication Oct 13, 1988. From the
Department of Pathology, St. Barnabas Medical Center, Livingston, NJ.
Reprint requests to Department of Pathology, St Barnabas Medical Center,
Old Short Hills Road, Livingston, NJ 07039 (Dr Rickert).

ABSTRACT: During the past several decades, immunohistologic techniques have been developed that may provide important adjunctive information to the diagnostic pathologist. These procedures are now widely available and commonly used in the pathology laboratory. Proper performance of immunohistochemical procedures and interpretation of their results require development and implementation of appropriate quality control and quality assurance measures. This article reviews the application of quality control standards in the immunohistochemistry laboratory and the integration of these activities into the overall quality assurance program of the department.

* * USE FORMAT 9 FOR FULL TEXT OF ARTICLE * *

CITED REFERENCES:

1. Coons AH, Creech HJ, Jones RN: Immunological properties of an antibody containing a fluorescent group. Proc Soc Exp Biol Med
1941;47:200-202.
2. Nakane PK, Pierce GB Jr: Enzyme-labeled antibodies: Preparation and

application for the localization of antigen. J Histochem Cytochem 1966;14:929-931.

3. DiStefano HS, Marucci AA, Dougherty RM: Immunohistochemical demonstration of avian leukosis virus antigens in paraffin embedded tissue. Proc Soc Exp Biol Med 1973;142:1111-1115.
4. Taylor CR, Burns J: The demonstration of plasma cells and other immunoglobulin-containing cells in formalin-fixed paraffin-embedded tissues using peroxidase-labeled antibody. J Pathol 1974;27:14-18.
5. Sternberger LA: Preparation of soluble antigen-antibody complexes (horseradish peroxidase-antihorseradish peroxidase) and its use in identification of spirochetes. J Histochem Cytochem 1970;18: 315-320.
6. Hsu SM, Raine L: Protein A, avidin, and biotin in immunohistochemistry. J Histochem Cytochem 1981;29: 1349-1353.
7. Rickert RR: Quality assurance in anatomic pathology. Clin Lab Med 1986;6:697-706.
8. College of American Pathologists: Standards for Laboratory Accreditation. Skokie, Ill, College of American Pathologists, 1987.
9. College of American Pathologists: Commission on Laboratory Accreditation Inspection Checklists. Skokie, Ill, College of American Pathologists, 1988.
10. Judd MA, Britten KJM: Tissue preparation for the demonstration of surface antigens by immunoperoxidase techniques. Histochem J 1982;14:747-753.
11. Meade JO Jr: Improved rapid freezing using cooled isopentane. J Histotechnol 1987;10:189.
12. Muensch H, Maslow WC: Interference of O.C.T. embedding compound with hormone receptor assays. Am J Clin Pathol 1984;82:89-92.
13. Nadji M: The potential value of immunoperoxidase techniques in diagnostic cytology. Acta Cytol 1980;24:442-447.
14. Chess O, Hajdu SI: The role of immunoperoxidase staining in diagnostic cytology. Acta Cytol 1986;30:1-7.
15. Roholl FJM, deJong ASH, Ramaekers FCS: Application of markers in diagnosis of soft tissue tumors. Histopathology 1985;9:1019-1035.
16. Abbott Laboratories: ER-ICA: Monoclonal, Immunocytochemical Assay for the Detection of Human Estrogen Receptor, package insert. North Chicago, Ill, Abbott Laboratories, April 1986.
17. Pappas PW: The use of chrome alum-gelatin (subbing) solution as a general adhesive for paraffin sections. Stain Technol 1971;46:121-124.
18. Huang WM, Gibson SJ, Facer P, et al: Improved section adhesion for

immunocytochemistry using high molecular weight polymers of L-lysine as a slide coating. Histochemistry 1983;77:275-279.

19. Maples JA: A method for the covalent attachment of cells to glass slides for use in immunochemical assays. Am J Clin Pathol 1985;83:356-363.
20. Vector Laboratories Inc: Vectastain ABC Kit Instructions, package insert (notes section). Burlingame, Calif, Vector Laboratories Inc, 1987.
21. Taschini PA, MacDonald DM: Protease digestion step in immunohistochemical procedures: Ficin as a substitute for trypsin. Lab Med 1987;18:532-536.
22. Battifora H, Kopinski M: The influence of protease digestion and duration of fixation on the immunostaining of keratins. J Histochem Cytochem 1986;34:1095-1100.
23. Ordonez NG, Manning JT, Brooks TE: Effect of trypsinization on the immunostaining of formalin-fixed, paraffin-embedded tissues. Am J Surg Pathol 1988;12:121-129.
24. Andrade RE, Hagen KA, Swanson PE, et al: The use of proteolysis with ficin, for immunostaining of paraffin sections. Am J Clin Pathol 1988;90:33-39.
25. Li C-Y, Ziesmer SC, Lazcano-Villareal C: Use of azide and hydrogen peroxide as an inhibitor for endogenous peroxidase in the immunoperoxidase method. J Histochem Cytochem 1987;35:1457-1460.
26. Burns J: Immunohistochemical methods and their application in the routine laboratory, in Anthony PP, Woolf N (eds): Recent Advances in Histopathology. New York, Churchill Livingstone, Inc, 1978, pp 337-350.
27. Cordell JL, Falini B, Erber WN, et al: Immunoenzymatic labeling of monoclonal antibodies using immune complexes of alkaline phosphatase and monoclonal anti-alkaline phosphatase. J Histochem Cytochem 1984;32:219-229.
28. Suffin SC, Muck KB, Young JC, et al: Improvement of the glucose oxidase immunoenzyme technic: Use of a tetrazolium whose formazan is stable without heavy metal chelation. Am J Clin Pathol 1979;71:492-496.
29. Wood GS, Warnke R: Suppression of endogenous avidin activity in tissues and its relevance to biotin-avidin detection system. J Histochem Cytochem 1981; 29:1196-1204.
30. Mesa-Tejada R, Pascal RR, Fenoglio CM: Immunoperoxidase: A sensitive immunohistochemical technique as a special stain in the diagnostic pathology laboratory. Hum Pathol 1977;8:313-320.
31. Ciocca DR, Adams DJ, Bjercke RJ, et al: Monoclonal antibody storage conditions, and concentration effects on immunohistochemical

specificity. J Histochem Cytochem 1983;31:691-696.

32. Weisburger EK, Russfield AB, Homburger F, et al: Testing of 21 environmental aromatic amines or derivatives for long-term toxicity or carcinogenicity. J Environ Pathol Toxicol Oncol 1978;2:325-356.
33. Nadji M, Morales AR: Immunoperoxidase Techniques: A Practical Approach to Tumor Diagnosis. Chicago, American Society of Clinical Pathologists Press, 1986.
34. Tubbs RR, Gephardt GN, Petras RE: Specimen processing and quality assurance, in Atlas of Immunohistology. Chicago, American Society of Clinical Pathologists Press, 1986, pp 16-27.
35. Pallesen G, Plesner T: Congress letter: The third international workshop on human leukocyte differentiation antigens with an up-to-date overview of the CD nomenclature. Leukemia 1987;1:231-234.
36. Machado-Vieira LM, Sarno EN: The efficacy of the immunoperoxidase technique for the detection of several antigens after destaining of stored stained sections. Braz J Med Biol Res 1982;15:265-268.
37. Milios J, Leong AS-Y: The application of the avidin-biotin technique to previously stained histological sections. Stain Technol 1987;62:411-416.
38. Buick MK, Budgeon LR, Brigati DJ: The automated use of monoclonal antibodies in diagnostic surgical pathology. Presented at the Spring Meeting of the American Society of Clinical Pathologists/College of American Pathologists, San Francisco, March 31, 1987.
39. Tubbs RR: Automation of immunohistochemical techniques. Arch Pathol Lab Med 1989;113:653-658.

apparent effects, overexpression of activated Notch in the same cells transiently blocks their proper cell-fate commitment, causing them to either adopt incorrect cell fates or to differentiate incompletely. Moreover, an activated Notch protein lacking the transmembrane domain is translocated to the nucleus, raising the possibility that Notch may participate directly in nuclear events.

15/7/4 (Item 4 from file: 5)
DIALOG(R)File 5:BIOSIS PREVIEWS(R)
(c) 1994 BIOSIS. All rts. reserv.

10805885 BIOSIS Number: 97005885

An activated notch receptor blocks cell-fate commitment in the developing *Drosophila* eye

Fortini M E; Rebay I; Caron L A; Artavanis-Tsakonas S
Dep. Cell Biol., Yale Univ., New Haven, CT 06536, USA
Nature (London) 365 (6446). 1993. 555-557.

Full Journal Title: Nature (London)

ISSN: 0028-0836

Language: ENGLISH

The Notch locus of *Drosophila melanogaster* encodes a 2,703-amino-acid transmembrane protein required for a variety of developmental processes, including neurogenesis, oogenesis and ommatidial assembly. The Notch protein contains a large extracellular domain of 36 epidermal growth factor-like repeats as well as three Notch/Lin-12 repeats and an intracellular domain with 6 Cdc10/ankyrin repeats, motifs that are highly conserved in several vertebrate Notch homologues. Truncation of the extracellular domain of the *Drosophila* Notch protein produces an activated receptor, as judged by its ability to cause phenotypes similar to gain-of-function alleles or duplications of the Notch locus. Equivalent truncations of vertebrate Notch-related proteins have been associated with malignant neoplasms and other developmental abnormalities. We present here an analysis of activated Notch function at single-cell resolution in the *Drosophila* compound eye. We find that overexpression of full-length Notch in defined cell types has no apparent effects but that overexpression of activated notch in the same cells transiently blocks their proper cell-fate commitment, causing them either to adopt incorrect cell fates or to differentiate incompletely. Moreover, an activated notch protein lacking the transmembrane domain is translocated to the nucleus, raising the possibility that Notch may participate directly in nuclear events.

15/7/5 (Item 5 from file: 5)
DIALOG(R)File 5:BIOSIS PREVIEWS(R)
(c) 1994 BIOSIS. All rts. reserv.

10110234 BIOSIS Number: 95110234

DLK A PUTATIVE MAMMALIAN HOMEOTIC GENE DIFFERENTIALLY EXPRESSED IN SMALL CELL LUNG CARCINOMA AND NEUROENDOCRINE TUMOR CELL LINE

LABORDA J; SAUSVILLE E A; HOFFMAN T; NOTARIO V

CENTER BIOL. RESEARCH, FDA., 8800 ROCKVILLE PIKE, BLDG. 29, BETHESDA, MD 20892, USA.

J BIOL CHEM 268 (6). 1993. 3817-3820. CODEN: JBCHA

Full Journal Title: Journal of Biological Chemistry

Language: ENGLISH

Gastrin releasing peptide is mitogenic for mouse Swiss 3T3 fibroblasts and certain human small cell lung carcinoma (SCLC) cells but not for mouse Balb/c 3T3 fibroblasts. To identify new molecules associated with the gastrin releasing peptide-responsive phenotype, clones isolated from a differential cDNA library between Swiss and Balb/c 3T3 fibroblasts were used to screen for their expression in human SCLC cell lines. Using this approach, we have isolated and characterized human and mouse cDNA clones encoding a novel protein. This protein is a putative transmembrane protein belonging to the epidermal growth factor-like superfamily. In vitro transcription and translation studies detect a 42-kDa protein, in agreement with the size predicted from the translated cDNA sequence. This protein (termed Delta-like or dlk) is highly homologous to invertebrate homeotic proteins, including Delta, and Notch, the products of neurogenic loci involved in normal neural differentiation in *Drosophila*. dlk is expressed in tumors with neuroendocrine features, such as neuroblastoma, pheochromocytoma, and a subset of SCLC cells lines. However, its expression in normal tissues is restricted to the adrenal gland and placenta. These data suggest that dlk may be involved in neuroendocrine differentiation and, because of its cellular location and restricted expression in normal tissues, it may be a potential therapeutic target in neuroendocrine tumors, particularly SCLC.

15/7/6 (Item 6 from file: 5)
DIALOG(R)File 5:BIOSIS PREVIEWS(R)
(c) 1994 BIOSIS. All rts. reserv.

9590824 BIOSIS Number: 94095824

EXPRESSION PATTERN OF MOTCH A MOUSE HOMOLOG OF DROSOPHILA NOTCH SUGGESTS AN IMPORTANT ROLE IN EARLY POSTIMPLANTATION MOUSE DEVELOPMENT

FRANCO DEL AMO F; SMITH D E; SWIATEK P J; GENDRON-MAGUIRE M; GREENSPAN R J; MCMAHON A P; GRIDLEY T

DEP. CELL DEVELOPMENTAL BIOL., ROCHE INST. MOLECULAR BIOLOGY, ROCHE RES. CENTER, NUTLEY, NJ 07110.

DEVELOPMENT (CAMB) 115 (3). 1992. 737-744. CODEN: DEVPE

Full Journal Title: DEVELOPMENT (Cambridge)

Language: ENGLISH

The Notch gene of *Drosophila* encodes a large transmembrane protein involved in cell-cell fate decisions in the *Drosophila* embryo. To determine if a gene homologous to *Drosophila* Notch plays a role in early mouse development, we screened a mouse embryo cDNA library with probes from the *Xenopus* Notch homolog, Xotch. A partial cDNA clone encoding the mouse Notch homolog which we have termed Motch, was used to analyze expression of the Motch gene. Motch transcripts were detected in a wide variety of adult tissues, which included derivatives of all three germ layers. Differentiation of P19 embryonal carcinoma cells into neuronal cell types resulted in increased expression of Motch RNA. In the postimplantation mouse embryo Motch transcripts were first detected in mesoderm at 7.5 days post coitum (dpc). By 8.5 dpc, transcript levels were highest in presomitic mesoderm, mesenchyme and endothelial cells, while much lower levels were detected in neuroepithelium was a major site of Motch expression. Transcripts were also abundant in cell types derived from neural crest. These data suggest that the Motch gene plays multiple roles in patterning and differentiation of the early postimplantation mouse embryo.

15/7/7 (Item 1 from file: 144)
DIALOG(R)File 144:Pascal
(c) 1994 INIST/CNRS. All rts. reserv.

10278296 PASCAL No.: 92-0484208

Expression pattern of Motch, a mouse homolog of Drosophila notch, suggests an important role in early postimplantation mouse development

DEL AMO F F; SMITH D E; SWIATEK P J; GENDRON-MAGUIRE M; GREENSPAN R J; MCMAHON A P; GRIDLEY T

Roche inst. molecular biology, dep. cell developmental biology, Nutley NJ 07110, USA

Journal: Development : (Cambridge), 1992, 115 (3) 737-744

ISSN: 0950-1991 Availability: INIST-7560; 354000020190410090

No. of Refs.: 1 p.1/2

Document Type: P (Serial) ; A (Analytic)

Country of Publication: United Kingdom

Language: English

The Notch gene of Drosophila encodes a large transmembrane protein involved in cell-cell interactions and cell fate decisions in the Drosophila embryo. To determine if a gene homologous to Drosophila Notch plays a role in early mouse development, we screened a mouse embryo cDNA library with probes from the Xenopus Notch homolog, Xotch. A partial cDNA clone encoding the mouse Notch homolog, which we have termed Motch, was used to analyze expression of the Motch gene. Motch transcripts were detected in a wide variety of adult tissues, which included derivatives of all three germ layers

15/7/8 (Item 1 from file: 155)
DIALOG(R)File 155:MEDLINE(R)
(c) format only 1994 Dialog Info.Svcs. All rts. reserv.

09041700 94356700

Analysis of phenotypic abnormalities and cell fate changes caused by dominant activated and dominant negative forms of the Notch receptor in Drosophila development.

Rebay I; Fortini ME; Artavanis-Tsakonas S

Howard Hughes Medical Institute, Department of Cell Biology, Yale University, New Haven, Connecticut 06536-0812.

C R Acad Sci III (FRANCE) Sep 1993, 316 (9) p1097-123, ISSN 0764-4469
Journal Code: CA1

Languages: ENGLISH, FRENCH

Document type: JOURNAL ARTICLE; REVIEW; REVIEW, TUTORIAL

The Notch gene of Drosophila plays an important role in cell fate specification throughout development. The Notch protein contains a large extracellular domain of 36 EGF-like repeats as well as 3 Notch/lin-12 repeats and an intracellular domain with 6 cdc10/ankyrin repeats, motifs which are highly conserved in several vertebrate Notch homologues [1-7]. In this review we summarize the results of two recent studies which attempt to establish structure-function relationships of the various domains of the Notch gene product [8, 9]. The functions of various structural domains of the Notch protein in vivo were investigated using a series of deletion mutants which have been ectopically expressed either under the hsp70 heat-shock promoter or under the sevenless eye-specific promoter. Truncation of the extracellular domain of Drosophila Notch produces an activated receptor as judged by its ability to cause phenotypes matching

those of gain-of-function alleles or duplications of the Notch locus [8]. Equivalent truncations of vertebrate Notch-related proteins have been associated with malignant neoplasms and other developmental abnormalities [3, 6, 10, 11]. In contrast, dominant negative phenotypes result from overexpression of a protein lacking most intracellular sequences. These results were extended by an analysis of activated Notch function at single-cell resolution in the *Drosophila* compound eye [9]. It was shown that while overexpression of full-length Notch in defined cell types has no apparent effects, overexpression of activated Notch in the same cells transiently blocks their proper cell-fate commitment, causing them to either adopt incorrect cell fates or to differentiate incompletely. Moreover, an activated Notch protein lacking the transmembrane domain is translocated to the nucleus, raising the possibility that Notch may participate directly in nuclear events. (68 Refs.)

15/7/9 (Item 2 from file: 155)
DIALOG(R)File 155:MEDLINE(R)
(c) format only 1994 Dialog Info.Svcs. All rts. reserv.

06701790 89003790

Expression of the differentiation antigen F7D6 in tumorous tissues of *Drosophila*.

Bedian V; Jungklaus CE

Department of Biology, Clarkson University, Potsdam, New York 13676.

Dev Genet (UNITED STATES) 1987, 8 (3) p165-77, ISSN 0192-253X

Journal Code: DEG

Languages: ENGLISH

Document type: JOURNAL ARTICLE

The 63-kDa antigen recognized by the monoclonal antibody F7D6 is present in all *Drosophila* embryonic cells and disappears from most tissues as each one reaches its final, differentiated state. Larval tissues lose the antigen around the time of hatching, imaginal tissues lose it during metamorphosis, and germ cells lose it during gametogenesis (Bedian et al: *Devel Biol* 115:105-118, 1986). The nervous system and spontaneously contracting musculature of the gut and gonads are exceptions and remain antigen positive at all stages. The F7D6 antigen appears to be associated with dividing, undifferentiated cells and electrogenic cells. This prompted us to test tumors for antigen presence. We tested four different recessive mutants that give rise to four different types of tumorous transformation: the embryonic tumor Notch, several larval melanotic tumors, the imaginal disc tumor 1(2)gl, and three alleles of the ovarian tumor otu. In all cases, tumorous tissues in homozygotes contained the F7D6 antigen. The electrophoretic mobility of the antigen appeared to be unaltered in tumorous tissues compared to normal cells, but the antigen is expressed at higher levels. The antigen is found on the cytoplasmic surface of plasma membranes and appears to be a marker of undifferentiated normal and tumorous cells. Similarities and differences between the F7D6 antigen and *Drosophila* c-src protein are discussed.

15/7/10 (Item 1 from file: 351)
DIALOG(R)File 351:DERWENT WPI
(c) 1994 Derwent Info Ltd. All rts. reserv.

009855324 WPI Acc No: 94-135180/16

XRAM Acc No: C94-062475

XRPX Acc No: N94-106287

Notch protein and nuclear acid compositions - is used for treatment of disorders of cell fate or differentiation esp. breast, colon or cervical cancer

Patent Assignee: (UYYA) UNIV YALE

Author (Inventor): ARTAVANIS-TSAKONAS S; BLAUMUELLER C M; FEHON R G; ZAGOURAS P

Number of Patents: 002

Number of Countries: 045

Patent Family:

CC Number	Kind	Date	Week	
WO 9407474	A1	940414	9416	(Basic)
AU 9453503	A	940426	9432	

Priority Data (CC No Date): US 955012 (920930); US 83590 (930625)

Applications (CC,No,Date): AU 9453503 (930930); WO 93US9338 (930930)

Language: English

EP and/or WO Cited Patents: 6.Jnl.Ref; US 5115096; US 5132212; US 5264557

Designated States

(National): AU; BB; BG; BR; BY; CA; CZ; FI; HU; JP; KP; KZ; LK; LV; MG; MN; MW; NO; NZ; PL; RO; RU; SD; SK; UA; US; UZ; VN

(Regional): AT; BE; CH; DE; DK; ES; FR; GB; GR; IE; IT; LU; MC; NL; OA; PT; SE

Filing Details: AU9453503 Based on WO 9407474

Abstract (Basic): WO 9407474 A

The pharmaceutical compsn. comprises a therapeutically effective amt. of a Notch protein (A) and a pharmaceutically acceptable carrier.

USE - The compsns. can be used for treatment of disorders of cell fate or differentiation. The therapeutic compsns. include Notch proteins and analogues, derivs. and fragments, antibodies, nucleic acid encoding, analogues and derivs., Notch antisense nucleic acids, toporythmic proteins and derivs. which bind or interact with Notch proteins, their encoding nucleic acids or Abs. The compsn. is pref. admin. to a cancerous condition, e.g. breast, colon or cervical cancer, or to prevent progression from a pre-neoplastic or non-malignant state into a neoplastic or malignant state. Dwg.0/17

Derwent Class: B04; D16; S03;

Int Pat Class: A61K-031/70; A61K-037/02; A61K-039/395; A61K-039/44;

C07H-021/04; G01N-033/53; G01N-033/68

15/7/11 (Item 2 from file: 351)

DIALOG(R)File 351:DERWENT WPI

(c) 1994 Derwent Info Ltd. All rts. reserv.

009400489 WPI Acc No: 93-093998/11

XRAM Acc No: C93-041615

DNA encoding GA binding protein sub-unit - allows investigation of sub-unit sequence motif functions, for control of rapid cell division e.g. in cancer; GUANOSINE ADENOSINE PURINE

Patent Assignee: (CARN-) CARNEGIE INSTITUTION WASHINGTON; (CARN-) CARNEGIE INST WASHINGTON

Author (Inventor): LAMARCO K L; MCKNIGHT S L; THOMPSON C C

Number of Patents: 003

Number of Countries: 019

Patent Family:

CC Number	Kind	Date	Week	
WD 9304166	A1	930304	9311	(Basic)
AU 9224857	A	930316	9328	
EP 598839	A1	940601	9421	

Priority Data (CC No Date): US 746032 (910816)

Applications (CC,No,Date): EP 92918552 (920817); WO 92US6748 (920817); WO 92US6748 (920817); AU 9224857 (920817)

Language: English

EP and/or WO Cited Patents: 19Jnl.Ref; WO 8909777; WO 9005745; WO 9107423

Designated States

(National): AU; CA; JP

(Regional): AT; BE; CH; DE; DK; ES; FR; GB; GR; IE; IT; LI; LU; MC; NL; SE

Filing Details: EP0598839 Based on WO 9304166; AU9224857 Based on WO 9304166

Abstract (Basic): WO 9304166 A

DNA encoding a GA binding protein (GABP) subunit, or an epitope specific, to it or a DNA fragment complementary to this DNA is new. Also claimed are: (1) a recombinant DNA molecule comprising the DNA segment and a vector; and (2) a host cell transformed with the DNA of (1).

GABP alpha has a 454 aminoacid sequence and GABP beta 1 has a 382 aminoacid sequence (both given in the specification). GABP is produced by culturing the transformed cells.

USE - The DNA encodes the subunits GABP alpha, GABP beta 1 or GABP beta 2, or portions of these. GABP alpha is related to the Ets transforming protein, and GABP beta contains a series of 33 aminoacid repeats related to, e.g. Notch of *Drosophila melanogaster*, Lin12 and Glp1 of *Caenorhabditis elegans* and SW14 and SW16 of *Saccharomyces cerevisiae*. These 2 protein sequence motifs contribute to the surfaces that form a multiprotein complex capable of stable and specific interaction with DNA. DNA sequences encoding these motifs may therefore be useful in investigating the problems of regulatory specificity, and may help define a discrete function for the 33 aminoacid repeat motifs. Dwg.0/13

Derwent Class: B04; D16;

Int Pat Class: C12N-015/12; C12N-015/63; C12N-015/70; C12N-015/74; C12N-015/79

15/7/12 (Item 1 from file: 357)

DIALOG(R)File 357:Derwent Biotechnology Abs

(c) 1994 Derwent Publ Ltd. All rts. reserv.

164909 DBA Accession No.: 94-07460 PATENT

Notch protein and antisense DNA - application in carcinoma diagnosis, therapy and gene therapy

PATENT ASSIGNEE: Univ.Yale 1994

PATENT NUMBER: WO 9407474 PATENT DATE: 940414 WPI ACCESSION NO.: 94-135180 (9416)

PRIORITY APPLIC. NO.: US 83590 APPLIC. DATE: 930625

NATIONAL APPLIC. NO.: WO 93US9338 APPLIC. DATE: 930930

LANGUAGE: English

ABSTRACT: A pharmaceutical composition comprising a Notch protein (A) and a carrier is claimed. More specifically, the composition comprises a

human Notch protein encoded by a specified DNA sequence which is bound by an antibody to a Notch protein. The following are also claimed: (1) a pure human Notch protein homolog of specified protein sequence; (2) nucleic acid encoding the protein of (1); (3) a recombinant cell containing the nucleic acid of (2); (4) a composition comprising a Notch protein or derivative (e.g. chimeric protein); (5) a composition comprising a molecule which antagonizes the function of a Notch protein; and (6) the use of the composition of (5) for treatment of cervix carcinoma, mamma carcinoma or colon carcinoma. In (4), the chimeric protein may include functionally active portions of the Notch protein encoded by human cDNA contained in plasmid pHN3k (ATCC 68609) and plasmid pHN5k (ATCC 68611). The therapeutic composition includes Notch proteins and analogs, antibodies, nucleic acid encoding the analogs, antisense nucleic acids, etc. which bind and interact with Notch proteins, their encoding nucleic acids or antibodies. (232pp)

15/7/13 (Item 1 from file: 399)
DIALOG(R)File 399:CA Search(R)
(c) 1994 American Chemical Society. All rts. reserv.

121026887 CA: 121(3)26887m PATENT

Therapeutic and diagnostic methods and compositions based on Notch proteins and nucleic acids

INVENTOR(AUTHOR): Artavanis-Tsakonas, Spyridon; Fehon, Richard Grant; Zagouras, Panayiotis; Blaumueller, Christine Marie

LOCATION: USA

ASSIGNEE: Yale University

PATENT: PCT International ; WO 9407474 A1 DATE: 940414

APPLICATION: WO 93US9338 (930930) *US 955012 (920930) *US 83590 (930625)

PAGES: 232 pp. CODEN: PIXXD2 LANGUAGE: English CLASS: A61K-031/00A;

A61K-031/70B; A61K-037/02B; A61K-039/44B; A61K-039/395B; C07H-021/04B;
G01N-033/53B; G01N-033/68B DESIGNATED COUNTRIES: AU; BB; BG; BR; BY; CA;
CZ; FI; HU; JP; KR; KZ; LK; LV; MG; MN; MW; NO; NZ; PL; RO; RU; SD; SK; UA;
US; UZ; VN DESIGNATED REGIONAL: AT; BE; CH; DE; DK; ES; FR; GB; GR; IE; IT
; LU; MC; NL; PT; SE; BF; BJ; CF; CG; CI; CM; GA; GN; ML; MR; NE; SN; TD;
TG

SECTION:

CA201006 Pharmacology

CA209XXX Biochemical Methods

IDENTIFIERS: human Notch protein therapeutic, cDNA antibody human Notch

DESCRIPTORS:

Gene, animal...

cDNA, for human Notch protein and Drosophila Delta protein

Deoxyribonucleic acid sequences, complementary...

for human Notch protein and Drosophila Delta protein

Alopecia... Cirrhosis... Intestine, neoplasm, colon, inhibitors... Keloid...
Lung, neoplasm, inhibitors... Mammary gland, neoplasm, inhibitors... Neoplasm
inhibitors, colon... Neoplasm inhibitors, lung... Neoplasm inhibitors, mammary
gland... Neoplasm inhibitors, melanoma... Psoriasis...

Notch protein as diagnostics and

Proteins, specific or class, gene Delta...

Notch protein as therapeutics in relation to

Deoxyribonucleic acids, complementary, antisense...

of human Notch gene, for diagnostics and therapeutics

Protein sequences...

of human Notch protein and Drosophila Delta protein
Gene,animal, Serrate...
protein of, Notch protein as therapeutics in relation to
Antibodies... Antibodies,monoclonal...
to human Notch protein, for diagnostics and therapeutics
Testis,neoplasm, seminoma... Uterus,neoplasm, cervix...
treatment and diagnosis of, Notch protein as diagnostics and

CAS REGISTRY NUMBERS:

146636-21-7 amino acid sequence of
156067-46-8 156067-47-9 156067-48-0 156067-49-1 156067-50-4
156067-51-5 amino acid sequence of, therapeutics contg.
146636-19-3 human Notch protein homologous to, as therapeutics
148513-28-4 156067-52-6 156067-53-7 156067-54-8 156067-55-9 nucleotide
sequence of
146636-08-0 146636-13-7 156067-43-5 156067-44-6 156067-45-7 nucleotide
sequence of, therapeutics contg. protein encoded by

15/7/14 (Item 2 from file: 399)
DIALOG(R)File 399:CA Search(R)
(c) 1994 American Chemical Society. All rts. reserv.

118184969 CA: 118(19)184969g JOURNAL
Mouse mammary tumor gene int-3: a member of the notch gene family
transforms mammary epithelial cells
AUTHOR(S): Robbins, Joan; Blondel, Bruno J.; Gallahan, Daniel; Callahan,
Robert
LOCATION: Lab. Tumor Immunol. Biol., Natl. Cancer Inst., Bethesda, MD,
20892, USA
JOURNAL: J. Virol. DATE: 1992 VOLUME: 66 NUMBER: 4 PAGES: 2594-9
CODEN: JOVIAM ISSN: 0022-538X LANGUAGE: English
SECTION:
CA203004 Biochemical Genetics
CA213XXX Mammalian Biochemistry
IDENTIFIERS: mouse mammary tumor gene int3 transformation, epithelium
transformation mouse notch like gene
DESCRIPTORS:
Epithelium...
cell, of mammary gland of mouse, gene int-3 transformation of
Deoxyribonucleic acid sequences...
for gene int-3 protein of mouse mammary tumor
Proteins,specific or class, gene int-3...
gene for, of mouse mammary tumor, sequence of and epithelial cell
transformation by
Virus,animal, murine mammary tumor...
gene int-3 integration site for, sequence of and epithelial cell
transformation by
Mouse...
gene int-3 of mammary tumor of, sequence of and epithelial cell
transformation by
Gene,animal, Notch...
mouse mammary tumor gene int-3 like, of Drosophila melanogaster,
sequence of and epithelial cell transformation by
Mammary gland,neoplasm...
notch family gene int-3 of mouse, sequence of and epithelial cell
transformation by

Drosophila melanogaster...

Best Available Copy

notch gene of, mouse mammary tumor gene int-3 as member of family of,
sequence of and epithelial cell transformation by

Protein sequences...

of gene int-3 protein, of mouse mammary tumor

Gene, animal, int-3...

of mouse mammary tumor, sequence of and epithelial cell transformation
by

Deoxyribonucleic acids, repetitive...

Saccharomyces cerevisiae cell cycle gene cdc-10 homolog, in gene int-3
of mouse mammary tumor

CAS REGISTRY NUMBERS:

146991-60-8 amino acid sequence of, complete

139861-79-3 nucleotide sequence of

15/7/15 (Item 1 from file: 434)

DIALOG(R)File 434:SCISEARCH(R)

(c) 1994 Inst for Sci Info. All rts. reserv.

13463041 Genuine Article#: PF811 Number of References: 62

Title: DELAMINATION AND DIVISION IN THE DROSOPHILA NEURECTODERM -

SPATIOTEMPORAL PATTERN, CYTOSKELETAL DYNAMICS, AND COMMON CONTROL BY
NEUROGENIC AND SEGMENT POLARITY GENES

Author(s): HARTENSTEIN V; YOUNOSSIHARTENSTEIN A; LEKVEN A

Corporate Source: UNIV CALIF LOS ANGELES, DEPT BIOL/LOS ANGELES//CA/90024

Journal: DEVELOPMENTAL BIOLOGY, 1994, V165, N2 (OCT), P480-499

ISSN: 0012-1606

Language: ENGLISH Document Type: ARTICLE

Abstract: Cytoskeletal changes occurring during the delamination of precursors of the peripheral (microchaete precursors in the pupal notum) and central nervous system (embryonic SI neuroblasts) were studied. The pattern of cell division in the ventral neurectoderm (VN) of wild-type embryos was analyzed using BrdU incorporation and correlated to the pattern of neuroblast delamination. Finally, defects in the pattern of proliferation of the VN and neuroblast delamination which occur in Notch and wingless mutant embryos were described. The results indicate that the patterns of delamination and mitosis are closely correlated: delamination occurs either immediately after a cell has divided (in case of microchaete precursors) or shortly before the division (in case of the neuroblasts). In addition, cytoskeletal changes similar to those occurring during mitosis can be seen in delaminating neuronal precursors. Thus, during both mitosis and delamination, the discrete apicobasally oriented microfilament-tubulin bundles break down. Microfilaments form a dense, diffuse cortical layer surrounding the entire cell body. Microtubules are concentrated at the apically located centrosome. The relationship between mitosis and delamination is supported by the finding that the neurogenic gene Notch and segment polarity gene wingless (wg) affect both proliferation and delamination in the ventral neurectoderm. Thus, in embryos expressing the truncated cytoplasmic domain of the neurogenic gene Notch under heat-shock control (Struhl et al., 1993), all ventral neurectodermal cells go into mitosis prematurely, followed by the absence of neuroblast delamination. In wg loss-of-function mutants, mitosis in the VN is irregular and generally postponed, accompanied by irregularities in the timing of neuroblast delamination in general and the absence of

15/7/16 (Item 2 from file: 434)
DIALOG(R)File 434:SCISEARCH(R)
(c) 1994 Inst for Sci Info. All rts. reserv.

13393826 Genuine Article#: PK060 Number of References: 48
Title: 3 GENES IN THE HUMAN MHC CLASS-III REGION NEAR THE JUNCTION WITH THE
CLASS-II - GENE FOR RECEPTOR OF ADVANCED GLYCOSYLATION END-PRODUCTS,
PBX2 HOMEBOX GENE AND A NOTCH HOMOLOG, HUMAN COUNTERPART OF MOUSE
MAMMARY-TUMOR GENE INT-3
Author(s): SUGAYA K; FUKAGAWA T; MATSUMOTO K; MITA K; TAKAHASHI E; ANDO A;
INOKO H; IKEMURA T
Corporate Source: NATL INST GENET,DEPT EVOLUTIONARY GENET,YATA
1111/MISHIMA/SHIZUOKA 411/JAPAN/; NATL INST GENET,DEPT EVOLUTIONARY
GENET/MISHIMA/SHIZUOKA 411/JAPAN/; GRAD UNIV ADV
STUDIES/MISHIMA/SHIZUOKA 411/JAPAN/; NATL INST RADIOL SCI/ANAGAWA/CHIBA
263/JAPAN/; TOKAI UNIV,SCH MED/ISEHARA/KANAGAWA 25911/JAPAN/
Journal: GENOMICS, 1994, V23, N2 (SEP 15), P408-419
ISSN: 0888-7543

Language: ENGLISH Document Type: ARTICLE

Abstract: Cosmid walking of about 250 kb from MHC class III gene CYP21 to
class II was conducted. The gene for receptor of advanced glycosylation
end products of proteins (RAGE, a member of immunoglobulin superfamily
molecules), the PBX2 homeobox gene designated HOX12, and the human
counterpart of the mouse mammary tumor gene int-3 were found. The
contiguous RAGE and HOX12 genes were completely sequenced, and the
human int-3 counterpart was partially sequenced and assigned to a Notch
homolog. This human Notch homolog, designated NOTCH3, showed both the
intracellular portion present in the mouse int-3 sequence and the
extracellular portion absent in the int-3. It thus corresponds to the
intact form of a Notch-type transmembrane protein. About 20 kb of dense
Alu clustering was found just centromeric to the NOTCH3. (C) 1994
Academic Press, Inc.

15/7/17 (Item 3 from file: 434)
DIALOG(R)File 434:SCISEARCH(R)
(c) 1994 Inst for Sci Info. All rts. reserv.

12891144 Genuine Article#: BZ51X Number of References: 95
Title: FREQUENT MUTATIONS IN BREAST-CANCER
Author(s): CALLAHAN R; GALLAHAN D; SMITH G; CROPP C; MERLO G; DIELLA F;
LISCIA D; LIDEREAU R
Corporate Source: NCI,BLDG 10,ROOM 5B50/BETHESDA//MD/20892; SAN GIOVANNI
VECCHIO HOSP,USSL 1,PATHOL SECT/I-10123 TURIN//ITALY/; CTR RENE
HUGUENIN/ST CLOUD//FRANCE/
Journal: ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, 1993, V698, P21-30
ISSN: 0077-8923
Language: ENGLISH Document Type: ARTICLE

15/7/18 (Item 4 from file: 434)
DIALOG(R)File 434:SCISEARCH(R)
(c) 1994 Inst for Sci Info. All rts. reserv.

12878833 Genuine Article#: MW435 Number of References: 111
Title: APICAL JUNCTIONS AND CELL SIGNALING IN EPITHELIA
Author(s): WOODS DF; BRYANT PJ
Corporate Source: UNIV CALIF IRVINE,CTR DEV BIOL/IRVINE//CA/92717
Journal: JOURNAL OF CELL SCIENCE, 1993, S17, P171-181
ISSN: 0021-9533

Language: ENGLISH Document Type: REVIEW

Abstract: Genetic analysis in Drosophila has led to the identification of several proteins that mediate cell-cell interactions controlling the fate and proliferation of epithelial cells. These proteins are localized or enriched in the adherens and septate junctions at the apical end of the lateral membranes between cells. The proteins localized or enriched at adherens junctions include Notch, which is important for the cell interactions controlling neuroblast and bristle patterning; Boss and sevenless, which are required for the cell interaction that establishes the R7 photoreceptor cell; and Armadillo, required for the wingless-dependent cell interactions that control segment polarity and imaginal disc patterning. Proteins localized at septate junctions include the product of the tumor suppressor gene dig, which is required for septate junction formation, apical basal cell polarity, and the cell interactions that control proliferation. The results suggest that the cell signalling events important for cell fate determination and for cell proliferation control in epithelia occur at the apical junctions. The migration of the nucleus to the apical surface of the epithelium for mitosis may enable it to interact directly with the junction-associated signalling mechanisms.

15/7/19 (Item 5 from file: 434)

DIALOG(R)File 434:SCISEARCH(R)

(c) 1994 Inst for Sci Info. All rts. reserv.

12471887 Genuine Article#: LP726 Number of References: 53
Title: SPECIFIC TRUNCATIONS OF DROSOPHILA NOTCH DEFINE DOMINANT ACTIVATED
AND DOMINANT-NEGATIVE FORMS OF THE RECEPTOR
Author(s): REBAY I; FEHON RG; ARTAVANISTSAKONAS S
Corporate Source: YALE UNIV,DEPT CELL BIOL,HOWARD HUGHES MED INST/NEW
HAVEN//CT/06536; YALE UNIV,DEPT BIOL/NEW HAVEN//CT/06536
Journal: CELL, 1993, V74, N2 (JUL 30), P319-329
ISSN: 0092-8674

Language: ENGLISH Document Type: ARTICLE

Abstract: The Notch gene of Drosophila plays an important role in cell fate specification throughout development. To investigate the functions of specific structural domains of the Notch protein in vivo, a series of deletion mutants have been ectopically expressed under the hsp70 heat shock promoter. Two classes of dominant phenotypes are observed, one suggestive of Notch loss-of-function mutations and the other of Notch gain-of-function mutations. Dominant activated phenotypes result from overexpression of a protein lacking most extracellular sequences, while dominant negative phenotypes result from overexpression of a protein lacking most intracellular sequences. These results support the notion that Notch functions as a receptor whose extracellular domain mediates ligand binding, resulting in the transmission of developmental signals by the cytoplasmic domain. Finally, the phenotypes observed suggest that the cdc10/ankyrin repeat region within the intracellular domain

plays an essential role in the postulated signal transduction events.

15/7/20 (Item 6 from file: 434)

11736855 Genuine Article#: J6755 Number of References: 74
Title: EXPRESSION PATTERN OF MOTCH, A MOUSE HOMOLOG OF DROSOPHILA-NOTCH,
 SUGGESTS AN IMPORTANT ROLE IN EARLY POSTIMPLANTATION MOUSE DEVELOPMENT
Author(s): DELAMO FF; SMITH DE; SWIATEK PJ; GENDRONMAGUIRE M; GREENSPAN RJ;
 MCMAHON AP; GRIDLEY T
Corporate Source: ROCHE INST MOLEC BIOL,ROCHE RES CTR,DEPT CELL &DEV
 BIOL/NUTLEY//NJ/07110; ROCHE INST MOLEC BIOL,ROCHE RES CTR,DEPT CELL
 &DEV BIOL/NUTLEY//NJ/07110; ROCHE INST MOLEC BIOL,ROCHE RES CTR,DEPT
 NEUROSCI/NUTLEY//NJ/07110
Journal: DEVELOPMENT, 1992, V115, N3 (JUL), P737&
Language: ENGLISH Document Type: ARTICLE
Abstract: The Notch gene of Drosophila encodes a large transmembrane
 protein involved in cell-cell interactions and cell fate decisions in
 the Drosophila embryo. To determine if a gene homologous to Drosophila
 Notch plays a role in early mouse development, we screened a mouse
 embryo cDNA library with probes from the Xenopus Notch homolog, Xotch.
 A partial cDNA clone encoding the mouse Notch homolog, which we have
 termed Motch, was used to analyze expression of the Motch gene. Motch
 transcripts were detected in a wide variety of adult tissues, which
 included derivatives of all three germ layers. Differentiation of P19
 embryonal carcinoma cells into neuronal cell types resulted in
 increased expression of Motch RNA. In the postimplantation mouse embryo
 Motch transcripts were first detected in mesoderm at 7.5 days post
 coitum (dpc). By 8.5 dpc, transcript levels were highest in presomitic
 mesoderm, mesenchyme and endothelial cells, while much lower levels
 were detected in neuroepithelium. In contrast, at 9.5 dpc,
 neuroepithelium was a major site of Motch expression. Transcripts were
 also abundant in cell types derived from neural crest. These data
 suggest that the Motch gene plays multiple roles in patterning and
 differentiation of the early postimplantation mouse embryo.

15/7/21 (Item 7 from file: 434)
DIALOG(R)File 434:SCISEARCH(R)
(c) 1994 Inst for Sci Info. All rts. reserv.

11694207 Genuine Article#: JD348 Number of References: 53
Title: DISORGANIZATION IS A COMPLETELY DOMINANT GAIN-OF-FUNCTION MOUSE
 MUTATION CAUSING SPORADIC DEVELOPMENTAL DEFECTS
Author(s): CROSBY JL; VARNUM DS; WASHBURN LL; NADEAU JH
Corporate Source: JACKSON LAB/BAR HARBOR//ME/04609; JACKSON LAB/BAR
 HARBOR//ME/04609; UNIV MAINE,DEPT BIOCHEM/ORONO//ME/04469
Journal: MECHANISMS OF DEVELOPMENT, 1992, V37, N3 (MAY), P121-126
Language: ENGLISH Document Type: ARTICLE
Abstract: Disorganization (Ds) is an exceptional mutation because of its
 diverse and profound developmental effects. Although other mouse
 mutations produce similar congenital defects, extreme pleiotropism,
 random occurrence, developmental independence of multiple defects, and
 type of anomaly make Ds unique. Examples of developmental defects

include cranioschisis, rachischisis, thoracoschisis, exencephaly,
hamartomas, and anomalies of appendages, digestive, genital and urinary
tracts, sense organs, limbs and girdles, tail and pharynx. No other
mutation in the mouse has such broad effects. Ds is therefore an

important model for studying not only the genetic control of lineage determination and pattern formation but also the occurrence of sporadic congenital defects. To characterize the effects of gene dosage, we examined the viability and phenotype of Ds homozygotes and the phenotype of + / + / Ds trisomic fetuses. Occurrence of homozygotes was tested by intercrossing Ds / + heterozygotes, typing genetic markers that flank Ds, and examining homozygotes for morphological abnormalities. Not only were Ds homozygotes found in their expected frequency, homozygotes were not more severely affected than heterozygotes. Trisomies provide a direct test for determining whether Ds is a gain-of-function mutation. Trisomic fetuses were derived by crossing Ds / Ds homozygous mice to hybrid mice that were heterozygous for two related Robertsonian translocations. Two trisomic fetuses had developmental defects characteristic of DS mice. Together these results demonstrate that Ds is a completely dominant, gain-of-function mutation.

15/7/22 (Item 1 from file: 442)
DIALOG(R)File 442:AMA Journals Online
(c) 1994 American Medical Assoc. All rts. reserv.

00092498
COPYRIGHT American Medical Association 1994

Gonadal Mixed Germ Cell Tumor Combined With a Large Hemangiomatous Lesion
in a Patient With Turner's Syndrome and 45,X/46,X, +mar Karyotype (ARTICLE)

TANAKA, YUKICHI; SASAKI, YOSHIROH; TACHIBANA, KATSUHIKO; MAESAKA, HATAE;
IMAIZUMI, KIYOSHI; NISHIHARA, HIROKAZU; NISHI, TOSHIJI
Archives of Pathology and Laboratory Medicine
November, 1994; Brief Reports: pt_1135
LINE COUNT: 01428
0363-0153

In this report, we describe bilateral gonadal tumors with characteristic histopathological findings in a patient with Turner's syndrome who had 45,X/46,X, +mar mosaicism. The left gonad contained a gonadoblastoma and a remnant of streak gonad. The right gonad was entirely replaced by a 15X11X7-cm solid and cystic tumor, which was revealed to be a combination of a mixed germ cell tumor and a cavernous hemangiomatous lesion. The latter occupied approximately half of the entire tumor volume, and there was an incomplete boundary between it and the mixed germ cell tumor lesion. To our knowledge, this is the first reported case of Turner's syndrome with a combination of a mixed germ cell tumor and a hemangiomatous lesion in the gonad. (Arch Pathol Lab Med. 1994;118:1135-1138)

* * USE FORMAT 9 FOR FULL TEXT OF ARTICLE * *

15/7/23 (Item 2 from file: 442)
DIALOG(R)File 442:AMA Journals Online
(c) 1994 American Medical Assoc. All rts. reserv.

00086699
COPYRIGHT American Medical Association 1992

Continuing Trends in the Prevalence of Right-Sided Lesions Among Colorectal
Carcinomas (ARTICLE)

CADY, BLAKE; STONE, MICHAEL D.; WAYNE, JEFFREY
Archives of Surgery
May, 1993; Paper: p505
LINE COUNT: 00444
0004-0010

The shift of colorectal carcinoma location toward the proximal colon has been reported. This study documents that this statistically significant trend has continued through 1992. An increase in transverse and descending colon cancers is now apparent also. Only 59% of all large-bowel cancers occurred distal to the descending colon between 1978 and 1992. Both right-sided and distal large-bowel cancers have significantly decreased in size, yet the incidence and frequency of lymph node metastases have not changed over a 65-year interval (from 1928 to 1992). This constant proportion of lymph node metastases may suggest distinct biological subsets of cancers (lymph node avid vs lymph node avoidance). The progression from small size with fewer metastases to large size with more lymph node metastases occurs only in some of the smallest distal colorectal cancers.

* * USE FORMAT 9 FOR FULL TEXT OF ARTICLE * *

?

12/7/1 (Item 1 from file: 5)
DIALOG(R)File 5:BIOSIS PREVIEWS(R)
(c) 1994 BIOSIS. All rts. reserv.

11066516 BIOSIS Number: 97266516

Ep-CAM: A human epithelial antigen is a homophilic cell-cell adhesion molecule

Litvinov S V; Velders M P; Bakker H A M; Fleuren G J; Warnaar S O
Dep. Pathol., State Univ. Leiden, Wassenaarsweg 62, P.O. Box 9603, 2300
RC Leiden, NET

Journal of Cell Biology 125 (2). 1994. 437-446.

Full Journal Title: Journal of Cell Biology

ISSN: 0021-9525

Language: ENGLISH

The epithelial glycoprotein 40 (EGP40, also known as GA733-2, ESA, KSA, and the 17-1A antigen), encoded by the GA-733-2 gene, is expressed on the baso-lateral cell surface in most human simple epithelia. The protein is also expressed in the vast majority of carcinomas and has attracted attention as a tumor marker. The function of the protein is unknown. We demonstrate here that EGP40 is an epithelium-specific intercellular adhesion molecule. The molecule mediates, in a Ca-2+-independent manner, a homophilic cell-cell adhesion of murine cells transfected with the complete EGP40 cDNA. Two murine cell lines were tested for the effects of EGP40 expression: fibroblastic L cells and dedifferentiated mammary carcinoma L1535 cells. The expression of the EGP40 protein causes morphological changes in cultures of transfected cells-increasing intercellular adhesion of the transfectants-and has a clear effect on cell aggregating behavior in suspension aggregation assays. EGP40 directs sorting in mixed cell populations, in particular, causes segregation of the transfectants from the corresponding parental cells. EGP40 expression suppresses invasive colony growth of L cells in EHS-matrigel providing tight adhesions between cells in growing colonies. EGP40 can thus be considered a new member of the intercellular adhesion molecules. In its biological behavior EGP40 resembles to some extent the molecules of the immunoglobulin superfamily of cell adhesion molecules (CAMs), although no immunoglobulin-like repeats are present in the EGP40 molecule. Certain structural similarities in general organization of the molecule exist between EGP40 and the lin-12/Notch proteins. A possible role of this adhesion molecule in formation of architecture of epithelial tissues is discussed. To reflect the function of the molecule the name Ep-CAM for EGP40 seems appropriate.

12/7/4 (Item 2 from file: 442)
DIALOG(R)File 442:AMA Journals Online
(c) 1994 American Medical Assoc. All rts. reserv.

00087493
COPYRIGHT American Medical Association 1992

Clinical Underestimation of Laryngeal Cancer Predictive Indicators (ARTICLE
)

NAKAYAMA, MEIJIN
Archives of Otolaryngology

Sep, 1993; Original Article: p950

LINE COUNT: 00421

0003-9977

Objective: To evaluate the accuracy of clinical staging of advanced laryngeal cancer and to morphologically analyze the underestimated cases. Design: We conducted a retrospective histopathologic study of larynges from patients who had had total laryngectomy and were seen over a 21-year period. Setting: Academic tertiary referral medical center. Participants: Forty-one patients had clinically staged T3 laryngeal cancer and 16 patients had T4 cancer. Intervention: Patients all underwent wide-field total laryngectomy. All larynges were processed as whole-organ serial sections in the coronal plane. Outcome Measure: The incidence of clinically underestimated laryngeal cancer. During this investigation, it became obvious that predictive indicators of thyroid cartilage involvement could be established. Results: Clinical underestimation had been made in approximately 50% of all T3 laryngeal cancer cases. The extent of the cartilage involvement in the underestimated group was characterized by microinvasion without penetration; approximately 90% of the cartilage involvement affected the thyroid notch and adjacent area. We established five objective indicators of thyroid cartilage involvement: (1) extensive cartilage ossification (risk for cartilage involvement, 73%); (2) glottic fixation (54%); (3) transglottic cancer (74%); (4) tumor length longer than the entire vocal fold length or longer than 2 cm (66%); and (5) extensive involvement of the anterior commissure (67%). Conclusions: Clinical underestimation of T4 laryngeal cancer was high because thyroid cartilage involvement was not accurately diagnosed. We believe our indicators of thyroid cartilage involvement will provide objective guidelines for laryngeal cancer staging and will contribute to more reliable clinical cancer-staging decisions. (Arch Otolaryngol Head Neck Surg. 1993;119:950-957)

* * USE FORMAT 9 FOR FULL TEXT OF ARTICLE * *

12/7/6 (Item 4 from file: 442)

DIALOG(R) File 442:AMA Journals Online

(c) 1994 American Medical Assoc. All rts. reserv.

00086703

COPYRIGHT American Medical Association 1992

Determination of Tumor Aggressiveness in Colorectal Cancer by K-ras-2 Analysis (ARTICLE)

FINKELSTEIN, SYDNEY D.; SAYEGH, RAOULF; BAKKER, ANKE; SWALSKY, PATRICIA

Archives of Surgery

May, 1993; Paper: p526

LINE COUNT: 00523

0004-0010

Markers that predict tumor aggressiveness on a case-by-case basis would enable individualization and optimization of oncologic therapy. To achieve this goal, the presence and specific type of K-ras-2 point mutation was determined from formalin-fixed, paraffin-embedded tissue sites in 247 primary and 166 metastatic-recurrent colorectal adenocarcinomas, using a novel approach consisting of topographic tissue selection, DNA

amplification, and direct sequencing applicable to large and needle-biopsy-sized specimens. The results provide the basis for a genotypic classification of colorectal cancer capable of predicting individual tumor aggressiveness, including the pattern and extent of metastasis.

* * USE FORMAT 9 FOR FULL TEXT OF ARTICLE * *

?

15/7/1 (Item 1 from file: 5)
DIALOG(R)File 5:BIOSIS PREVIEWS(R)
(c) 1994 BIOSIS. All rts. reserv.

11292950 BIOSIS Number: 97492950

An activated Notch suppresses neurogenesis and myogenesis but not gliogenesis in mammalian cells

Nye J S; Kopan R; Axel R

Dep. Neurol., Inst. Cancer Res., Coll. Physicans Surg., Columbia Univ.,
New York, NY 10032, USA

Development (Cambridge) 120 (9). 1994. 2421-2430.

Full Journal Title: Development (Cambridge)

ISSN: 0950-1991

Language: ENGLISH

P19 cells, a mouse embryonal carcinoma line, can be induced to differentiate into neurons. After induction, however, only a small subpopulation of cells develop as neurons, suggesting that equipotent cells adopt different cell fates. In invertebrate systems, the lin-12-Notch family of genes is thought to control the choice of cell fate. We have therefore asked whether activation of murine Notch (mNotch) regulates neuronal differentiation in P19 cells. We demonstrate that a dominant gain-of-function mutant of mNotch suppresses neurogenesis, as well as myogenesis in P19 cells. Overexpression of the full-length mNotch protein also suppresses neurogenesis. In contrast, the differentiation of glia is not affected by an activated mNotch homologue. These data indicate that mNotch may play a central role in the choice of cell fate in differentiating cells in culture and suggests that mNotch may play a similar role in the choice of fate in the developing mammalian embryo.

15/7/2 (Item 2 from file: 5)
DIALOG(R)File 5:BIOSIS PREVIEWS(R)
(c) 1994 BIOSIS. All rts. reserv.

11066516 BIOSIS Number: 97266516

Ep-CAM: A human epithelial antigen is a homophilic cell-cell adhesion molecule

Litvinov S V; Velders M P; Bakker H A M; Fleuren G J; Warnaar S O

Dep. Pathol., State Univ. Leiden, Wassenaarsweg 62, P.O. Box 9603, 2300
RC Leiden, NET

Journal of Cell Biology 125 (2). 1994. 437-446.

Full Journal Title: Journal of Cell Biology

ISSN: 0021-9525

Language: ENGLISH

The epithelial glycoprotein 40 (EGP40, also known as GA733-2, ESA, KSA, and the 17-1A antigen), encoded by the GA-733-2 gene, is expressed on the baso-lateral cell surface in most human simple epithelia. The protein is also expressed in the vast majority of carcinomas and has attracted attention as a tumor marker. The function of the protein is unknown. We demonstrate here that EGP40 is an epithelium-specific intercellular adhesion molecule. The molecule mediates, in a Ca-2+-independent manner, a homophilic cell-cell adhesion of murine cells transfected with the complete EGP40 cDNA. Two murine cell lines were tested for the effects of EGP40 expression: fibroblastic L cells and dedifferentiated mammary carcinoma

L1535 cells. The expression of the EGP40 protein causes morphological changes in cultures of transfected cells-increasing intercellular adhesion of the transfectants-and has a clear effect on cell aggregating behavior in suspension aggregation assays. EGP40 directs sorting in mixed cell populations, in particular, causes segregation of the transfectants from the corresponding parental cells. EGP40 expression suppresses invasive colony growth of L cells in EHS-matrigel providing tight adhesions between cells in growing colonies. EGP40 can thus be considered a new member of the intercellular adhesion molecules. In its biological behavior EGP40 resembles to some extent the molecules of the immunoglobulin superfamily of cell adhesion molecules (CAMs), although no immunoglobulin-like repeats are present in the EGP40 molecule. Certain structural similarities in general organization of the molecule exist between EGP40 and the lin-12/Notch proteins. A possible role of this adhesion molecule in formation of architecture of epithelial tissues is discussed. To reflect the function of the molecule the name Ep-CAM for EGP40 seems appropriate.

15/7/3 (Item 3 from file: 5)
DIALOG(R)File 5:BIOSIS PREVIEWS(R)
(c) 1994 BIOSIS. All rts. reserv.

10830219 BIOSIS Number: 97030219

Analysis of phenotypic abnormalities and cell fate changes caused by dominant activated and dominant negative forms of the Notch receptor of *Drosophila* development

Rebay I; Fortini M E; Artavanis-Tsakonas S

Howard Hughes Med. Inst., Dep. Cell Biol., Yale Univ., New Haven, CT 06536-0812, USA

Comptes Rendus de l'Academie des Sciences Serie III Sciences de la Vie 316 (9). 1993. 1097-1123.

Full Journal Title: Comptes Rendus de l'Academie des Sciences Serie III Sciences de la Vie

ISSN: 0764-4469

Language: FRENCH ENGLISH

The Notch gene of *Drosophila* plays an important role in cell fate specification throughout development. The Notch protein contains a large extracellular domain of 36 EGF-like repeats as well as 3 Notch/lin-12 repeats and an intracellular domain with 6 cdc10/ankyrin repeats, motifs which are highly conserved in several vertebrate Notch homologues (1-7). In this review we summarize the results of two recent studies which attempt to establish structurefunction relationships of the various domains of the Notch gene product (8, 9). The functions of various structural domains of the Notch protein in vivo were investigated using a series of deletion mutants which have been ectopically expressed either under the hsp70 heat-shock promoter or under the sevenless eye-specific promoter. Truncation of the extracellular domain of *Drosophila* Notch produces an activated receptor as judged by its ability to cause phenotypes matching those of gain-of-function alleles or duplications of the Notch locus (8). Equivalent truncations of vertebrate Notch-related proteins have been associated with malignant neoplasms and other developmental abnormalities (3, 6, 10, 11). In contrast, dominant negative phenotypes result from overexpression of a protein lacking most intracellular sequences. These results were extended by an analysis of activated Notch function at single-cell resolution in the *Drosophila* compound eye (9). It was shown that while overexpression of full-length Notch in defined cell types has no

4/7/1 (Item 1 from file: 5)
DIALOG(R)File 5:BIOSIS PREVIEWS(R)
(c) 1994 BIOSIS. All rts. reserv.

8646875 BIOSIS Number: 92111875
TAN-1 THE HUMAN HOMOLOG OF THE DROSOPHILA NOTCH GENE IS BROKEN BY
CHROMOSOMAL TRANSLOCATIONS IN T LYMPHOBLASTIC NEOPLASMS
ELLISEN L W; BIRD J; WEST D C; SORENG A L; REYNOLDS T C; SMITH S D; SKLAR
J
STANFORD UNIV. SCH. MED., STANFORD, CALIF. 94305.
CELL 66 (4). 1991. 649-662. CODEN: CELLB
Full Journal Title: Cell
Language: ENGLISH

Previously we described joining of DNA in the .beta. T cell receptor gene
to DNA of an uncharacterized locus in a t(7;9)(q34;q34.3) chromosomal
translocation from a case of human lymphoblastic leukemia (T-ALL). We now
show that the locus on chromosome 9 contains a gene highly homologous to
the Drosophila gene Notch. Transcripts of the human gene, for which we
propose the name TAN-1, and its murine counterpart are present in many
normal human fetal and adult mouse tissues, but are most abundant in
lymphoid tissues. In t(7;9)(q34;q34.3) translocations from three cases of
T-ALL, the breakpoints occur within 100 bp of an intron in TAN-1, resulting
in truncation of TAN-1 transcripts. These observations suggest that TAN-1
may be important for normal lymphocyte function and that alteration of
TAN-1 may play a role in the pathogenesis of some T cell neoplasms.

4/7/2 (Item 1 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 1994 Elsevier Science B.V. All rts. reserv.

8583130 EMBASE No: 92259041
Sun-less tans may be possible with new synthetic hormone
Vanchieri C.F.
Journal Office, R. A. Bloch Intl. Cancer Info. Ctr., 9030 Old Georgetown
Rd., Bethesda, MD 20814 USA
J. NATL. CANCER INST. (USA) , 1992, 84/16 (1234-1235) CODEN: JNCIA
ISSN: 0027-8874
LANGUAGES: English

4/7/3 (Item 1 from file: 155)
DIALOG(R)File 155:MEDLINE(R)
(c) format only 1994 Dialog Info.Svcs. All rts. reserv.

08122975 92260975
Cancer, chromosomes, and genes.
Nowell PC
Department of Pathology and Laboratory Medicine, University of
Pennsylvania, School of Medicine, Philadelphia.
Lab Invest (UNITED STATES) Apr 1992, 66 (4) p407-17, ISSN 0023-6837
Journal Code: KZ4
Languages: ENGLISH
Document type: JOURNAL ARTICLE; REVIEW; REVIEW, ACADEMIC

(67 Refs.)

4/7/4 (Item 1 from file: 399)
DIALOG(R)File 399:CA Search(R)
(c) 1994 American Chemical Society. All rts. reserv.

120130975 CA: 120(11)130975d DISSERTATION
TAN-1, the human homolog of Drosophila "Notch", is involved in
chromosomal translocations in human lymphoblastic neoplasma
AUTHOR(S): Ellisen, Leif William
LOCATION: Stanford Univ., Stanford, CA, USA
DATE: 1992 PAGES: 80 pp. CODEN: DABBBA LANGUAGE: English CITATION:
Diss. Abstr. Int. B 1993, 53(7), 3307 AVAIL: Univ. Microfilms Int., Order
No. DA9234046
SECTION:
CA214001 Mammalian Pathological Biochemistry
CA203XXX Biochemical Genetics
IDENTIFIERS: gene TAN1 chromosome translocation lymphoblastic leukemia
DESCRIPTORS:
Leukemia,T-cell acute lymphocytic...
gene TAN-1 translocation in, in human
Recombination,genetic, translocation...
of gene TAN-1, in human T-cell acute lymphoblastic leukemia
Gene,animal...
TAN-1, chromosomal translocation of, in human T-cell lymphoblastic
leukemia
Chromosome,human 7...
TAN-1 gene translocation from, in human T-cell lymphoblastic leukemia

4/7/5 (Item 1 from file: 442)
DIALOG(R)File 442:AMA Journals Online
(c) 1994 American Medical Assoc. All rts. reserv.

00050915

Secretory Carcinoma of the Breast (Article)

Rosen, Paul Peter, MD; Cranor, Milicent L.
Archives of Pathology & Laboratory Medicine
1991; 115: 141 (4)
0363-0153

Most studies of secretory carcinoma of the breast have been single case reports or separate analyses of the problem in either children or adults. We studied 10 female patients, aged 5 to 87 years. Most patients presented with a palpable mass, often near the areola. Five of six tumors were estrogen receptor negative; three analyzed for progesterone receptor were positive. Histologic patterns present in varying proportions were "classic" secretory carcinoma with microacini, abundant secretion with papillary features, and with prominent solid and papillary apocrine features. The tumors had strong reactivity for α -lactalbumin, S100, and carcinoembryonic antigen (polyclonal) and were negative for gross cystic disease full protein and anti-carcinoembryonic antigen (monoclonal). Six patients had mastectomy; four had local excision; none had axillary nodal

metastases initially. With follow-up of 3 to 72 months (mean, 47 months; median, 48 months), two patients treated by local excision had local recurrences, one patient had axillary nodal metastases. All patients are alive. Comparison of patients under and over 30 years of age revealed one important difference: younger patients had a longer interval between detection and biopsy -- 30 vs 2 months. Treatment recommendations are initial wide excision or quadrantectomy with low axillary dissection in most cases and, in premenarchal patients, strong effort to preserve the breast bud without jeopardizing local control.

* * USE FORMAT 9 FOR FULL TEXT OF ARTICLE * *

4/7/6 (Item 2 from file: 442)
DIALOG(R)File 442:AMA Journals Online
(c) 1994 American Medical Assoc. All rts. reserv.

00040379

Copyright (C) 1988 American Medical Association

The Relationship of Basal Cell Carcinomas and Squamous Cell Carcinomas to Solar Keratoses (STUDIES)

MARKS, ROBIN; RENNIE, GEORGE; SELWOOD, THOMAS

Archives of Dermatology

July, 1988; 124: 1039-1042

LINE COUNT: 00202

WORD COUNT: 02797

ISSN: 0003-987X

CORPORATE SOURCE: Accepted for publication March 1, 1988. From the Anti-Cancer Council of Victoria, Carlton South (Dr Marks and Mr Rennie), and the Monash University Department of Social and Preventive Medicine, Alfred Hospital, Melbourne, Australia (Dr Selwood). Reprints not available. This work was partly supported by grants from the Peter Grant Hay Cancer Research Fund, the Skin and Cancer Foundation, Sydney, and the Anti-Cancer Council of Victoria. We thank Abe Dorevitch, Peter Foley, Greg Goodman, Danny Lanzer, Rosemary Nixon, Wendy Pakes, Michael Ponsford, and Ruth Salom who helped in these studies.

ABSTRACT: Six thousand four hundred sixteen people aged 40 years and over from three different locations in Victoria (Australia) were examined on the hands, forearms, head, and neck for the presence of solar keratoses and basal (BCCs) and squamous cell carcinomas (SCCs). Analysis of the relationship between these tumors revealed that the factors which predicted the likelihood of developing a solar keratosis were essentially the same as those that predicted the likelihood of developing a BCC and/or an SCC. These were age, sex, years of residence in Australia, indoor or outdoor occupation, tanning ability, propensity to sunburn, and location of residence. The presence of a coexisting solar keratosis was necessary for the development of an SCC in contrast to the development of a BCC. The findings suggest that unlike BCCs, the majority of SCCs in light-exposed areas may arise from preexisting solar keratoses. Whereas the prevalence of solar keratoses differed markedly in direct relation to the degree of insolation. This suggests that solar keratoses are a more sensitive indicator of sunlight exposure than invasive carcinoma.

* * USE FORMAT 9 FOR FULL TEXT OF ARTICLE * *

CITED REFERENCES:

1. Marks R, Ponsford MW, Selwood TS, et al: Non-melanotic skin cancer and

- solar keratoses in Victoria. Med J Aust 1983; 2: 618-622.
2. Epstein JH: Photocarcinogenesis, skin cancer, and aging. J Am Acad Dermatol 1983; 9: 487-503.
 3. Goodman G, Marks R, Selwood TS, et al: Non-melanotic skin cancer and solar keratoses in Victoria: II. Clinical studies. Aust J Dermatol 1984; 25: 103-106.
 4. Ponsford MW, Goodman G, Marks R: The prevalence and accuracy of diagnosis of non-melanotic skin cancer in Victoria. Aust J Dermatol 1983; 24: 79-82.
 5. Engelman L: Stepwise logistic regression, in Dixon WJ (ed): BMDP Statistical Software. Berkeley, University of California Press, 1981, pp 330-344.
 6. Marks R, Selwood TS: Solar keratoses: The association with erythematous ultraviolet radiation in Australia. Cancer 1985; 56: 2332-2336.
 7. Sanderson KV, Mackie R: Tumors of the skin, in Rook A, Wilkinson DS, Ebling FJG (eds): Textbook of Dermatology, ed 3. Boston, Blackwell Scientific Publications Inc, 1979, pp 2179-2182.
 8. Marks R, Foley P, Goodman G, et al: Spontaneous remission of solar keratoses: The case for conservative management. Br J Dermatol 1986; 115: 649-655.
 9. Lung cancer mortality and pre-malignant changes in bronchial epithelium, in The Health Consequences of Smoking: Cancer: A Report of the Surgeon General, US Dept of Health and Human Services, 1982, pp 55-59.
 10. Campion MJ, McCance DJ, Cuzick J, et al: Progressive potential of mild cervical atypia: Prospective cytological, colposcopic, and virological study. Lancet 1986; 2: 237-240.

4/7/7 (Item 3 from file: 442)

DIALOG(R)File 442:AMA Journals Online

(c) 1994 American Medical Assoc. All rts. reserv.

00037493

Copyright (C) 1985 American Medical Association

Papillary Cystic Tumor of the Pancreas (LETTERS TO THE EDITOR)

WARREN, RENEE B.

Archives of Pathology and Laboratory Medicine

August, 1985; 109: 706-707

LINE COUNT: 00064

WORD COUNT: 00892

ISSN: 0363-0153

* * USE FORMAT 9 FOR FULL TEXT OF ARTICLE * *

CITED REFERENCES:

1. Morrison DM, Jewell LD, McCaughey WTE, et al: Papillary cystic tumor of the pancreas. Arch Pathol Lab Med 1984;108:723-727.

2. Friedman AC, Lichtenstein E, Fishman EK, et al: Solid and papillary epithelial neoplasm of the pancreas. Radiology 1985;154:333-337.
3. Compagno J, Dertel JE, Kiemzar M: Solid and papillary epithelial neoplasms of the pancreas, probably of small duct origin: A clinicopathologic study of 52 cases. Lab Invest 1979;40:248-249.
4. Boor PJ, Swanson MR: Papillary cystic neoplasm of the pancreas. Am J Surg Pathol 1979; 3:69-75.
5. Schlosnagle DC, Campbell WC: The papillary and solid neoplasm of the pancreas: A report of two cases with electron microscopy, one containing neurosecretory granules. Cancer 1981;108:2603-2610.
6. Hamoudi AB, Misugi KM, Grosfeld JL, et al: Papillary epithelial neoplasm of pancreas in a child. Cancer 1970;26:1126-1134.
7. Kloppel G, Morohosi T, John HD, et al: Solid and cystic acinar cell tumor of the pancreas. Virchows Arch Pathol Anat 1981;392:171-182.

4/7/8 (Item 1 from file: 444)
 DIALOG(R)File 444:NEJM Online
 (c) 1994 New England Journal of Medicine. All rts. reserv.

00112461
 Copyright 1994 by the Massachusetts Medical Society

Mechanisms of Disease: The Molecular Basis Of Leukemia (Review Articles)

Cline, Martin J.
 The New England Journal of Medicine
 Feb 3, 1994; 330 (5),pp 328-336
 LINE COUNT: 00515 WORD COUNT: 07111
 ISSN: 0028-4793

CORPORATE SOURCE: From the Division of Hematology, Center for the Health Sciences, 10833 LeConte Ave., Los Angeles, CA 90024-1678, where reprint requests should be addressed to Dr. Cline. - Supported by funds from the Ludwig Institute for Cancer Research, Middlesex Branch, London; the Leukaemia Research Fund, United Kingdom; and a Public Health Service grant (R01 CA 50275).

CITED REFERENCES

1. Bos JL, Verlaan-de Vries M, van der Eb AJ, et al. Mutations in N-ras predominate in acute myeloid leukemia. Blood 1987;69:1237-4.
2. Ahuja HG, Foti A, Bar-Eli M, Cline MJ. The pattern of mutational involvement of ras genes in human hematologic malignancies determined by DNA amplification and direct sequencing. Blood 1990;75:1684-90.
3. van Kamp H, de Pijper C, Verlaan-de Vries M, et al. Longitudinal analysis of point mutations of the N-ras proto-oncogene in patients with myelodysplasia using archived blood smears. Blood 1992;79:1266-70.
4. Konopka JB, Watanabe SM, Singer JW, Collins SJ, Witte ON. Cell lines and clinical isolates derived from Ph1-positive chronic myelogenous leukemia patients express c-abl proteins with a common structural

- alteration. *Proc Natl Acad Sci U S A* 1985;82:1810-4.
5. Voncken JW, Morris C, Pattengale P, et al. Clonal development and karyotype evolution during leukemogenesis of BCR/ABL transgenic mice. *Blood* 1992;79:1029-36.
 6. Gishizky ML, Witte ON. Initiation of deregulated growth of multipotent progenitor cells by bcr-abl in vitro. *Science* 1992;256:836-9.
 7. Muller AJ, Young JC, Pendergast AM, et al. BCR first exon sequences specifically activate the BCR/ABL tyrosine kinase oncogene of Philadelphia chromosome-positive human leukemias. *Mol Cell Biol* 1991;11:1785-92.
 8. Kelliher M, Knott A, McLaughlin J, Witte ON, Rosenberg N. Differences in oncogenic potency but not target cell specificity distinguish the two forms of the BCR/ABL oncogene. *Mol Cell Biol* 1991;11:4710-6.
 9. O'Bryan JP, Frye RA, Cogswell PC, et al. axl, A transforming gene isolated from primary human myeloid leukemia cells, encodes a novel receptor tyrosine kinase. *Mol Cell Biol* 1991;11:5016-31.
 10. Tsujimoto Y, Gorham J, Cossman J, Jaffe E, Croce CM. The t(14;18) chromosome translocations involved in B-cell neoplasms result from mistakes in VDJ joining. *Science* 1985;229:1390-3.
 11. Croce CM, Nowell PC. Molecular basis of human B cell neoplasia. *Blood* 1985;65:1-7.
 12. Erikson J, Finger L, Sun L, et al. Deregulation of c-myc by translocation of the alpha-locus of the T-cell receptor in T-cell leukemias. *Science* 1986;232:884-6.
 13. Inaba T, Roberts WM, Shapiro LH, et al. Fusion of the leucine zipper gene HLF to the E2A gene in human acute B-lineage leukemia. *Science* 1992;257:531-4.
 14. Bernard O, Azogui O, Lecointe N, et al. A third tal-1 promoter is specifically used in human T cell leukemia. *J Exp Med* 1992;176:919-25.
 15. Xia Y, Brown L, Yang CY, et al. TAL2, a helix-loop-helix gene activated by the (7;9)(q34;q32) translocation in human T-cell leukemia. *Proc Natl Acad Sci U S A* 1991;88:11416-20.
 16. Visvader J, Begley CG. Helix-loop-helix genes translocated in lymphoid leukemia. *Trends Biochem Sci* 1991;16:330-3.
 17. Fisch P, Boehm T, Lavenir I, et al. T-cell acute lymphoblastic lymphoma induced in transgenic mice by the RBTN1 and RBTN2 LIM-domain genes. *Oncogene* 1992;7:2389-97.
 18. Royer-Pokora B, Loos U, Ludwig WD. TTG-2, a new gene encoding a cysteine-rich protein with the LIM motif, is overexpressed in acute T-cell leukaemia with the t(11;14)(p13;q11). *Oncogene* 1991;6:1887-93.
 19. Kennedy MA, Gonzalez-Sarmiento R, Kees UR, et al. HOX11, a homeobox-containing T-cell oncogene on human chromosome 10q24. *Proc Natl Acad Sci U S A* 1991;88:8900-4.
 20. Hatano M, Roberts CW, Minden M, Crist WM, Korsmeyer SJ. Deregulation of a homeobox gene, HOX11, by the t(10;14) in T cell leukemia. *Science* 1991;253:79-82.
 21. Tkachuk DC, Kohler S, Cleary ML. Involvement of a homolog of *Drosophila* trithorax by 11q23 chromosomal translocations in acute leukemias. *Cell* 1992;71:691-700.
 22. Gu Y, Nakamura T, Alder H, et al. The t(4;11) chromosome translocation of human acute leukemias fuses the ALL-1 gene, related to *Drosophila* trithorax, to the AF-4 gene. *Cell* 1992;71:701-8.
 23. Kakizuka A, Miller WH Jr, Umesono K, et al. Chromosomal translocation t(15;17) in human acute promyelocytic leukemia fuses RAR alpha with a novel putative transcription factor, PML. *Cell* 1991;66:663-74.
 24. Kastner P, Perez A, Lutz Y, et al. Structure, localization and

- transcriptional properties of two classes of retinoic acid receptor alpha fusion proteins in acute promyelocytic leukemia (APL): structural similarities with a new family of oncoproteins. *EMBO J* 1992;11:629-42.
25. Pandolfi PP, Alcalay M, Fagioli M, et al. Genomic variability and alternative splicing generate multiple PML/RAR alpha transcripts that encode aberrant PML proteins and PML/RAR alpha isoforms in acute promyelocytic leukaemia. *EMBO J* 1992;11:1397-407.
 26. Bakhshi A, Jensen JP, Goldman P, et al. Cloning the chromosomal breakpoint of t(14;18) human lymphomas: clustering around JH on chromosome 14 and near a transcriptional unit on 18. *Cell* 1985;41:899-906.
 27. Ngan B-Y, Chen-Levy Z, Weiss LM, Warnke RA, Cleary ML. Expression in non-Hodgkin's lymphoma of the bcl-2 protein associated with the t(14;18) chromosomal translocation. *N Engl J Med* 1988;318:1638-44.
 28. Raghoebier S, van Krieken JH, Kluin-Nelemans JC, et al. Oncogene rearrangements in chronic B-cell leukemia. *Blood* 1991;77:1560-4.
 29. Athan E, Foitl DR, Knowles DM. bcl-1 Rearrangement: frequency and clinical significance among B-cell chronic lymphocytic leukemias and non-Hodgkin's lymphomas. *Am J Pathol* 1991;138:591-9.
 30. Williams ME, Meeker TC, Swerdlow SH. Rearrangement of the chromosome 11 bcl-1 locus in centrocytic lymphoma: analysis with multiple breakpoint probes. *Blood* 1991;78:493-8.
 31. Wulczyn FG, Naumann M, Scheidereit C. Candidate proto-oncogene bcl-3 encodes a subunit-specific inhibitor of transcription factor NF-kappaB. *Nature* 1992;358:597-9.
 32. Ahuja H, Bar-Eli M, Advani SH, Benchimol S, Cline MJ. Alterations in the p53 gene and the clonal evolution of the blast crisis of chronic myelocytic leukemia. *Proc Natl Acad Sci U S A* 1989;86:6783-7.
 33. Ahuja H, Bar-Eli M, Arlin Z, et al. The spectrum of molecular alterations in the evolution of chronic myelocytic leukemia. *J Clin Invest* 1991;87:2042-7.
 34. Foti A, Ahuja HG, Allen SL, et al. Correlation between molecular and clinical events in the evolution of chronic myelocytic leukemia to blast crisis. *Blood* 1991;77:2441-4.
 35. Fenaux P, Preudhomme C, Quiquandon I, et al. Mutations of the P53 gene in acute myeloid leukaemia. *Br J Haematol* 1992;80:178-83.
 36. Fenaux P, Jonveaux P, Quiquandon I, et al. P53 gene mutations in acute myeloid leukemia with 17p monosomy. *Blood* 1991;78:1652-7.
 37. Fenaux P, Jonveaux P, Quiquandon I, et al. Mutations of the p53 gene in B-cell lymphoblastic acute leukemia: a report on 60 cases. *Leukemia* 1992;6:42-6.
 38. Jonveaux P, Berger R. Infrequent mutations in the P53 gene in primary human T-cell acute lymphoblastic leukemia. *Leukemia* 1991;5:839-40.
 39. Gaidano G, Ballerini P, Gong JZ, et al. p53 Mutations in human lymphoid malignancies: association with Burkitt lymphoma and chronic lymphocytic leukemia. *Proc Natl Acad Sci U S A* 1991;88:5413-7.
 40. Ahuja HG, Jat PS, Foti A, Bar-Eli M, Cline MJ. Abnormalities of the retinoblastoma gene in the pathogenesis of acute leukemia. *Blood* 1991;78:3259-68.
 41. Ginsberg AM, Raffeld M, Cossman J. Inactivation of the retinoblastoma gene in human lymphoid neoplasms. *Blood* 1991;77:833-40.
 42. Miwa H, Beran M, Saunders GF. Expression of the Wilms' tumor gene (WT1) in human leukemias. *Leukemia* 1992;6:405-9.
 43. Ahuja HG, Foti A, Zhou D-J, Cline MJ. Analysis of proto-oncogenes in acute myeloid leukemia: loss of heterozygosity for the Ha-ras gene. *Blood* 1990;75:819-22.

44. von Lindern M, Fornerod M, van Baal S, et al. The translocation (6;9), associated with a specific subtype of acute myeloid leukemia, results in the fusion of two genes, *dek* and *can*, and the expression of a chimeric, leukemia-specific *dek-can* mRNA. *Mol Cell Biol* 1992;12:1687-97.
45. Ziemer-van der Poel S, McCabe NR, Gill HJ, et al. Identification of a gene, *MLL*, that spans the breakpoint in 11q23 translocations associated with human leukemias. *Proc Natl Acad Sci U S A* 1991;88:10735-9. Erratum, *Proc Natl Acad Sci U S A* 1992;89:4220.]
46. Ellisen LW, Bird J, West DC, et al. *Tan-1*, the human homolog of the *Drosophila notch* gene, is broken by chromosomal translocations in T lymphoblastic neoplasms. *Cell* 1991;66:649-61.
47. Miyoshi H, Shimizu K, Kozu T, Maseki N, Kaneko Y, Ohki M. *t(8;21)* Breakpoints on chromosome 21 in acute myeloid leukemia are clustered within a limited region of a single gene, *AML1*. *Proc Natl Acad Sci U S A* 1991;88:10431-4.
48. Meeker TC, Hardy D, Willman C, Hogan T, Abrams J. Activation of the interleukin-3 gene by chromosome translocation in acute lymphocytic leukemia with eosinophilia. *Blood* 1990;76:285-9.
49. Croce CM. Role of chromosome translocations in human neoplasia. *Cell* 1987;49:155-6.
50. Korsmeyer SJ. Chromosomal translocations in lymphoid malignancies reveal novel proto-oncogenes. *Annu Rev Immunol* 1992;10:785-807.
51. Cleary ML. Oncogenic conversion of transcription factors by chromosomal translocations. *Cell* 1991;66:619-22.
52. Rowley JD. Recurring chromosome abnormalities in leukemia and lymphoma. *Semin Hematol* 1990;27:122-36.
53. Ford AM, Ridge SA, Cabrera ME, et al. In utero rearrangements in the *trithorax*-related oncogene in infant leukaemias. *Nature* 1993;363:358-60.
54. Wasserman R, Galili N, Ito Y, Reichard BA, Shane S, Rovera G. Predominance of fetal type DJH joining in young children with B precursor lymphoblastic leukemia as evidence for an in utero transforming event. *J Exp Med* 1992;176:1577-81.
55. Nowell FC, Hungerford DA. Chromosome studies on normal and leukemic human leukocytes. *J Natl Cancer Inst* 1960;25:85-109.
56. Rowley JD. A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. *Nature* 1973;243:290-3.
57. Pawson T. Conviction by genetics. *Nature* 1992;356:285-6.
58. Cicchetti P, Mayer BJ, Thiel G, Baltimore D. Identification of a protein that binds to the SH3 region of *Abl* and is similar to *Bcr* and *GAP-rho*. *Science* 1992;257:803-6.
59. Warrell RP Jr. All-trans-retinoic acid: what is it good for? *J Clin Oncol* 1992;10:1659-61.
60. Bourne HR, Sanders DA, McCormick F. The GTPase superfamily: conserved structure and molecular mechanism. *Nature* 1991;349:117-27.
61. Weinberg RA. Tumor suppressor genes. *Science* 1991;254:1138-46.
62. Vogelstein B, Kinzler KW. *p53* Function and dysfunction. *Cell* 1992;70:523-6.
63. Friend SH, Bernards R, Rogelj S, et al. A human DNA segment with properties of the gene that predisposes to retinoblastoma and osteosarcoma. *Nature* 1986;323:643-6.
64. Clarke AR, Maandag ER, van Roon M, et al. Requirement for a functional *Rb-1* gene in murine development. *Nature* 1992;359:328-30.
65. Nevins JR. *E2F*: a link between the *Rb* tumor suppressor protein and

- viral oncoproteins. *Science* 1992;258:424-9.
66. Levine AJ, Momand J, Finlay CA. The p53 tumor suppressor gene. *Nature* 1991;351:453-6.
67. Diaz MD, Rubin CM, Harden A, et al. Deletions of interferon genes in acute lymphoblastic leukemia. *N Engl J Med* 1990;322:77-82.
68. Nakai H, Misawa S, Toguchida J, Yandell DW, Ishizaki K. Frequent p53 gene mutations in blast crisis of chronic myelogenous leukemia, especially in myeloid crisis harboring loss of a chromosome 17p. *Cancer Res* 1992;52:6588-93.
69. Sakashita A, Hattori T, Miller CW, et al. Mutations of the p53 gene in adult T-cell leukemia. *Blood* 1992;79:477-80.
70. Fiedler W, Weh HJ, Zeller W, et al. Translocation (14; 18) and (8; 22) in three patients with acute leukemia/lymphoma following centrocytic/centroblastic non-Hodgkin's lymphoma. *Ann Hematol* 1991;63:282-7.
71. Bar-Eli M, Ahuja H, Gonzalez-Cadavid N, Foti A, Cline MJ. Analysis of N-RAS exon-1 mutations in myelodysplastic syndromes by polymerase chain reaction and direct sequencing. *Blood* 1989;73:281-3.
72. Sheridan BL, Reis MD. Oncogene involvement in myelodysplasia and acute myeloid leukemia. *Tumour Biol* 1990;11:Suppl 1:44-58.
73. Allieri M-A, Fabrega S, Ozsahin H, Donay L, Barbu V, Gorin NC. Detection of BCR/ABL translocation by polymerase chain reaction in leukemic progenitor cells (ALL-CFU) from patients with acute lymphoblastic leukemia (ALL). *Exp Hematol* 1992;20:312-4.
74. Janssen JWG, Fonatsch C, Ludwig W-D, Rieder H, Maurer J, Bartram CR. Polymerase chain reaction analysis of BCR-ABL sequences in adult Philadelphia chromosome-negative acute lymphoblastic leukemia patients. *Leukemia* 1992;6:463-4.
75. Wasserman R, Galili N, Ito Y, et al. Residual disease at the end of induction therapy as a predictor of relapse during therapy in childhood B-lineage acute lymphoblastic leukemia. *J Clin Oncol* 1992;10:1879-88.
76. Guerrasio A, Martinelli G, Saglio G, et al. Minimal residual disease status in transplanted chronic myelogenous leukemia patients: low incidence of polymerase chain reaction positive cases among 48 long disease-free subjects who received unmanipulated allogeneic bone marrow transplants. *Leukemia* 1992;6:507-12.
77. Lo Coco F, Diverio D, Pandolfi PP, et al. Molecular evaluation of residual disease as a predictor of relapse in acute promyelocytic leukaemia. *Lancet* 1992;340:1437-8.
78. Szczylik C, Skorski T, Nicolaides NC, et al. Selective inhibition of leukemia cell proliferation by BCR-ABL antisense oligodeoxynucleotides. *Science* 1991;253:562-5.
79. Sorrentino BP, Brandt SJ, Bodine D, et al. Selection of drug-resistant bone marrow cells in vivo after retroviral transfer of human MDR1. *Science* 1992;257:99-103.
80. Su Huang H-J, Yee J-K, Shew J-Y, et al. Suppression of the neoplastic phenotype by replacement of the RB gene in human cancer cells. *Science* 1988;242:1563-6.
81. Yonish-Rouach E, Resnitzky D, Lotem J, Sachs L, Kimchi A, Oren M. Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6. *Nature* 1991;352:345-7.

* * USE FORMAT 9 FOR FULL TEXT OF ARTICLE * *